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Abstract 
Neuronal cell loss and damage in the central nervous system are characteristics of 
debilitating brain related-degenerative disorders such as Parkinson’s disease. The last 
four decades of research have focused on the promise of cell replacement therapy to 
replace lost cells, repair the damage and provide functional recovery in affected 
neural circuits. A thorough understanding of the signals implicated in the 
development of neurons will greatly facilitate the use of cell replacement therapy.  
This project aimed to investigate the possibility of using nicotinamide, the amide 
form of vitamin B3, to promote the development of mature neuronal subtypes from 
mouse embryonic stem cells, and whether these could form a dopaminergic 
phenotype, to progress research in stem cell-derived therapies for Parkinson’s 
disease.  
Treatment of mouse embryonic stem cell monolayer cultures (46C Sox1GFP reporter 
cell line) with nicotinamide at the early onset of development not only increased the 
efficiency of neuronal generation but also enriched the ratio of purified neurons to 
non-neuronal cells. Nicotinamide acted at the initial stages of differentiation to 
promote accelerated neural lineage entry by embryonic stem cells in adherent 
monolayer cultures. The pluripotent stem cell and neural progenitor cell populations 
could be reduced by treating cells with nicotinamide, which also facilitated 
accelerated neuronal differentiation. 
Nicotinamide selectively enhanced the production of catecholaminergic, serotonergic 
and GABAergic neurons and, moreover, accelerated neuronal maturation. A 
reduction in the proportion of proliferating cells in nicotinamide-treated cultures was 
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demonstrated– that is, nicotinamide enhanced cell-cycle exit, thereby promoting 
neuronal differentiation.  
The potential of nicotinamide was introduced to a novel, small-molecule-based 
strategy using pluripotent stem cell sources. Nicotinamide was shown to function 
synergistically with signalling molecules known to enhance a dopaminergic 
phenotype, to direct differentiating cells to adopt a dopaminergic cell fate. 
Thus, novel findings suggest that nicotinamide is a key signalling factor in brain 
development, and is required in a definable dosage range and times for the normal 
formation of dopamine neurons. This study supports previous evidence that vitamins 
and their metabolites play a fundamental role in neuronal development.  
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Chapter 1: General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
1.0 Introduction 
This project aimed to investigate the possibility of using nicotinamide, the amide 
form of vitamin B3, to promote the development of mature neuronal subtypes from 
mouse embryonic stem cells (mESCs) and whether these could form a dopaminergic 
(DAergic) phenotype. ESCs are considered to be an invaluable in vitro biological 
tool not only for examining the mechanisms of pluripotency, but also to study effects 
of different factors for directing cell fate decisions throughout early development.  
In order to gain an in-depth comprehension of the whole project and for 
experimental design purposes, it is essential to have an understanding of the basal 
ganglia (BG) circuitry [the functional brain structure affected by Parkinson’s disease 
(PD)]; PD; transcriptional control of midbrain DAergic neuronal development; how 
stem cells give rise to DAergic progenitors/neurons; and the role of vitamins and 
their active metabolites in influencing neural development in the early embryo and 
the adult central nervous system.  
 
1.1 The anatomy of the basal ganglia 
 
Our understanding of the anatomical and functional organisation of the BG circuitry 
began more than three decades ago
1,2
. Research from the last decade accomplished 
additional refinement of pathophysiological BG circuitry models
1,3–5
, thus advancing 
our scientific knowledge regarding the normal and diseased BG; a major cause of 
impairment in psychomotor disorders.  Most importantly, clinical requirements 
promoted the drive for the development of new therapies in PD. The BG circuitry 
plays a fundamental role in the control of movement, in addition to associative 
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learning, planning, working memory and emotion. This chapter will focus on the 
“motor circuit”.   
1.1.1 Cells and neurotransmitters of the basal ganglia 
The BG is comprised of five interconnected brain nuclei with the majority sending 
their projections exclusively to other nuclei located within the BG circuitry, 
establishing a vast subcortical network throughout the forebrain and midbrain. The 
major nuclei of BG circuitry are the striatum, globus pallidus (GP), subthalamic 
nucleus (STN) and substantia nigra (SN) (Figure 1.1).  The striatum, derived from 
the telencephalon, is made up of two functionally distinct nuclei; the caudate nucleus 
and the putamen, composed of neuronal cells sharing similar morphologies. These 
brain nuclei are partly divided by corticofugal and corticopetal fibers. In rodents, the 
striatum is shown to exist as an anatomically homogeneous formation. The GP can 
be subdivided into the globus pallidus external segment (GPe) and globus pallidus 
internal division (GPi). The SN is located in the mesencephalon (midbrain) and is 
comprised of an area containing a diffuse portion of neurons called substantia nigra 
pars reticulata (SNpr) which is comparable to the GP cytologically, and a densely 
pigmented area called the substantia nigra pars compacta (SNpc), the latter 
containing DAergic neurons
6
. 
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Figure 1.1 The topography of the cortical regions of the brain (left image) and a 
cross section of the human brain identifying associated structures of the BG 
circuitry (right image) are illustrated. (Diagram adapted from 
https://syntaptogaming.files.wordpress.com/2012/01/basalganglia_image1.jpg).  
 
 
 
1.1.1.1 Striatal neurons  
The striatum is composed mainly of projection neuron types with interspersed 
populations of interneurons
7
. Neurons located in the striatum are represented mainly 
by medium spiny neurons (MSNs), i.e. neurons whose dendrites are 
characteristically enveloped in dense dendritic spines, which account for 90-95% of 
total striatal neurons
8
. The output nuclei of the BG, i.e. internal and lateral segments 
of the GP and the SNpr, receive a major input from spiny projection neurons
1,2
. 
Spiny neurons appear to have a spherical arborisation and utilise γ-amino-butyric 
acid (GABA) as their predominant neurotransmitter
9
, which can be co-localised with 
substance P/dynorphin (DYN) or enkephalin (ENK)
10
. 
Five subtypes of dopamine (DA) receptors exist in the striatum. Striatal projection 
neurons express two main types of DA receptors; D1Rs and D2Rs which are G-
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protein coupled receptors responsible for modulating the MSNs’ response to DA 
released from nigrostriatal terminals. The inhibitory or excitatory effect carried out 
by DA is reliant on the type of receptor activated in the postsynaptic element. An 
enriched level of D1R mRNA is found on striatonigral substance-P-containing 
neurons in the direct pathway (see below), whilst D2Rs are linked to striato-pallidal 
ENK-immunoreactive neurons in the indirect pathway
11
.  
The striatum is the only BG nucleus containing various types of interneurons; 
small/parvalbumin GABAergic medium aspiny neurons
8,9
, large cholinergic 
interneurons 
8
 and aspiny interneurons containing somatostatin, neuropeptide Y, and 
nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) diaphorase
12
.  
Cholinergic, tonically active neurons (TANs) containing choline acetyltransferase 
and GABAergic fast-spiking interneurons (FSIs) are the most abundant types of 
striatal interneurons. TANs pre-synaptically inhibit glutamatergic input, therefore 
regulating the excitability of MSNs. The main role of GABAergic interneurons is to 
synapse on the dendritic shaft of nearby MSNs, thus enabling local collateral 
arborisation and inhibition to be achieved
13
. 
 
1.1.1.2 Pallidal and nigral neurons 
Pallidal and nigral neurons receive innervation from the striatum. Neurons from both 
pallidal segments use GABA as a neurotransmitter, co-localised with ENK, resulting 
in an inhibitory effect on their target neurons in the thalamus or sub-thalamic nucleus 
respectively
14
. SNpc neuronal cell types contain neuromelanin and utilse DA as a 
neurotransmitter. SNpr neurons are GABAergic
15
. Synaptic boutons cover pallidal 
and nigral neurons.  
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1.1.1.3 Subthalamic neurons 
The STN is the only nucleus of the BG circuitry which contains glutamatergic 
neurons, causing an excitatory effect on its targets: the GPi and SNpr
16
.   
 
1.1.2 The nigrostriatal pathway 
Pioneering research carried out by Carlsson, Falck and Hillarp in the 1960s 
highlighted the existence of two major types of catecholamine neurons in the brain: 
noradrenaline and DA, identified by applying the formaldehyde histofluorescence 
method
17
. This anatomical study outlined three dominant trajectories of midbrain DA 
(mDA) neurons; dorsal striatum, ventral striatum (including nucleus accumbens) and 
the prefrontal cortex
18
. 
In the 1970s, immunohistochemical studies employing the rate-limiting enzyme of 
DA synthesis, tyrosine hydroxylase (TH) enabled the positioning and expression 
pattern of DA neurons in the central nervous system (CNS) to be revealed. There are 
nine distinct DAergic cell groups present in the mammalian brain, extending from 
the mesencephalon to the olfactory bulb (Figure 1.2.)
19
.  
The use of more refined tract-tracing techniques illustrated the anatomical 
organisation and projection arrangement of TH
+
 DA neurons arising from the ventral 
part of the brain which was much more complex than was originally conceived. 
Ventral midbrain DA (mDA) cell sources can be classified into three main groups 
according to their location; A8 (retrorubral area), A9 (SN) and A10 (ventral 
tegmental area, VTA) (Figure 1.2). Recent research discovered that DA neurons 
located in the SN not only innervate the striatum, but also project to the STN, GPe 
and GPi
20
. Furthermore, cells located in the A8 region produce a dorsal and caudal 
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continuation of the A9 DA cell group, extending their projections to striatal, limbic 
and cortical areas
21
. These projections have been termed as the nigro-extrastriatal 
pathway and it has been proposed that they play a fundamental role in BG 
pathophysiologic disorders and/or perhaps influence the compensatory mechanisms 
predominant at the early stages of PD.  
 
 
 
Figure 1.2 DA neuronal subtypes located in the CNS.  
This diagram illustrates the location of TH
+ 
DA neurons corresponding to A8-A15 groups 
in the developing mammalian brain. mDA neurons emerge from the ventral mesencephalic 
flexure comprising of A9 SNpc and A10 VTA sets of neurons, shown by the red arrow.   
(Diagram adapted from Siew-Lan Ang, 2006)
22
.  
 
 
The nigrostriatal DA pathway (Figure 1.3) is derived from neurons in both the dorsal 
and ventral tier of the SNpc, a chief source of DA innervations of the sensorimotor 
striatum. The nigrostriatal projection is conveyed in a topographical manner, 
segregated into medial-lateral and dorso-lateral highly convergent projections. The 
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nigrostriatal system is mainly comprised of neurons from the A9 region in the 
mesencephalon
21
. 
 
 
Figure 1.3 Nigrostriatal Pathway. In the normal brain, DAergic neurons localised in the 
SN region project their axons to the striatum; composed of the putamen and caudate nucleus. 
(Diagram adapted from © 2001 Terese Winslow, Lydia Kibiuk) 
 
DA neuronal cell types can be characterised by their medium size and non-spiny 
morphology. Dendritic branches of DA neurons are exceptionally arborised and it 
has been estimated that a single DA axonal projection can give rise to 1,000,000 
terminals
23
. DA axonal projections are thin with a diameter of 0.1-0.8 μm. DA axons 
projecting exclusively to the dorsal striatum do not project to other areas such as the 
ventral striatum or neocortex, implying that each subtype of DA neurons has a 
distinct role within its target area
24
. 
mDA neurons can be segregated into a dorsal and ventral tier in relation to their 
connectivity and morphological properties. Cells dorsally located in the VTA and 
SN comprise of the dorsal tier, in addition to A8 cells projecting to the ventral 
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striatal, limbic, cortical areas and matrix compartment of the dorsal striatum
21
. 
Dorsal tier cell types can be characterized by their round shape and are calbindin-
positive. These cells express low levels of DA transporter (DAT). Dense, angular 
cells located in the ventral region of the VTA and SN constitutes the ventral tier, 
sending their projections exclusively to the striatum. Compared to dorsal tier cell 
types, these cells are calbindin-negative and are shown to express relatively high 
levels of DAT in addition to the G protein-activated inward rectifier potassium 
channel 2 (GIRK2)
25
. In the SN, ventral tier DA neurons release neurotransmitter 
DA from a network of dendritic terminals projecting to the striatum where 
postsynaptic targets are affected. Ventral tier neurons are crucially positioned to 
influence and directly modulate neurotransmission in the BG. mDA neurons not only 
play a fundamental role at the level of the caudate and putamen, but also regulate the 
activity of output pallidal, STN and nigral neurons
26
. 
The patch and matrix compartmental organisation of the dorsal striatum is critical in 
regulating the complex, numerous parallel pathways connecting the midbrain, BG, 
thalamus and cortex responsible for movement
27
. Smaller, patch compartments are 
embedded in larger matrix compartments, based on the laminar organisation of the 
cortex. It has been shown that patch neurons preferentially project to ventral tier 
DAergic neurons in the SNpc and DA cell islands located within the SNr, whereas 
matrix neurons project to GABAergic neurons found in the SNr
4
. 
 
1.1.3 Functional anatomy of the basal ganglia circuitry 
The main objective of the BG circuitry is to process signals arising from virtually the 
whole cerebral cortex. This is accomplished by what is now considered as the classic 
view of the BG
1,2,28
. Corticostriatal projections carry cortical information to the 
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striatum where it is processed and integrated with other inputs to the BG, including 
intralaminar thalamic nuclei, amygdala, hippocampus and dorsal raphe. BG nuclei 
then generate output signals, which travel through the thalamic target back to the 
cortex via a direct and an indirect pathway resulting in the modulation of motor, 
sensory and cognitive cortical information processing
29
. 
Researchers employing anatomical and physiological studies illustrated the existence 
of projections from different cortical areas to specific regions of the caudate and 
putamen, establishing five parallel information processing circuits. These circuits 
include a motor, oculomotor, dorsolateral prefrontal, lateral orbitofrontal and an 
anterior cingulate circuit
30
. The supplementary motor cortex is the major target of the 
BG motor circuit; however the subcortical ‘premotor’ areas such as the superior 
colliculus, the PPN and reticular formation are also influenced.  
The striatum (caudate and putamen collectively) is considered to be the main input 
nucleus to the BG circuitry, whereas the GPi and the SNpr can be classified as the 
two output nuclei. Like the striatum, it is now accepted that the STN is also 
recognised as another input nucleus as this structure directly receives afferents from 
the cerebral cortex, thalamus and brainstem (reviewed in Utter and Basso, 2008)
31
. 
The direct pathway is innervated by striatal spiny neurons which directly synapse 
with neurons in the GPi and the SNpr, the majority of which are output neurons 
(reviewed in Bolam et al, 2000)
32
. Neurons in the striatum which innervate the SNpr 
and GPi are GABAergic and express DYN as a co-transmitter and possess D1Rs. 
Under resting conditions, striatal neurons are quiescent. GPi/SNpr neurons are also 
GABAergic and can be characterised by their high discharge rate which maintains 
targeted structures in the thalamus (ventral thalamic or subcortical premotor region 
neurons) and brainstem under tonic inhibitory control.  
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Firing of corticostriatal glutamatergic neurons activates the circuit, resulting in an 
initiation of striatal neuron discharge. Consequently, output neurons in the SNpr and 
GPi are inhibited, resulting in a reduction of their firing. This leads to disinhibition 
of neurons in the thalamus, resulting in movement. Therefore, in the normal state and 
functioning of the BG, activation of the direct pathway facilitates movement (Figure 
1.4.).  
In the indirect pathway, an opposite physiological effect occurs. GABAergic 
projections exist from the striatum to the GPe, which in turn project to the STN. In 
turn, glutamatergic outputs in the STN send their axons to the GPi and SNr, which 
then innervate the thalamus. Upon depletion of DA, striatopallidal neurons inhibit 
tonically active GPe neurons, thereby freeing STN excitatory neurons from 
inhibition. Excitation of GABAergic neurons located in the GPi and SNr occurs as a 
result of the disinhibited STN neurons, causing an inhibitory effect on thalamic 
output. This leads to reduced excitation on neurons found in the supplementary 
motor area and movement is arrested (Figure 1.4)
2,27
. 
In addition to the cortex and thalamus, the DAergic system carries out a fundamental 
role in each pathway in the BG circuitry. DA modulates glutamatergic synapses from 
corticostriatal inputs to the BG circuitry. It has an excitatory effect on D1R-
expressing striatal neurons in the direct pathway and an inhibitory effect on D2R-
expressing neurons in the indirect pathway
1
. Therefore, impairment in the control of 
voluntary movements stems from a loss of DA innervation from the SN, resulting in 
the deficient release of DA in the striatum.  
12 
 
.  
Figure 1.4 Schematic diagram of the BG-thalamocortical circuitry in normal 
conditions. Parallel neuronal networks make up the ‘direct’ and ‘indirect’ pathway and are 
illustrated connecting the striatum (putamen) to the BG output nuclei. GABAergic 
inhibitory neurons are shown as red; glutamatergic excitatory neurons are shown in orange; 
dopaminergic neurons are shown as green. 
Abbreviation: SP (Substance P); Enk (enkephalin); GABA (γ-amino-butyric acid); GPe 
(external globus pallidus); GPi (internal globus pallidus); STN (subthalamic nucleus); SNr 
(substantia nigra pars reticulata), SNc (substantia nigra pars compacta); PPN 
(pedunculopontine nucleus) (Diagram modified from Lewis et al, 2003).  
 
 
The highly selective death of DA neurons in the SNpc and insufficient release of 
neurotransmitter DA in the corpus striatum, results in a decreased inhibitory effect 
of the indirect pathway, with a reduced excitatory response in the direct pathway 
13 
 
(Figure 1.5) The outcome of this activity translates to an excessive activation of the 
output nuclei of the BG circuitry (GPi and SNr), with a consequential inhibitory 
affect in the thalamocortical and brainstem motor centres, thus resulting in the 
development of Parkinsonian motor features
33
.  
 
 
 
Figure1.5 Schematic diagram of the BG-thalamocortical circuitry in Parkinson’s 
disease. GABAergic striatal neurons projecting to the GPi and SNr become depleted, 
resulting in a reduced inhibitory response from both these BG structures. Therefore, 
neuronal activity in the direct pathway is reduced, resulting in neurons in the indirect 
pathway becoming activated. An inhibitory effect on excitatory thalamic neurons is 
produced from GABAergic neurons localised in the GPi and SNr. This leads to reduced 
excitation of neurons present in the thalamus, in turn generating a less excitatory response to 
neurons in the cortex. Attenuated cortical output activity hinders the initiation and execution 
of voluntary movement, thus resulting in movement arrest and rigidity, which is evident in 
patients suffering from PD. 
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GABAergic inhibitory neurons are shown as red; glutamatergic excitatory neurons are 
shown in orange. 
Abbreviation: SP (Substance P); Enk (enkephalin); GABA (γ-amino-butyric acid); GPe 
(external globus pallidus); GPi (internal globus pallidus); STN (subthalamic nucleus); SNr 
(substantia nigra pars reticulata), SNc (substantia nigra pars 
 
 
1.2 Parkinson’s disease  
“Until we are better informed respecting the nature of the disease, the 
employment of internal medicine is scarcely warrantable.” – J. Parkinson.  
Extensive research has been conducted by scientists on the ontogeny of A9 DA 
neurons, with the aim of gaining a more in-depth knowledge of the chronic human 
progressive and neurodegenerative disorder, PD. The majority of PD cases are 
sporadic (approximately 95%), commonly referred to as idiopathic PD.
34
 Idiopathic 
PD is the second most common neurodegenerative disorder worldwide after 
Alzheimer’s disease, affecting approximately 0.5-1% of the population between the 
ages of 65-69 years, whilst 1-3% of the population are affected over the age of 80 
years
35
. In 1817, neurologist James Parkinson first detailed the syndrome and 
neuropathology of PD in his monograph entitled “An Essay on the Shaking Palsy” or 
“paralysis agitans”. In his work, he described six patients with “involuntary 
tremulous motion, with lessened muscular power in parts not in action and even 
when supported; with a propensity to bend the trunk forward, and to pass from 
walking to a running pace: the senses and intellects being uninjured”36. Despite 
James Parkinsons’ request for a more comprehensive understanding of the 
underlying causes of this disorder to be achieved for the development of therapies, it 
was not until 50 years later that any advancement or additional pathophysiological 
understanding was accomplished
37
.  
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Jean-Martin Charcot, a French physician acknowledged the London apothecary’s 
formal description of PD and established a more elaborated account of the motor 
abnormities linked to the disease process
38
 and also proposed in 1888 that the 
syndrome should be entitled “maladie de Parkinson” (Parkinson’s disease). In the 
1950s, Arvid Carlsson and colleagues started to investigate the underlying 
physiological and anatomical areas of the brain related to the PD process, and found 
that 80% of DA in the brain is contained within the BG
39
. In 1960, Ehringer and 
Hornykiewicz observed that the movement abnormalities associated with PD were 
due to the degeneration of the nigrostriatal circuit originating from the A9 DA cell 
group. Hornykiewicz noted a significantly higher concentration of DA in the 
striatum of the normal human brain in comparison to low levels of DA localised in 
the nucleus caudatus, putamen, nucleus accumbens, SN and GP of PD post mortem 
samples
40
. Shortly after these discoveries, Levodopa (L-Dopa) was introduced as a 
treatment for the cardinal motor features of PD. The clinical management of PD 
symptoms has advanced significantly since the 1960s; however, at present it still 
remains a challenge to halt the progression of the disease or to restore lost functions 
in the damaged nigrostriatal pathway.  
1.2.1 Clinical and neuropathological characteristics of Parkinson’s disease 
Deficiencies of nigrostriatal DAergic neurons with a resultant loss of the 
neurotransmitter DA in the corpus striatum (the brain region controlling movement) 
underlie the pathology of PD. One of the pathological hallmarks of PD is the 
presence of Lewy bodies, eosinophilic proteinaceous cytoplasmic inclusions 
containing alpha (α)-synuclein which are observed in prevailing SNpc neurons41. 
Heiko Braak proposed that Lewy body (LB) pathological alterations are not 
restricted to the SNpc, implying that these protein aggregates follow a distinct 
16 
 
pattern of pathological change with disease progression. Autopsied brains have 
shown that pathology commences in the olfactory apparatus and caudal brainstem 
(dorsal motor nucleus of the vagus in the medulla), before extending rostrally up the 
brainstem where neuronal cell loss is evident in the SNpc
42
.   
PD can be characterised clinically by the development of three cardinal symptoms 
namely tremor at rest, rigidity and hypokinesia
34
. Other motor symptoms include 
bradykinesia, postural abnormalities and a freezing (sometimes referred to as motor 
block) phenomenon (Table 1.1). 
 
 
Table 1.1 Glossary of Parkinson’s Disease Symptoms 
 
Akinesia 
“Without motion”; inability to initiate movement and is 
associated with temporary paralysis. 
Apathy State of indifference linked to motivation, personality and 
cognition. 
Ataxia Loss of balance and coordination. 
Bradykinesia Slowness of movement. 
Dyskinesia Abnormal involuntary movements associated with the onset of 
striatonigral DAergic degeneration and chronic L-Dopa 
administration. 
Dysphagia Difficulty in swallowing. 
Freezing Inability to initiate muscular movement in any desired direction. 
Masked Facies Facial muscles become immobilized, resulting in the appearance 
of a “blank expression” 
Micrographia Tendency for handwriting to become smaller in size. 
On-off phenomenon Alterations between periods of being “on”, which represent the 
patients’ ability to control their movements owing to a good 
responsiveness to medication. "Off" fluctuations develop when 
the patients experiences symptoms of their underlying 
parkinsonism, i.e. bradykinesia, rigidity and loss of muscular 
coordination.   
Tremor Tremor, measuring 4-5 Hz at rest, is the first visible clinical 
feature recognised in 70% of PD patients, but may be absent in 
20%. 
Pill-rolling Tremor can be classified by “pill-rolling”, a hand action involving 
the thumb and forefinger, occurring as a result of involuntary 
oscillatory movements of agonist and antagonist muscles.  
Postural abnormalities Loss of balance or “unsteady feeling” 
Rigidity Increased muscular tone resulting in stiffness and resistance of 
bodily movements 
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Non-motor symptoms occur in over 90% of PD patients and can sometimes be 
observed as “premotor” phenomena. They include neuropsychiatric symptoms, 
autonomic disturbances, sensory symptoms such as olfactory impairment, and sleep 
disorders (Table 1.2)
43
. The appearance of the clinical symptoms of PD occurs with 
the loss of approximately 60% of the DA neurons in the SNpc and 80% of striatal 
DA content. This poses a major problem for the treatment of PD, as patient diagnosis 
occurs only when this neurodegenerative disorder has already advanced to a serious 
pathological level. 
 
 
 
Cardinal features 
 
Tremor at rest, rigidity, bradykinesia/hypokinesia/akinesia, flexed 
posture/loss of postural reflexes, freezing gait.  
 
Non-motor 
symptoms 
Neuropsychiatric 
Dementia, depression, anhedonia, apathy, anxiety, slowness of 
thought, psychosis, sleep disturbances, sexual dysfunction 
Craniofacial    Hypomimia, impaired accommodation, sialorrhea and dysphagia, 
olfactory hypofunction, dysarthria 
Autonomic 
dysfunctions    
Bladder dysfunction, erectile dysfunction, impaired gastrointestinal 
dysfunction, constipation, abnormal thermoregulation and increased 
sweating. 
Sensory symptoms     Reduced sense of smell, pain, numbness and paresthesiae. 
 
Skin     Seborrhoea. 
Musculosketal Scoliosis, peripheral oedema. 
Table 1.2. Cardinal and non-motor symptoms linked to the pathology of PD.  
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1.3 Developmental differentiation of midbrain dopamine neurons 
Approximately 400,000-600,000 DAergic neurons (~75 % of all DA neurons) are 
located within the human ventral mesencephalon (VM), comparable to 20,000-
30,000 in the mouse VM
44
.  Recent progress, specifically over the last five decades 
in mouse genetics and knowledge of vertebrate development have aided our 
understanding of the development of mDA neurons from multipotent progenitors, 
facilitated through expression of key genetic cascades (activation of internal 
transcription factors) and cell-extrinsic environmental cues. This information is 
crucial to further efforts to generate high yields of SNpc DA neurons from stem cell-
derived sources (detailed in this chapter), to move us closer to a cell replacement 
therapy for PD.  
In general, during embryonic development, midbrain territory along the anterior-
posterior axis and the ventral region of the ventral-dorsal axis is defined by 
patterning events, closely followed by the induction of mDA neural progenitors in 
the VM
44
. An important characteristic of these progenitor cells is to maintain a state 
of pluripotency throughout the development of DA neurons, in addition to 
responding to key signaling proteins regulating their fate. mDA neurons are then 
generated from these progenitor cells in the floor plate of the caudal diencephalon 
and midbrain, producing three distinct clusters of mDA neurons (termed A8; 
retrorubal field, A9; SNpc and A10; ventral tegmental area). I will discuss the 
“normal development” of mDA neurogenesis in the SNpc, focusing on cellular and 
molecular determinants influencing their regional specification, induction, 
postmitotic differentiation, maturation and maintenance, in order to functionally 
project and integrate into their desired destinations within the CNS.  
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1.3.1 Ventral midbrain regionalisation  
The commencement of regionalisation occurs during early development when 
neuralisation causes the lateral edges of the neural plate to scroll upwards to become 
dorsal. Molecular and cell-fate mapping techniques demonstrated that the temporal 
and spatial region of neuroepithelial cells (i.e. neurogenic ectoderm) determine the 
timing and modifications of transcription factors, which in turn influence the 
specification of DA neurons
45
.  
The organisation of both A9 and A10 groups is triggered by two important signaling 
centers located in close proximity: the isthmus, a neuroepithelial  signaling center at 
the midbrain hindbrain boundary (MHB), and the floor plate of the ventral midline of 
the mesencephalon. This arrangement allows both signaling centers to have an 
influential effect on both sets of neurons following the secretion of diffusible signals, 
thus directing the terminal specification of cells within the VM
22
.  
The axial position of the MHB is established from co-repressive interactions of both 
orthodentical homolog 2 (Otx2) and gastrulation brain homeobox 2 (Gbx2) 
expression domains, and is maintained by FGF8 expression, a fibroblast growth 
factor8 expressed from the anterior MHB. It should be noted that paired box gene 
(Pax2) is necessary for the induction of FGF8 expression. Additionally, glycoprotein 
Wnt 1 and Engrailed-1 (En1) function synergistically with Otx2 and Gbx2 to further 
refine the position of FGF8 expression at the isthmus. Expression of En2 and Pax5 in 
the MHB commences following the induction and positioning of FGF8 expression, 
to promote regional specification of the VM
22
.  
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Ventral cells located in the neural plate acquiring regional identity of the midbrain 
react to the morphogen, Sonic hedgehog (Shh), expression at mouse E8.0 , by 
obtaining a DA cell fate
46
. Therefore, both the induction and positional location of 
DA neurons is reliant on overlapping regions of secreted FGF8 and Shh expression 
(Figure 1.7) emanating from the notochord below the ventral floorplate, as the 
interplay between these factors will influence where mDA progenitors will arise
47
.  
1.3.2 Derivation of midbrain dopamine neurons from progenitor cells  
Following appropriate early patterning events of the VM, the induction and 
maintenance of mDA progenitor cells which will ultimately differentiate into mDA 
neurons is dependent on a number of factors present in the ventral midbrain: Shh, 
En1 and En2, Wnt factors, Otx2, Pax2 and Pax5 and Sox genes (Table 1.3.; Figure 
1.6)
22,44
. The interaction of all of these factors present in the ventral midbrain 
provides a fundamental basis of graded cues enabling neural progenitors to adopt 
different phenotypes according to their position, (as reviewed by Orme et al
48
). 
Extensive research has been carried out on the specific identity of these progenitor 
cells due to their potential to be translated as a cell source to replace DAergic 
neurons lost in PD. Recent research revealed the precise identity of these progenitor 
cells and showed that floor plate cells residing in the murine VM became neurogenic 
and later gave rise to DA neurons
49
.  
1.3.3 Transcription factors: control of midbrain dopamine neuron development  
Newly generated progenitor cells are localised within the ventral most proliferative 
zone of the midbrain neuroepithelium, travelling in a ventral and then lateral manner 
as they commence the process of differentiation. They can be characterised by their 
expression of transcription factors which have all been shown to significantly affect 
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the development of mDA neurons including Lmx1a, Foxa2, Lmx1b, Msx1/2, Ngn2, 
Nurr1, Wnt and (Figure 1.6) at a developmental earlier stage, Shh expression
50
. 
mDA progenitors have the ability to downregulate Sox2 expression and are also 
capable of initiating βIII-tubulin, a neuronal marker expressed in postmitotic 
immature and mature mDA neurons
51
 (Figure 1.6).  
 
Figure 1.6 Model of mDA neuron generation from early DA progenitors to 
mature DAergic neurons. This diagram represents the series of stages and the 
subsequent timing of the activation of transcription factors required for the 
generation of DA neurons during early embryonic development. (Diagram adapted 
from Siew-Lan Ang, 2006)
19
. 
 
1.3.4 Appearance of terminally differentiated A9 dopamine neurons in the 
midbrain 
In summary, at approximately mouse E10, mDA neural progenitors located in the 
ventricular zone featuring distinct proliferative capabilities migrate along radial glial 
fibres until they reach the mantle zone, where they further continue their 
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differentiation into DA neurons
52
. A number of early specification genes already 
expressed by these migrating precursors include En1/2, Lmx1a/b and Foxa1/2 and 
then begin to express aromatic L-amino acid decarboxylase (AADC). AADC 
functions in converting Dopa into the neurotransmitter DA and experiments have 
shown that immature DA neurons already express AADC mRNA transcripts
53
. At 
E10.5, the orphan nuclear receptor for Nurr1 is expressed and subsequently followed 
by the exit of precursors from the cell cycle to commence their conversion into 
postmitotic precursors. This is due to the fact that they have not yet developed into 
fully differentiated mature DA neurons by this developmental stage. The terminal 
differentiation step by which cells obtain a DA phenotype is marked by the onset of 
TH expression, which is present between E9.5 and E11.5 in the ventral midbrain of 
mice (Figure 1.7). It should be taken into account that this developmental stage is 
arrested if cells do not express Nurr
53
. During this time point at E11.0, the 
expression of paired-like homeodomain transcription factor, Pitx3, indicates the 
generation of fully differentiated DA neuronal phenotypes, along with Engrailed and 
Nurr1 which have functional roles at this terminal stage of DA mature neuronal 
differentiation (Table 1.3; Figure 1.7).  
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Figure 1.7 Model of mDA neuron generation. (A) This diagram illustrates the 
signalling cascades involved in the development of mDA neurons. (B) Midbrain 
tissue identity is established during regionalisation of the neural tube. The inductive 
signals Shh and FGF8 (arising from the notochord (grey circle) and the MHB (blue) 
respectively), in combination with Otx2 expression play important roles during this 
stage (E7.75-9). Specification of mDA neuronal identity occurs between E9-14 
within the proliferative zone (grey) of the ventral midline. During this developmental 
stage, Msx1 and Foxa2 drive neurogenesis by regulating Ngn2. Importantly, Lmx1a, 
in combination with Msx1, specifies mDA neuron cell fate. mDA neuron progenitors 
enter the intermediate zone (yellow) when they become postmitotic. At this stage, 
mDA neuron progenitors begin to express the pan neuronal marker, Tuj1, followed 
by the DA neuron transmitter regulator, Nurr1. Lmx1b and Wnt1 regulate early Pitx3 
expression in some Nurr1-expressing cells. The final phase in mDA neuronal 
differentiation commences as the Pitx3-expressing cells migrate ventrally to the 
peripheral zone (pink). Eventually, this cell population migrates laterally to 
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constitute the neural population of the SNpc. At this stage, cells begin to express TH. 
En1 and En2 are required to promote and maintain survival of the mature mDA 
neurons localised in the ventral midbrain
50
.  
 
1.3.5 Functional maturation of dopaminergic neurite projections from the ventral 
midbrain 
Terminally differentiated mDA neurons undergo functional maturation involving 
axonal pathfinding and synaptogenesis. Development of mDA axons occurs at E11 
in mice (E13 in rat) and by E14.5, the majority of axons have reached their 
destination. In 2004, Gates and colleagues found that axons initially send their 
projections dorsally before migrating ventro-rostrally toward the forebrain, by 
responding to extrinsic instructive cues in the dorsal midbrain and repulsive cues 
emanating from the caudal brain stem
54
. Chemoattraction then directs migration of 
these axons toward the telencephalon via the medial forebrain bundle, through the 
diencephalon where the axons terminate in the striatum and cerebral cortex. This 
axonal migration and relevant striatal innervation by nigral DA neurons is directed 
by chemmoattractive cues from the striatal region and chemorepulsion from the 
cortex. Gates et al also showed that contact-dependent inhibitors further assist axonal 
pathfinding of VM DA neurons by hindering their access through the thalamus. 
Recently, a study showed how transcription factor Nurr1 coordinated the expression 
of the axon genesis gene topoisomerase IIβ (TopIIβ), thereby having a regulatory 
effect on DAergic neuron axonal extensions. A number of molecules implicated in 
establishing the development of VM DA circuitry and axonal guidance include: 
Ephrin B2 and its receptor EphB1, netrin receptor DCC and expression patterns of 
the SLIT family and their receptors robo1/2
44
.  
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1.3.6 Neuroprotective growth factors 
Following development of the VM DA circuitry and appropriate innervation of 
DAergic targets, newly formed axons of these neurons are prone to cell death so 
therefore contest to develop functional synapses and for survival. Naturally 
occurring DAergic cell death occurs in the rat near birth, peaking at P2, in addition 
to a second peak of apoptosis at P14
55
. A family of proteins called neurotrophic 
factors function to promote growth, survival of newly developing neurons and 
maintenance of mature neurons. Cell survival at this point is reliant on the limited 
availability of target derived neurotrophic factors to protect VM DA neurons, namely 
glial cell line-derived neurotrophic factor (GDNF)
56
, neurturin (NTN; member of the 
GDNF protein family)
57
, transforming growth factor βs (TGFβs)58, brain-derived 
nerve factor (BDNF)
59
 and growth/differentiation factor 5 (GDF5)
60
.  
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Transcription 
Factor 
Expression 
day in the 
mDA 
lineage 
Function in mDA cells References 
Otx2 E7.0 Determine forebrain and midbrain territories within developing neural tube. Specification 
of mDA progenitors 
Puelles et al (2003); Vernay et 
al (2005) 
Foxa2 E7.0 Influence mDA neuronal development. Regulate Nurr1 and En1 expression in immature 
neurons. Also controls TH and AADC expression in differentiated mature DA neurons. 
Ferri et al (2007). 
Pax2 E7.5 Coordinate precise development of mid/hindbrain area through En2 signalling. Induction 
of FGF8 expression.  
Bouchard et al (2005); Ye et al 
(2001) 
Lmx1b E7.5 Maintenance of Wnt1 expression and of mature mDA neurons.  Smidt et al (2000) 
Foxa1 E7.5 Influence mDA neuronal development. Regulate Nurr1 and En1 expression in immature 
neurons. Also controls TH and AADC expression in differentiated mature DA neurons. 
Ferri et al (2007). 
En1/2 E8.0 Generation and survival of mature mDA neurons Simon et al (2001); Alberi et al 
(2004) 
Wnt1 E8.0 Controls En1/2 expression. Regulates DA progenitor pool and mature DA neuron 
differentiation.  
Danielian and McMahon 
(1996); Prakash et al (2006); 
McMahon et al (1992) 
Shh E8.0 Ventral patterning events. DA neuron induction. Govern transcription factor expression in 
NPCs.  
Hynes et al (1995); Briscoe et 
al (2000) 
FGF8 E8.0 Maintenance of MHB. Specification of mesencephalic progenitors.  Ye et al (1998) 
Lmx1a E9.0 Regulates expression of Msx1 for determining DA neuronal cell fate.  Andersson et al (2006a) 
Msx1 E9.0 Required for neuronal differentiation. Regulates Ngn2 expression. Andersson et al (2006b) 
Ngn2 E10 Required for neuronal differentiation.  Andersson et al (2006a); Kele 
et al (2006) 
Nurr1 E10.5 Maintenance of mature mDA neurons. Expression of late differentiation markers:  
TH, AADC, DAT and VMAT.  
Smits et al (2003) 
Pitx3 E11.0 Essential for TH expression in mature neurons. Survival of SNpc and VTA neurons.  Hwang et al (2003); Nunes et 
al (2003); van den Munckhof 
et al (2003); Smidt et al 
(2004); Maxwell et al (2005). 
Table 1.3 Summary of the role of transcription factors required during DAergic neuronal development
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1.4 Current approaches to the treatment of PD 
At present, no beneficial therapies have been established to potentially prevent the 
onset of PD or offer support to remaining neurons. Current drug and surgical 
therapies are capable of reducing PD symptoms but do not prohibit the progressive 
nature of the disease. Oral preparations of L-3, 4-dihydroxyphenylalanine (L-DOPA) 
and DA receptor agonists are administered as a PD treatment, with the aim of 
alleviating motor symptoms. L-DOPA increases DA concentrations in PD patients 
and unlike DA; it crosses the blood brain barrier (BBB) where it enters the CNS. 
Here, it is converted to DA by the enzyme aromatic L-amino acid decarboxylase, 
commonly referred to as dopa decarboxylase (DDC).  Continuous L-DOPA delivery 
via intestinal treatment can also be used, and this continuous release has been 
attributed to the prevention of L-dopa induced dyskinesias (LIDs). DA agonists 
function by stimulating DA receptors, thereby aiming to ameliorate motor symptoms 
associated with PD. In advanced PD cases, administration of apomorphine proves to 
be an effective non-selective DA agonist, activating D1Rs and D2Rs.  
A major disadvantage of employing long-term utilisation of DAergic drug therapies 
is generation of disabling adverse effects, including production of drug-induced 
motor complications such as on-off fluctuations and LIDs
61
. Deep brain stimulation 
(DBS) is a surgical treatment used to mitigate PD motor symptoms, involving 
implantation of a brain pacemaker (electrode) to deliver electrical pulses to two 
common target structures within the BG; STN and GP. One of the main effects of 
DBS is to reduce tremor by targeting the STN
62
.   
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1.4.1 Cell replacement therapy 
The last four decades of research have brought us closer to turning cell replacement 
therapy (CRT) into a reality, by aiming to achieve effective repair and functional 
recovery in brain damage and disease. The premise behind such a therapy would be 
that identical A9 nigral DA specific neurons transplanted to the DA-depleted 
striatum could restore DAergic neurotransmission, thereby generating a functionally 
efficient substitute for the neurons lost/damaged in PD
61–64
. This important attribute 
of the SNpc component of the striatal grafts enables transplanted neurons to re-
innervate and activate the dorsolateral region of the host striatum.  
It is evident from previous clinical trials that transplantation of human fetal ventral 
mesencephalic (hfVM) tissue to the striata of PD patients proved that such grafts 
were capable of promoting restoration of DAergic function to the striatum
65
. More 
recent trials provided further proof of concept that transplanted grafts (using hfVM 
tissue) could functionally reinnervate the denervated striatum, restore DA release 
and promote significant long-term clinical advancements in a number of PD 
patients
66
.  
It should be noted that scientists realised the key to accomplishing effective repair in 
the adult brain was to transplant specific neuronal subtypes lost to the disease 
process. Studies showed that it is important for donor neurons to be transplanted at a 
precise time when their fate is already specified, as reviewed by Dunnett and Rosser, 
2011
63
. This is due to the fact that expression of developmental signals in the foetal 
brain are not present in the adult brain to direct neuronal differentiation. 
Additionally, donor cells must be within a particular developmental window, i.e. 
cells too developmentally advanced would be less likely to survive the 
transplantation procedure.
63
 Post transplantation, local signals prompt host axons to 
29 
 
sprout and innervate graft tissue, thereby forming reciprocal connections between 
graft and host neurons. This was an important finding and turning point in light of 
the theories surrounding the limited plasticity of the adult mammalian brain, since 
the time of Cajal
63,67
.  
 
1.4.1 .1 Human fetal ventral mesencephalon tissue 
The obvious source of cells for a replacement therapy for PD would be from hfVM 
68
, since this tissue contains postmitotic cells committed to the DAergic lineage. The 
first cell transplants in PD patients provided proof-of-principle that ectopic 
engraftments of fetal VM tissue to the striatum not only survived well, as visualised 
using fluorodopa PET imaging, but also induced functional recovery of motor 
symptoms, enhanced the functional efficacy of concurrent L-Dopa and moreover 
augmented the proportion of each day spent in the “on” phase62,66,68. DA series of 
similar translational clinical trial studies in PD patients using intrastriatal hfVM 
tissue demonstrated long-lasting symptomatic relief in some patients for more than 
16 years post-transplantation
62
.   
Despite some success in the clinic, not all patients experienced positive outcomes 
and initial clinical trials were impeded by lack of consistent outcomes and graft-
induced dyskinesias (GIDs) present in a subgroup of patients
69
. Post-operative GIDs 
may result from excessive DA release due to continuous neural outgrowths of the 
grafts
70
 or atypical regulatory release of DA originating from the transplanted 
tissue
71
. Furthermore, the presence of serotonergic neurons (in relation to low yields 
of appropriate DA nerve cells within the grafts) could potentially lead to false DA 
release; serotonergic neurons are capable of producing and discharging the 
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neurotransmitter DA derived from exogenous L-Dopa, but do not have the 
mechanisms seen in DA neurons to modulate release and re-uptake of DA
72
. 
Serotonin 1A agonists (buspirone) effectively suppress serotonergic neurons within 
grafts or alternatively, cell sorting could minimise the prevalence of serotonergic 
components when generating mDA neurons from SC sources
70,73
.   
Despite recent suggestions for overcoming these limitations regarding intrastriatal 
transplantations, it is doubtful that hfVM tissue grafts will be considered as a routine 
therapeutic procedure for PD, owing to shortcomings with tissue availability and 
standardisation of the grafts
74
. Furthermore, the harvest of this tissue from 
termination of pregnancies and requirement of large numbers of foetuses (between 
three and six foetuses per side of the brain grafted) to produce adequate 
transplantable neurons further limits the use of this source
62
.  
 
1.4.2 Stem cells for dopamine replacement 
So, despite success with hfVM transplants and more well-defined understanding of 
DAergic pathology, there is still no cell replacement therapy (CRT) for PD. Ethical 
and logistical issues surrounding the use of tissue obtained from aborted human 
embryos hinder the translation of hfVM to clinic. In this respect, current research is 
now focusing on generating A9 DA neurons for transplantation from stem cell 
sources. Research has turned to generating donor cells from stem cell sources, of 
which human pluripotent stem cells are powerful contenders, with human embryonic 
stem cells (hESCs) advancing the furthest
74
.  
However, it remains crucial that a number of prerequisites are met concerning the 
clinical implementation of pluripotent stem cells toward large-scale clinical 
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applications to provide a readily available, renewable and bankable source of cells to 
generate functionally DA neuronal populations
61,63,64,75
. The issues to be considered 
are outlined as follows: 
 
I. Establishing criteria for directing efficient and robust differentiation and 
predictive validity of competitive clinical grade protocols.  
 
II. Yields of cells of appropriate neuronal phenotype remain variable. It is 
fundamental that cells cultured in vitro are generated in adequate numbers to 
achieve a substantial level of engraftment in a clinical setting. 
 
III. It is necessary to ensure that nigral DA neurons are accurately defined. This 
can be achieved using immunostaining techniques for specific markers 
typical of these cells, as well as demonstrating gene and transcription factor 
profiles definitive of distinct brain regions during early embryonic 
development. Neurophysiological measures and controlled dopamine release 
must be tested to authenticate neuronal excitability. To eliminate unwanted 
cells in cultures with respect to ESC and induced pluripotent stem cell (iPSC) 
sources, cell types must be identified, particularly the number of nonnigral 
DA neurons, serotonergic neurons, glial cells, undifferentiated stem cells, 
progenitor cells and nonneural cells.  
 
 
IV. Post CRT, long term retention of target phenotypes remains poor with limited 
integration to the host circuitry. Adequate numbers of transplanted DA cells 
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(i.e. more than 100,000 per human putamen) are required to grow axons and 
provide reinnervation to the host striatum over distances suitable for the size 
of the human brain. Stem cell-derived neurons should reverse motor deficits 
underlying PD over a prolonged period of time to provide symptomatic relief 
in patients.  
 
V. Finally, it is imperative that risk of adverse effects such as GIDs, secure 
regulation of proliferation and potential for tumourigenesis encountered using 
pluripotent and multipotent stem cell sources, neural outgrowths and immune 
reactions are eliminated from stem cell sources.  
 
1.4.2.1 Embryonic stem cells  
Prior to implantation, the inner cell mass (ICM) of the blastocyst generates a source 
of primitive and highly proliferative cells known as ESCs. ESCs are capable of 
differentiating into cell types of the three germ layers (pluripotent cell source), 
including DAergic neurons. Advantageous properties of ESCs include their aptitude 
to be cultured for extended periods in vitro whilst sustaining their pluripotency and 
their capacity for self-renewal
76
.   
Transplantation of rodent ESC-derived DAergic neurons to the striatal region of PD 
rat animal models promoted some degree of functional and behavioural recovery, 
with axons projecting their extensions beyond the graft core to establish synaptic 
connections with the host striatum. However, the relatively low survival rate of these 
neurons is a disadvantage of ESC-derived DAergic neurons
77
.  
Nevertheless, recent protocols for generating DAergic neurons from ESC sources 
employing the genetic manipulation of transcription factors to programme the cells 
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have shown great potential in directing differentiation to high yields of more 
authentic nigral neurons
78,79
. Despite such encouraging results, further research is 
required to generate substantial numbers of A9 nigral numbers showing extensive 
fibre outgrowth and to eradicate the risk of tumourigenesis within transplants
63,74
. 
Ethical implications inherent with human ESC derivation remain an additional 
consideration.  
 
1.4.2.1.1 Mouse embryonic stem cells  
Early transplantation studies using undifferentiated mESCs showed that this stem 
cell source could be successfully grafted to the rodent striatum,
80
 and were capable 
of generating DA neurons, and alleviate some of the behavioural deficits in rodent 
models of PD
81
. However, these studies also demonstrated the formation of 
teratoma-like tumours.  
Specifically, it was first reported that mESCs could be directed to a neural fate by 
administrating retinoic acid (RA)
82
, or bFGF to cultures
83
. Later work focused on the 
application of developmentally relevant DA specific factors, including Shh, FGF8, 
BDNF and ascorbic acid (AA), to generate higher yields of DA neuronal 
populations.
83
 This approach increased the number of DA-expressing neurons to ~ 
20-30% of the total cell population. Following the discovery that cell-intrinsic 
transcription factors play a fundamental role during the normal development of DA 
neurons, scientific studies shifted to a new approach involving the over-expression of 
these genes in ESCs. In this regard, over-expression of Nurr1, Pitx3, Lmx1a and 
Lmx1b lead to the production of large numbers of DA neurons in vitro
84–86
. More 
recently, inhibition of certain pathways has directed the production of large number 
of neuronal populations in culture from ESCs. For example, disruption of the FGF 
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signalling pathway has been reported to increase the numbers of DA neurons in vitro 
(this will be discussed in detail in Chapter 6)
87
. 
1.4.2.1.2 Human embryonic stem cells  
The early studies with mESCs lead to the isolation of ESC lines from primate 
models
88
 and humans
89
. However, differences between mESCs and hESCs became 
apparent; discussed in detail in Chapter 6. Over-expression of transcription factors 
implicated in DA neuron development was translated to hESCs (via transient 
transfection), to increase the yield of hESC derived DA neurons in culture, which 
included Lmx1a, Nurr1 and Pitx3
90,91
. Recent research showed that inhibiting certain 
molecular pathways, such as the Contraction of Sma and Mad (Mothers against 
decapentaplegic) pathway (involved in TGFβ signalling), resulted in the rapid 
conversion of hESCs to a neural fate under in vitro culture conditions
92
. Thus, these 
important studies demonstrated that the ability to reproduce and reliably generate 
DA neurons in vitro from an ESC source was possible.  
1.4.2.2 Epiblast stem cells 
Recent research found that epiblast stem cells (EpiSCs) provide a more efficient and 
developmentally-suitable source of pluripotent stem cells for neural induction in 
vitro, and moreover for efficiently directing nigral and striatal neuronal phenotypes 
in vitro (reviewed in detail in Chapter 6). Jaeger and colleagues found that EpiSCs 
provide a more accelerated DAergic neural differentiation protocol over ESC 
differentiation methods
87
.  
1.4.2.3 Patient-specific reprogrammed cells  
In light of the limitations associated with hfVM tissue and ESCs, research has also 
been conducted to investigate patient-specific derived neurons as a potential cell 
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source which would circumvent some of the key challenges. Studies aimed to 
reprogramme patients’ somatic cells i.e. skin fibroblasts to a stage of pluripotency 
before directing their conversion to iPSCs and subsequent differentiation to DAergic 
neurons. In 2006, Yamamaka and associates reprogrammed adult somatic cells to an 
ESC-like state by applying four defined factors; Oct 3/ 4, Sox2, c-myc and Klf4. 
These somatic cells were then converted by retroviral transduction to a pluripotent 
cell type (i.e. iPSC)
93
. iPSCs are not as restricted by ethical issues to the same extent 
as human ESCs and hFVM tissue and avoid the risk of immune rejection and 
subsequent immunosuppressive therapy following autologous transplantation.  
However, a number of issues need to be addressed if this stem cell type is to be 
clinically translated as a PD treatment, owing to the fact that iPSCs derived from PD 
patients are associated with the prevalence of mutations, polymorphisms or 
epigenetic marks, making them more susceptible to the occurrence of PD-like 
features
94
. In addition to this, c-myc and Klf4 linked to oncogenic activity and viral 
vectors integrated into the genome increase the risk of tumour formation and 
mutations.  
 
1.4.2.4 Fetal Brain Neural Stem Cells  
Fetal brain neural stem cells (NSCs) are classified as multipotent stem cells due to 
their restricted ability to differentiate only into neural phenotypes, i.e. neurons, 
astrocytes and oligodendrocytes. This cell type can be obtained directly from an 
affected PD patient, therefore eradicating risks associated with graft or immune 
rejection and tumour formation
95
. Early studies using non-differentiated NSCs 
derived from human tissue transplanted into rat models showed limited 
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differentiation capabilities in vivo. Similarly, translational studies in primate models 
highlighted the restricted abilities of the NSC progeny to differentiate into DAergic 
neuronal cell types
62
. However, it should be noted that Shh and Wnt5a signalling did 
increase DAergic cell yield from differentiated NSCs in vitro
96
. Advanced 
differentiation protocols will need to be devised in order to produce specific cell 
types from NSCs and establish improved homogeneity between grafts.  
1.4.2.5 Bone marrow-derived stromal cells and mesenchymal stem cells  
Bone marrow-derived stromal cells and mesenchymal stem cells (MSCs) comprise a 
small population of cells localised in the bone marrow with the capacity to give rise 
to adipocytes, chondrocytes and osteoblasts, both in vitro and in vivo
62
. TH
+ 
neurons 
generated from non-differentiated murine MSCs were shown to enhance motor 
performance in mice models
97
. Similar results were observed in MSC-derived 
DAergic neurons obtained from both rats and human samples post-transplantation in 
PD animal models
98
. In 2010, an open-labelled clinical trial utilising unilateral 
autologous MSCs transplanted into the sublateral ventricular zone in PD patients 
exhibited no adverse effects after 12 months of receiving the transplantation; 
however only modest clinical improvement was observed in human participants
99
.  
1.5 Vitamins  
A number of key antioxidants, specifically the biologically active metabolites of 
vitamins including vitamin A (RA), vitamin C (AA) and vitamin D3 (calcitriol) 
known to play crucial roles in embryonic development, particularly in mDA 
neuronal development, have successfully been applied in vitro to control cell 
differentiation. This section will summarise unique roles for these vitamins 
throughout the CNS and most importantly their functioning in stem cell 
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differentiation and transplantation. Finally, similar possibilities for nicotinamide, the 
vitamin B3 metabolite will be discussed, with implications for potential neuronal 
replacement therapies.  
1.5.1 Calcitriol 
1.5.1.1 The role of calcitriol in the central nervous system 
Calcitriol is the hormonally active metabolite of fat-soluble vitamin D. The vitamin 
D receptor (VDR) protein is widely expressed throughout human and rat brains and 
specifically in the BG, pontine-midbrain area, cerebellum, thalamus, hypothalamus, 
hippocampus and olfactory system
100
. VDR is present in most neurons and some 
glial cells, with robust expression levels observed in SNpc DAergic neurons
101
. This 
receptor is significantly increased during CNS development, notably during 
gestation periods (day 12-21) in the rodent brain, with expression levels 
preferentially localised in areas of cell proliferation, neuroepithleium and 
differentiating fields
102
. Interestingly, raised VDR expression at E18 in the rat brain 
corresponds to increasing apoptosis and a reduction in mitosis, suggestive of a role 
in the maintenance of normal brain functioning
103
.  
In 2010, Orme and colleagues performed multiplexed quantitative proteomic 
analysis of the embryonic midbrain to investigate and identify signalling proteins 
governing neuronal differentiation, maturation and survival in E11-14 tissue. VDR 
was one of the candidate signalling proteins expressed in developing midbrain tissue 
at E12 (critical time point in the development of mDA neurons), therefore suggesting 
a function for vitamin D during DAergic neuron specification.  
 
1.5.1.2 The role of calcitriol during cell differentiation 
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Orme et al investigated the role of the vitamin D3 metabolite, calcitriol, in primary 
culture differentiation. Primary E12 VM cultures treated with calcitriol elicited a 
dose-responsive increase in the number of DAergic neurons. This study showed that 
the increase in number of DA neurons was directly attributable to a calcitriol-
induced increase in GDNF expression
104
.  
Specifically, the role of the neurotrophic factor GDNF as a neuroprotective agent 
during both embryonic development and against various forms of neuronal insults 
has been validated in a number of in vitro and in vivo studies, and has been long 
acknowledged to confer neuroprotection to mDA neurons
104–106
. The active 
metabolite of vitamin D3 is a potent inducer of GDNF expression
107,108
. Unlike 
GDNF, vitamin D3 has the ability to cross the BBB, suggesting a potential 
neuroprotective function for this compound against neuronal injury.  
Wang et al found that VM primary rodent cultures pre-treated with vitamin D3, 
induced neuroprotection of VM-derived neurons against 6-hydroxydopamine (6-
OHDA) or hydrogen peroxide (H2O2)-induced cell death in vitro. This group also 
found that administration of vitamin D3 significantly improved peak locomotor 
activity and normalised SNpc DA neurons and its metabolites in lesioned 6-OHDA 
animal in vivo, an effect possibly mediated via a GDNF mechanism
109
.  
1.5.2 Retinoic acid 
1.5.2.1 The role of retinoic acid in the central nervous system 
RA is a well known endogenous morphogen with important roles in the patterning of 
the CNS and neuronal differentiation. Specifically, this vitamin metabolite functions 
in the anteroposterior and dorsoventral patterning of the neural plate and neural tube. 
Newly formed somites in the dorsoventral axis of the developing neural tube are 
responsible for generating RA during development, along with other factors, such as 
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Shh and FGFs, which play fundamental roles in determining cell fate of subsets of 
sensory neurons, interneurons and motor neurons
110
. With regards to PD research, 
there is evidence for the functioning of RA at late development, with a suggested 
role in the establishment of appropriate mDA identity
111
. 
 
1.5.2.2 The role of retinoic acid during cell differentiation 
RA has successfully been applied to a number of in vitro differentiation protocols 
including neuronal and retinal protocols
112–114
. The binding of RA to the retinoic acid 
receptor (RAR) and retinoid X receptor (RXR) stimulates the transcription of tissue 
specific genes resulting in cellular differentiation
115
. RA functions cooperatively 
with signalling proteins such as Shh and FGFs to improve the regional identity of 
progenitor cells derived from human ESCs
116
.  
With respect to PD, high levels of RA signalling functions in the striatum. DAergic 
neurons localised throughout the nigrostriatal circuit contain high levels of 
retinaldehyde dehydrogenase family 1 gene (RALDH1), potentially generating RA 
in axonal terminals which in turns functions in an autocrine manner on 
neurotransmission or alternatively in a paracrine fashion on striatal cells. The 
DAergic receptor gene, D2 contains a functional retinoic acid response element 
(RARE), which is strongly activated by a RARα-RXRγ heterodimer. Nurr1 is an 
example of another heterodimeric partner of the RXRs; proving a clear role for RA 
signalling in the normal functioning of the nigrostriatal circuitry
115
. 
 
1.5.3 Ascorbic acid 
1.5.3.1 The role of ascorbic acid in the central nervous system 
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Vitamin C and its metabolite AA are highly concentrated throughout the CNS, and 
function as antioxidative agents to maintain the normal functioning of brain 
structures. High levels of vitamin C are necessary in the brain to deal with elevated 
levels of oxidative stress
117,118
. Along with its neuroprotective role in the CNS, 
vitamin C is a cofactor in several enzymatic reactions including the synthesis of 
catecholamines
119
, along with a specific role in promoting Schwann cell myelination 
in the PNS
120
.  
The foetal rodent brain exhibits high levels of vitamin C expression; and levels have 
been reported to double between gestation day 15-20 before decreasing significantly 
prior to birth
121
. Indeed, amongst all organ systems, the highest concentrations of AA 
are attained in neural tissue, which may be attributable to the existence of an AA-
transporter system in neurons, necessary for regulating the steep intra/extracellular 
concentration gradient
122
. Notably,  high concentrations of AA are found in forebrain 
structures including the neostriatum, a structure abundant in DA terminals with 
evidence suggesting that the SN plays a crucial role in governing the release of AA 
in the neostriatum.  
 
1.5.3.2 The role of ascorbic acid during cell differentiation 
High levels of SVCT2, the vitamin C transporter are expressed in CNS precursors 
and embryonic mesencephalic neurons, implying a direct effect on the process of 
DAergic differentiation
123
. Vitamin C has been used to modulate stem cell 
transplantation. A number of studies showed that stem cells treated with AA could 
direct differentiation into increased numbers of DAergic cells
124–126
. Incubation of 
mouse or human somatic cells with vitamin C generates an increase in the induction 
of stem cells, mediated in part by regulation of histone demethylase activity, a family 
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of enzymes necessary for Nanog expression (a master transcription factor for self-
renewal of undifferentiated ESCs)
127
. However, AA has been reported to elicit a 
“double edged sword” effect in a study carried out by Bagga et al, where low 
concentrations of AA had no effect on neuronal numbers and high concentrations 
were linked to neuronal cytotoxic effects
124
.    
The anti-oxidative properties of vitamin C have been shown to eliminate free radical 
accumulation generated by both the endogenous tissue and transplanted exogenous 
stem cell-derived neurons
122
. Bagga et al further demonstrated significantly higher 
numbers of surviving DAergic neurons in grafts treated with AA, compared to 
control treatment groups
124
. Similar findings were described by Agrawal and 
colleagues, who used AA glutathione in combination, to significantly enhance 
DAergic neuronal survival post transplantation
128
. The potential of this vitamin to 
significantly reduce apoptosis and moreover, directly favour stem cell generation and 
differentiation towards a DAergic lineage make ascorbic acid an attractive co-
adjuvant to accomplish a CRT for PD. 
 
1.5.4 Nicotinamide 
Nicotinamide, the amide form of niacin (vitamin B3), is classified as a water-soluble 
B complex vitamin. Sources of nicotinamide are obtained from the diet and from the 
metabolism of endogenous tryptophan, an essential amino acid. Catabolism of the 
active component of nicotinamide is primarily via N-methylation to N-methyl 
nicotinamide (main excretory product) by the xenobiotic enzyme nicotinamide N-
methyltransferase (NNMT). Remaining nicotinamide produces two important co-
enzymes; nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine 
dinucleotide phosphate (NADP), implicated in over 200 enzymatic reactions.
129
 This 
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compound is integral for the formation of mitochondrial ATP along with other 
various neuroprotective and anti-oxidant roles
130
.  
1.5.4.1 The role of nicotinamide in the central nervous system 
Nicotinamide can cross the BBB to the CNS via an active transporter. In the CNS, 
nicotinamide regulates neuronal and vascular cell populations following brain injury. 
In the early stages of developing cerebral infarction in the ischemic brain, decreased 
levels of NAD
+
 are observed, preceding neuronal apoptosis. Interestingly, 
administration of nicotinamide 1-2 hours post ischaemia increased brain NAD
+ 
levels and mitigated necrotic and apoptotic brain injury following focal brain 
injury
131
.  
With relevance to PD, NADH is fundamental for the normal functioning of 
mitochondrial complex 1, which is well established to be defective in MPTP 
Parkinsonism
132
 and idiopathic PD
133,134
. NADH is also integral to the production of 
tetrahydrobiopterin
135
, a co-factor necessary for TH, the rate limiting enzyme in 
catecholamine biosynthesis, also deficient in PD. NADH is also linked to reduced 
glutathione, an important anti-oxidant shown to be insufficient at the early stages of 
PD
129,136
.  
 
1.5.4.2 The role of nicotinamide during cell differentiation  
Historically, experimental research dating from the 1970s depicted a role for 
nicotinamide, the active form of vitamin B3 to function as a morphogen during the 
process of differentiation to influence cell fate specification. A morphogen is defined 
as a signalling molecule which directly influences specific cellular responses based 
on its local concentration. In this context, experiments conducted by Caplan and 
Ordahl, showed that intracellular NAD played a fundamental role in directing the 
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choice of cell fate between muscle or cartilage phenotypes. Interestingly, they found 
that internal pool sizes of NAD localised within the limb mesenchymal cell nucleus 
were directly influenced by extracellular concentrations of its precursor 
nicotinamide. The choice mechanism regulating the differentiation of cartilage 
versus muscle lineages was linked to distinct high internal concentrations of NAD 
promoting muscle differentiation and low internal NAD levels determining a bone-
like phenotype characterised by chondrogenic expression
137
.  
Consistent with the functioning of other vitamins and their metabolites to effectively 
direct stem cell differentiation to appropiate cell fates, nicotinamide has also been 
shown to promote efficient differentiation of pluripotent stem cells toward specific 
cell populations (detailed account provided in Chapter 3). In addition, Maiese et al 
found that nicotinamide increased cell survival and functions as a neuroprotective 
agent in vitro
138
. Nicotinamide is an inhibitor of Poly-ADP-Ribose (PARP), an 
enzyme implicated in DNA repair and cell death leading to depletion of both NAD
+
 
and ATP. Inhibition of PARP by nicotinamide can protect cells from oxidative 
stress, in addition to apoptosis and necrotic forms of cell death, and influences DNA 
degradation via a number of cell pathways encompassing PARP, Akt, forkhead 
transcription factor, mitochondrial membrane polarization, cytochrome C and is an 
inhibitor of caspase-1, caspase-3 and caspase-8
136
.  
In animal models of PD, nicotinamide demonstrated neuroprotective properties by 
attentuating striatal DA depletion and nigral cell loss in acute MPTP-treated 
animals
139
, and significantly enhanced locomotor activity and protected DAergic 
neurons against MPTP induced neurodegeneration
140
. Thus nicotinamide may 
potentially offer new therapeutic strategies, as a neuroprotective agent for 
neurodegenerative disorders of the CNS
141
. In this regard, there is an active uptake 
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mechanism for nicotinamide in the brain and following systemic administration, this 
vitamin metabolite is evenly distributed throught brain tissue. 
1.6 Aims and strategies of the project.  
During neural development, the specification of neurons, their maintenance, axonal 
elongation and connectivity with other neurons requires complex signalling cascades 
that are both spatially and temporarily restricted. These signalling cascades can be 
either internal to developing neurons or exogenously triggered by small molecules. 
Such exogenous signals include vitamins and their active metabolites. Vitamins are 
small organic molecules required throughout development and life. Until recently 
very little research has been undertaken into nicotinamides role in neural 
development or idiopathic Parkinson’s disease. This project aims to investigate the 
influence of nicotinamide on the development and function of neurons during early 
embryonic development. The research aims can be described in detail as follows:  
i. Maintain mESCs in an undifferentiated state using LIF (made in house). 
ii. To determine whether the biologically active vitamin B3 metabolite, 
nicotinamide, could direct the differentiation of mouse embryonic stem cells, 
cultured as monolayers, into neurons at either early or late stages of development. If 
yes, what is the mechanism responsible for nicotinamide-mediated change in cell 
fate? 
iii. Does nicotinamide treatment influence the proportion of undifferentiated 
and/or neural progenitor cells in culture? 
iv. Does nicotinamide preferentially influence specific cell types?  
v. To generate epiblast stem cells.  
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vi. To investigate whether nicotinamide administration to these epiblast cells 
potentiates the generation of dopaminergic neurons. 
 
Detailed descriptions of the chapter objectives are stated at the end of the 
introductions to each experimental chapter. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
All reagents used throughout this study were purchased from Sigma, UK, unless 
specified otherwise (media and solution components are detailed in Appendix 2).  
2.1.1 Maintenance of undifferentiated mESCs with Leukaemia Inhibitory 
Factor 
2.1.1.1 Maintenance of HEK293 Cell Line 
The human embryonic kidney (HEK) 293 cell line (a kind gift from Dr. Mark 
Pickard, School of Life Sciences, Keele University, UK) was used for the production 
of leukaemia inhibitory factor (LIF), required to maintain undifferentiated mESCs in 
vitro. The HEK cell line has been reported to provide a robust and reliable platform 
for gene delivery in in vitro biological studies
142
. HEK cells were cultured on a T25 
culture flask in RPMI-HEK medium comprising RPMI-1640 medium supplemented 
with 10% foetal calf serum (FCS) (Biosera, UK) and 4 mM L-glutamine. HEK cells 
were passaged once they reached a confluency of approximately 90-100% (Figure 
2.1). RPMI-HEK medium, 0.025% trypsin solution and phosphate buffered saline 
(PBS) were pre-warmed to 37°C in a water bath for 1 hour (h). RPMI-HEK medium 
was aspirated and cells were washed briefly with 5 ml PBS. Trypsin (0.025%; 1 ml) 
was evenly distributed over the surface of the culture flask and detached cells were 
centrifuged, and then re-suspended in fresh medium. Cells were split 1:5 every 2 
days in 5 ml RPMI-HEK medium and maintained at a temperature of 37°C and CO2 
level of 5.0%. All cell cultures described in this chapter were grown under these 
conditions.  
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Figure 2.1 Representative image of HEK293 cell line. HEK cells were passaged 
once they reached a confluency of approximately 90-100%, indicated in the 
brightfield image. Scale bar = 100 µm 
 
2.1.1.2 Transfection reagent optimisation study  
A transfection optimisation experiment was conducted using FuGENE
®
 HD 
(Fugene) (Promega, Southampton, UK) and X-tremeGENE HP DNA Transfection 
Reagent (X-tremeGENE) (Roche, West Sussex, UK), to accomplish the highest 
transfection efficiency for gene delivery into HEK adherent cells. For this 
comparative study, the plasmid pmaxGFP coding for green fluorescent protein 
(GFP) (size 3.5kb; Amaxa Biosciences, Cologne, Germany) was used to determine 
transfection efficiency (Figure 2.2).  
One day prior to transfection, HEK cells were passaged and plated at a density of 1.6 
x 10
5
 cells per well of a 24-well plate, in 500 μl RPMI-HEK medium, in accordance 
with the transfection reagent manufacturers’ guidelines. It is important to point out 
that experiments were conducted in the absence of antibiotics in medium, due to 
their adverse effects on transfection
143
. After overnight culture, different ratios 
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(volume) of Fugene and X-tremeGENE to pmaxGFP plasmid were tested in 
accordance with the manufactures’ guidelines and recommendations (Table 2.1 and 
2.2).  
Table 2.1 Transfection optimisation: Fugene 
pmaxGFP 
Plasmid (0.55 µg) 
Sterile deionized 
water 
Ratio FuGENE
®
 HD 
 (µl) 
1.1 µl 25.75 µl 3:1 1.65 µl 
1.1 µl 25.75 µl 2:1 1.1 µl 
1.1 µl 25.75 µl 4:1 2.2 µl 
Table 2.2 Transfection optimisation: X-tremeGENE  
pmaxGFP 
Plasmid (0.55 µg) 
Sterile deionized 
water 
Ratio X-tremeGENE 
(µl) 
1 µl 49 µl 1:1 0.5 µl 
1 µl 49 µl 2:1 1 µl 
1 µl 49 µl 3:1 1.5 µl 
1 µl 49 µl 4:1 2 µl 
Table 2.1 and Table 2.2 Different ratios of Fugene and X-tremeGENE to pmaxGFP 
plasmid were tested for the transfection reagent optimisation study, in line with the 
manufactures’ guidelines and recommendations.  
 
The following day, transfection levels were determined by examining cultures using 
fluorescence microscopy and brightfield microscopy. Brightfield microscopy 
demonstrated that both reagents tested were not toxic to HEK cell cultures (Figure 
2.2). The highest level of transfection was achieved in the presence of 1.65 µl 
Fugene in combination with 0.55 µg pmaxGFP, in comparison to X-tremeGENE 
which was not as potent for gene delivery [Figure 2.2 (A-B)]. In conclusion, these 
findings suggested that Fugene was an appropriate reagent to transfect HEK cells for 
LIF production, to maintain undifferentiated mESC in a pluripotent state.  
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Figure 2.2 Transfection reagents were optimised using HEK 293 cells with 
pmaxGFP, prior to LIF production (A&B) Representative images showing 
brightfield, GFP fluorescence and merged images.  Scale bars = 100 μm. (A) The 
highest level of transfection was achieved in the presence of 1.65 µl Fugene in 
combination with 0.55 µg pmaxGFP, in comparison to X-tremeGENE, which was 
not as potent for gene delivery (B). (A&B) Healthy HEK 293 cells maintained their 
morphology once transfected. 
 
2.1.1.3 Transfection of HEK Cells for LIF Production 
HEK cells were plated onto 6-well plates (1.6 x 10
5
 cells/well; 2.5 ml RPMI-HEK 
medium). The following day, human LIF cDNA (made in house by Dr. Eunju Shin, 
School of Life Sciences, Keele University, UK) and Fugene
 
were used to transiently 
transfect HEK cells for LIF production. For transfection complex preparation, 772.5 
µl sterile deionized water and 49.5 µl Fugene
 
were mixed gently. After 5 min, 12 µg 
(33 µl) Human LIF cDNA was carefully pipetted directly into the mixture and 
incubated at room temperature (RT) for 10 minutes (min). Transfection complexes 
were then added in a dropwise manner to HEK cells per well, gently swirling the 6-
well plate to ensure even distribution over the entire well surface and cultured 
overnight.  
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The following day, medium was replaced in each well with 2.5 ml RPMI-HEK 
medium. Following a 4 day culture period, RPMI-HEK medium was collected and 
centrifuged at 1200 rpm for 5 min and the supernatant collected. The supernatant 
was centrifuged again and filter-sterilised using a 0.22 µm filter (Millipore, Watford, 
UK).  
2.1.1.4 Titration of LIF 
A titration assay was used to determine the concentration of LIF required to maintain 
pluripotent 46C Sox1GFP mESCs (a kind gift from Professor Meng Li, 
Neuroscience and Mental Health Research Institute, Cardiff University, UK) in an 
undifferentiated state. 46C mESCs were plated in a 24-well plate at a density of 10
4
 
per well in 1 ml FCS medium. Cells were allowed to settle in an incubator for 
approximately 4 h. Medium was replaced with fresh LIF medium, which was serially 
diluted across the plate (Table 2.3). For control wells, FCS medium supplemented 
with stock LIF (made in house by Dr. Eunju Shin) or no LIF was added to the last 4 
wells of the plate. mESCs were incubated for 4 days.  
Table 2.3 Serial diluted LIF medium. The first well had 1500 µl of 1/40 diluted 
new LIF/FCS medium. FCS medium (750 µl) was placed in the rest of the wells. 
Medium from the first well (750 µl) was then transferred to the second well and 
mixed well. This was repeated until the 5
th
 well from last.  
 
Table 2.3 Serial diluted LIF medium 
1/40 1/80 1/160 1/320 1/640 1/1280 
1/2560 1/5120 1/10240 1/20480 1/40960 1/81920 
1/163840 1/327680 1/655360 1/1310720 1/2621440 1/5242880 
1/10485760 1/20971520 No LIF No LIF Stock LIF Stock LIF 
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To determine the titrated LIF concentration, medium was aspirated and 0.5 ml 
Leishman’s solution was added to each well for a 5 min incubation. Each well was 
rinsed with sterile deionized water for 1 min. Water was aspirated from each well 
and plates air-dried. mESC morphology was analysed by holding the plates over 
white paper for observation. Distinct morphological differences exist between 
undifferentiated and differentiated mESC. Undifferentiated pluripotent 46C cells 
form intensely stained small compact colonies which are tightly packed. Cells 
undergoing differentiation in the absence of LIF appear as larger and faintly stained 
colonies (Figure 2.3). 
Positive and negative LIF controls were observed to specify the limiting dilution of 
LIF. The highest level of inhibition of differentiation was considered as 1 U/ml. The 
stock concentration of LIF was determined at 100,000 U/ml, since the final 
concentration of LIF required is 100 U/ml (allows for dilution between stock and 
final of 1:1000). Aliquots containing the relevant amount of LIF concentration were 
stored at 20°C, until required.   
Figure 2.3 Leishman stained mESC colonies under various culture conditions. 
(A&B) 46C mESCs incubated with LIF maintained cells in an undifferentiated 
pluripotent state. Cells appeared as small rounded intensely stained colonies. (C) The 
absence of LIF induced cell differentiation, indicated by the appearance of larger, 
spread-out and weaker stained colonies. Scale bar = 100 µm.  
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2.1.2 Embryonic Stem Cell Culture 
ESCs were cultured in Glasgow Modified Eagles Medium (Invitrogen, UK) with the 
addition of 10% FCS, 0.1 M β-mercaptoethanol, 1 mM L-glutamine, 10 mM non-
essential amino acids, 100 mM sodium  pyruvate and 100 U/ml LIF (detailed in 
appendix 2).  
2.1.2.1 Thawing 
A cryotube of frozen 46C-derived mESCs was rapidly thawed in a water bath heated 
to 37°C, until a small amount of ice remained. Pre-warmed FCS/LIF medium was 
added to thaw the remainder of the vial.  Cells were centrifuged at 1200 rpm for 3 
min. The supernatant was aspirated and cell pellets were re-suspended in warm 10 
ml FCS/LIF in a 0.1% gelatin-coated T25 flask.  
2.1.2.2 Passage 
The 46C mESC line was routinely cultured at a constant plating density of 1 x 10
6
 
cell/cm
2  
and passaged every 2 days, when cells reached approximately 80% 
confluency. Prior to passaging, FCS/LIF medium, 0.025% trypsin solution and PBS 
were pre-warmed to 37°C in a water bath for 1 h. Gelatin solution (0.1%) was used 
to coat a new T25 culture flask. FCS/LIF medium was aspirated from a confluent 
T25 flask and the culture was washed twice with 5 ml PBS. Trypsin (1 ml) was 
evenly dispersed in the culture flask for 1 min at 37°C. Once undifferentiated cells 
exhibited round morphologies, observed using phase contrast microscopy, the flask 
was tapped gently by hand to detach the cells. FCS/LIF (5 ml) medium was added to 
the flask and transferred to a sterile universal centrifuge tube. Cells were centrifuged 
at 1200 rpm for 3 min. The supernatant was aspirated and cells were re-suspended in 
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2 ml FCS/LIF. A 1 ml blue pipette tip was used to carefully dissociate cell clumps 
into a single cell suspension. Cell viability and counts were performed using trypan 
blue (Invitrogen, Paisley, UK) and a haemocytometer. Undifferentiated
 
mESCs (10
6
) 
were plated in 10 ml FCS/LIF and stored in a 5.0% CO2 incubator at 37°C.  
2.1.2.3 Freezing 
The same steps were followed as in 2.1.2.2, as far as the cell viability check. Instead 
of plating cells in flasks, the supernatant was aspirated and cell pellets were diluted 
in 10% dimethyl sulfoxide (DMSO) in FCS/LIF medium. 2 x 10
6
 cells in 800 μl 
were aliquoted into cryotubes and placed in a cryochamber at -80°C overnight, 
before transfer to liquid nitrogen for long-term storage.  
2.1.3 In vitro Neural Differentiation of mESCs 
2.1.3.1 Monolayer Differentiation  
For neural induction, undifferentiated mESCs were plated at a density of 9 x 10
4 
cells/cm
2
 per well of a 0.1% gelatin-coated 6-well dish (day 0).  N2B27 serum-free 
medium (5 ml; appendix 2), was added to each well. Medium was refreshed every 
alternate day.  
Cells differentiated up to a total of 14 days of the monolayer culture period, were 
washed twice with 5 ml pre-warmed PBS. Trypsin solution (2 ml)was added to each 
well of the 6-well dish to detach the cells and incubated at 37°C for approximately 1 
min. Cells were re-suspended in 10 ml FCS/LIF and centrifuged at 1200 rpm for 3 
min. The supernatant was removed and N2B27 medium was added to the pellet and 
thoroughly pipetted to dissociate cells. Cell viability was observed and cell counts 
were calculated. Single cells (3x10
4) were replated in 30 μl N2B27 medium on 13 
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mm glass coverslips pre-treated with poly-L-lysine (PLL) (10 µg/ml) and laminin (2 
µg/ml) in 24-well plates. Laminin was aspirated from wells prior to cell plating. 
Following an overnight incubation, wells were flooded with 500 µl N2B27 medium 
and medium was refreshed every other day until day 14.  
2.1.4 Epiblast Stem Cell Culture 
2.1.4.1 Generation of epiblast stem cells from 46C-derived mESCs 
Mouse Epiblast stem cells (mEpiSCs) were generated from 46C Sox1GFP cell line. 
To begin establishing EpiSC cultures from mESCs, the same initial steps were 
followed described in section 2.1.2.2.  
Briefly, once undifferentiated 46C cells reached 80% confluency in a T25 culture 
flask, medium was aspirated and cells were rinsed with pre-warmed PBS. Trypsin 
solution was added to mESCs, and the enzymatic action was quenched with feeder 
media. mESCs were transferred to a sterile universal centrifuge tube and centrifuged 
at 1200 rpm for 3 min. The supernatant was aspirated and cells were re-suspended in 
2 ml PBS solution. Cell clumps were gently dissociated into a single cell solution 
using a 1 ml blue pipette tip and counts were manually performed using trypan blue 
and a haemocytometer.  
Undifferentiated
 
mESCs (500,000 cells) were plated in 3 ml FCS/LIF per well of a 
0.1% gelatin coated 6-well culture plate. mESCs were incubated overnight at 37°C. 
The following day once cells reached 60-70% confluency, mESC medium was 
aspirated from each well and cultures rinsed twice with pre-warmed PBS solution. 
EpiSC medium (2 ml; appendix 2) was added to each well and cells incubated 
56 
 
overnight at 37°C. The following day, cells reached approximately 90-100% 
confluency.  
A 6-well culture plate were coated with FCS for 30 min at 37°C. Wells were washed 
with PBS and 3 ml EpiSC culture medium was added to each well. EpiSCs are 
typically split 1:1, 1:2 and 1:4 every 2 days (the density at which EpiSCs are 
generated is very important, detailed in section 6.3.4). One well was chosen to be 
passaged by observing morphology of the cells in the optimal dilution. EpiSCs were 
rinsed briefly with 1 ml PBS. The rinse was repeated once more with 1 ml PBS and 
incubated for 2 min at 37°C. The PBS wash was aspirated and replaced with 1 ml 
pre-warmed EpiSC medium. Cell colonies were scratched and triturated using a 2 ml 
sterile plastic pipette and cells were plated at three different densities in 2.5 ml 
EpiSC culture medium per well of a 6-well plate and incubated at 37°C.  
2.1.4.2 In vitro Neural Differentiation of Epiblast Stem Cells  
At day-1, a 6-well plate was coated with fibronectin (30 μg/mL – stock solution 2 
mg/mL), for 30 min at 37ºC. Cells were passaged and allowed to reach 
approximately (~) 50-60% confluency at day 0. EpiSC medium was aspirated from 
each well and cultures were rinsed twice with PBS. EpiSC retinol-free N2B27 
medium (2 ml; appendix 2) was added to each well. At day 2, cells were passaged 
(detailed in 2.1.4.1) and transferred to a 12-well culture plate. Medium was changed 
every alternate day, until day 14 of differentiation.  
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2.1.5 Immunocytochemistry 
2.1.5.1 Immunocytochemistry using fluorescent antibodies 
Differentiated cells were fixed with 4% paraformaldehyde (PFA) for 20 min at 4°C. 
Fixed cells were washed three times with Tris buffered saline (TBS; appendix 2) for 
5 min. Cells were blocked against non-specific binding and permeabilised with 
0.02% Triton X-100 and 5% normal goat serum (NGS) (PAA, The Cell Culture 
Company, Somerset, UK), for 1 h at RT. Primary antibodies (detailed in appendix 3) 
diluted in 1% NGS blocking buffer were added to cultured cells overnight at 4°C. 
Negative primary controls consisted of cells treated with blocking buffer without the 
addition of primary antibodies.  
The next day, 3 TBS washes were applied to the cells for 5 min followed by 
incubation with fluorescent dye-conjugated secondary antibodies (appendix 3), 
diluted to 1:300 in 1% NGS blocking buffer, for 2 h at RT. Cultures were washed 
three times with TBS for 5 min. Coverslips were mounted onto the slides using 
Vectashield hardset mounting medium with 4', 6-diamidino-2-phenylindole (DAPI) 
(Vector Labs, Peterborough, UK) to counterstain cell nuclei before visualisation the 
following day.  
2.1.5.2 Primary antibody optimisation 
Experimental procedures involving animals were conducted with strict adherence to 
guidelines outlined by the UK Animals, Scientific Act, 1986. At E15, dissection, 
tissue collection and cell viability counts of striatal and lateral ganglionic eminence 
(LGE) tissue were carried out by Munyaradzi Kamudzandu (School of Life Sciences, 
Keele University). 
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With respect to culturing of dissected tissue, sterile 13 mm glass coverslips were 
placed in individual wells of 24-well plates and treated with 410 µl PLL (10 µg/ml) 
and laminin (5 µg/ml) solution. Dissociated cells (3x10
4) were plated in 30 μl 
primary culture medium (appendix 2) as drop cultures for 4-6 h to facilitate cell 
adherence. Wells were flooded with 500 µl medium, and following 72 h, an 
additional 500 µl was added to the wells. Medium was refreshed every 3 days and 
primary cells were maintained in a 5.0% CO2 incubator at 37°C. The same steps 
were followed in section 2.1.5.1. for antibody optimisation using 
immunocytochemistry with fluorescent antibodies. 
2.1.6 Cell proliferation assay 
To determine the proliferative effect of nicotinamide on ESC-derived cells, a Click-
iT® EdU (5-ethynl-2’-deoxyuridine) cell proliferation assay (Invitrogen, Paisley, 
UK) was used, in accordance with the manufacturer’s instructions.  
Briefly, adherent monolayer cells were pulsed with EdU (10 μM) for 1 h prior to cell 
fixation. It is important to point out that the incubation time with EdU is dependent 
on the cell line’s population rate of cell cycle entry and progression (~12 h; personal 
discussion with Professor Meng Li
144
).  
Standard PFA fixation (4% formaldehyde) and detergent permeabilisation (0.5% 
Triton X-100) were required to facilitate access of the detection reagent to DNA. For 
EdU detection, a Click-iT® reaction cocktail (appendix 2) was prepared and applied 
to cells for 30 min. Cells were rinsed with 3% bovine serum albumin (BSA) in PBS 
for 2 min, followed by PBS for 2 min. To perform dual labelling of cultured cells 
with EdU and primary antibodies (appendix 3), cells were blocked and permeabilised 
59 
 
with 0.02% Triton X-100 and 5% NGS for 1 h.   Immunocytochemsitry with 
fluorescent antibodies was then performed as detailed in section 2.1.5.1.  
2.1.7 Apoptotic assay 
The Click-iT® TUNEL Alexa Fluor® imaging assay (Invitrogen, Paisley, UK) was 
employed to assay nuclear DNA fragmentation; an important biochemical indicator 
of apoptotic cell death. Fragmented DNA characteristic of apoptotic cells was 
measured by catalytically integrating fluorescein-12-dUTP at 3´-OH DNA ends, 
where a polymeric tail was formed. This reaction was catalyzed by the enzyme 
Terminal Deoxynucleotidyl Transferase (TdT), generating TdT-mediated dUTP 
Nick-End Labelling.  
Monolayer adherent cells were fixed in 4% PFA for 15 min at 4°C. Cells were 
permeabilised with 0.2% Triton X-100 in PBS for 5 min. Cells were rinsed twice 
with deionized water. TdT reaction buffer was added to each coverslip for 10 min at 
RT. Following this, the TdT reaction buffer was removed, and 100 µl TdT reaction 
cocktail (appendix 2) was added to each coverslip. Coverslips were incubated for 60 
min at 37°C, avoiding exposure to light sources. Cells were rinsed with 3% BSA in 
PBS for 2 min. A Click-iT® reaction cocktail (100 µl) was added to each coverslip 
for 30 min at RT, protected from light. Cells were rinsed with 3% BSA in PBS for 5 
min. To perform dual labelling, cells were blocked and permeabilised with 0.02% 
Triton X-100 and 5% NGS for 1 h.   Immunocytochemsitry with fluorescent 
antibodies was then performed as detailed in section 2.1.5.1. 
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2.1.8 Cell Sample Analysis Methods  
2.1.8.1 Fluorescence Intensity Measures  
Fluorescence Intensity (FI) measures were obtained to determine levels of protein 
expression of specific neuronal populations derived from Sox1GFP mESCs, using 
ImageJ image analysis software (version 1.45s; NIH). Cell samples were captured at 
fixed exposure settings using a Hamamatsu ORCA camera with NIS Elements 
imaging software. Undifferentiated and neural cells located in cell clusters were 
excluded from FI analyses. FI values were evaluated by converting each colour 
image to grayscale, calibrated using an FI step tablet and FI readings were corrected 
for the background.  
2.1.8.2 Morphometric Analysis of Neurite Outgrowth 
Neuronal cells were photographed from eight to ten random fields per coverslip from 
three independent experiments using a Hamamatsu ORCA camera equipped with 
NIS-Elements imaging software. Neuronal cells within cell clusters were omitted 
from morphometric analysis. Neuritic branching per cell, length of the longest 
primary neurite and total extent of neurite were analysed to evaluate the effect of 
nicotinamide on neuritic morphology. Neuronal processes greater than two cell 
diameters in length were considered as true neurites and neurites of labelled cells 
were manually traced using the ImageJ plug-in NeuronJ (version 1.4.2; NIF). Neurite 
length was defined as the distance from the soma to the tip of the longest primary 
branch and the combined lengths of all neurites per cell were defined as total neurite 
length. Data obtained represent an average of approximately 50 neurons in each 
treatment group. 
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2.1.8.3 Automated Cell Counter 
A Countess
TM
 automated cell counter was used to automate cell counting in order to 
determine total cell counts and viability; taking into account live, dead and total cells 
differentiated from Sox1GFP reporter mESCs. The automated cell counter used the 
standard trypan blue technique, used for manual cell counting with a 
haemocytometer. For a typical cell count, 10 μl cell suspensions comprising of both 
live and dead cells was added to 10 μl 0.4% trypan blue stain. The cell sample 
mixture (10 µl) was added into one chamber of the Countess
TM
 cell counting 
chamber slide. The image was optimised using a focusing knob to alter the image for 
analysis. Live cells appeared to have a bright centre surrounded by a dark edge, 
whilst dead cells displayed a homogenous blue colour without bright centres.  
2.1.8.4 Manual cell counting and statistical analysis 
Cell samples were analysed using fluorescence microscopy (Nikon Eclipse 80i 
microscope) and images acquired using a Hamamatsu ORCA camera. NIS-Elements 
imaging software, version Br 3.2 was used to manually quantify positive staining in 
DAPI-stained cultures. Independent experiments were replicated three times and 
three to four coverslips per group were counted within an experiment. Specific cell 
populations were analysed by capturing six to eight random fields per coverslip 
(detailed within each experimental chapter). Data obtained represent an average of 
approximately 50 DAPI-labelled cells per field of view.  
Statistical analysis was performed using GraphPad Prism, version 5.00 (GraphPad 
Software Inc.) and data were expressed as mean ± standard error of the mean (SEM). 
Unpaired two-tailed t test was used when comparing two groups. Differences 
between more than two different groups were analysed using one way analysis of 
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variance (ANOVA), and post hoc analysis was carried out using Tukey’s multiple 
comparison test. Differences in p-values less than (≤) 0.05 were considered 
significant.  
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Chapter 3: Effect of Nicotinamide on Neuronal 
Differentiation from Mouse Embryonic Stem 
Cells In Vitro 
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3.1 Introduction 
Currently, a major challenge in advancing stem cell therapies to treat a myriad of 
debilitating brain-related degenerative disorders is to rapidly and efficiently direct 
pluripotent stem cells to differentiate into pure, high yield populations of desired and 
mature neuronal phenotypes
145
. To date, protocols for directing in vitro 
differentiation of ESCs have been established; however, additional purification 
methods to collect homogeneous cell populations are frequently required
146–148
. One 
main reason for such heterogeneity of stem cell-derived populations is that the 
majority of ESCs differentiate asynchronously into lineage-biased subsets, thereby 
generating a chaotic mixture of both undifferentiated and differentiated cells with 
mixed phenotypes within differentiated progenies
149
. Moreover, for a regenerative 
cell population, their high capacity for self-renewal predispose them to tumour 
formation, mostly teratomas or overproliferation of NPCs
150
. In this regard, this 
potential for tumourigenesis may limit future clinical applications of ESC-derived 
transplant populations.  
Methods for replicating the multistep signalling cascade regulating embryonic 
development in vivo have demonstrated great promise in vitro for differentiating 
neurons from ESCs. Protocols for directing lineage-specific differentiation routinely 
add or remove inductive signalling molecules to cell cultures. Vitamins are 
frequently included in differentiation strategies to enhance the in vitro derivation of 
desirable postmitotic cells. The biologically active form of the vitamin is most 
commonly used, as many cells lack the required metabolic enzymes to convert the 
inactive form of the vitamin. For example, the active forms of vitamin A (retinoic 
acid)
116,151–153
 and vitamin C (ascorbic acid)
78,79,87,124,126,154,155
 are commonly 
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included in current studies to drive stem cell differentiation toward desired neuronal 
cell fates.   
Vitamins are well-studied small organic molecules known to be vital in the adult, 
and during growth to support and maintain a healthy brain. They are also well known 
to play crucial roles during early neuronal development in 
embryogenesis
104,124,126,152,156
. Experiments dating from the 1970s depict an 
important role for nicotinamide as a regulator of morphogenesis and cell 
differentiation (i.e. myogenic and chrondrogenic differentiation)
137
. Nicotinamide, 
the amide form of vitamin B3, has since been applied as a differentiation agent to a 
number of protocols to promote differentiation to specific cell populations from 
mESCs
157–159
 and hESCs
160–163
. Interestingly, existing literature suggests a paucity of 
information on the potential of nicotinamide to drive ESC differentiation into neural 
and neuronal populations. Therefore, this experimental chapter sought to determine 
if nicotinamide could influence the conversion of Sox1GFP knock-in mESCs 
undergoing neural differentiation to mature neurons, based on an adherent 
monolayer differentiation protocol developed by Ying and co-workers (Figure 
3.1)
164
.  
46C mESCs harbour a knock-in of GFP to one allele of the neural specification 
marker gene Sox1, which is expressed concomitant with the formation of the neural 
plate in mice
165
.  Sox1 is expressed in neuroepithelial cells. Therefore, the 46C ESC 
cells express GFP under the control of Sox1 upon becoming NPCs, and detection of 
green fluorescence enabled a convenient and facile experimental system to monitor 
and visualise the process of neural specification. This property makes the 46C ESCs 
ideal cells to study in the monolayer culture and differentiation system, particularly 
to evaluate the distinct effects of nicotinamide on self-renewal and terminal 
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differentiation into mature neurons, astrocytes and oligodendrocytes. Furthermore, 
this in vitro culture system also facilitates visual analysis of the morphological 
changes of the ESCs during the course of their differentiation and the effect of 
nicotinamide on this process. A simple and fast protocol was established to:  
I. Maintain 46C mESCs in an undifferentiated state using LIF (made in house). 
  
II. Investigate whether nicotinamide facilitates the generation of higher yields of 
homogenous populations of neurons suitable for transplantation. 
 
 
III. Systematically investigate whether nicotinamide influences the transition 
through stem cell, neural induction and neuronal differentiation of mESCs, 
by evaluating the expression of the pluripotency protein, Oct4, associated 
with tumour forming cells and/or Sox1GFP
+
 NPC populations.  
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Figure 3.1 Schematic diagram illustrating the overall hypothesis and aim of this 
study. Developing strategies to channel the promise of stem-cell-derived neurons for 
future therapies is crucial. Clinical translations of stem cell candidates, such as 
ESCs, can only commence once all the important challenges have been adequately 
resolved and protocols are improved to restrict proliferation linked to tumour 
formation, and to promote differentiation of ESCs to higher and purer yields of 
desired cell phenotypes
145,166
. Current methods for driving stem cell differentiation 
towards clinically-relevant lineages routinely apply small molecules, including 
vitamins A (retinoic acid) and vitamin C (ascorbic acid)
78,79,87
.A number of reports 
also demonstrate that the biologically active metabolite of vitamin B3, nicotinamide, 
efficiently potentiates stem cell differentiation as highlighted in various retinal 
pigmented epithelium (RPE)
161,162
, cardiac
167
 and pancreatic
158
 stem cell 
differentiation studies. The present study, for the first time, thoroughly investigates 
whether nicotinamide could direct neuronal differentiation derived from Sox1GFP 
reporter mESCs, specifically examining its potential across a spectrum of 
developmental stages toward cell-based therapeutics.  
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3.2 Experimental Procedure  
Taking advantage of GFP expression in the Sox1-GFP knock-in 46C cell line, the 
effect of nicotinamide on neural differentiation was investigated over a 14 day 
differentiation period. GFP is undetectable in undifferentiated mESCs, but only 
becomes evident following withdrawal of the cytokine LIF to induce neural 
differentiation [self-renewal capacity of mESC cells is maintained through LIF-
activated signalling
168
; Figure 3.3 (C)].  
3.2.1 Cell culture and nicotinamide treatment  
It is well documented that undifferentiated ESCs commit to a neural lineage when 
cultured in feeder-free adherent monolayers, using serum-free N2B27 medium 
(appendix 2)
164,169
. The latter medium is used because serum acts as a potent 
antagonist of neural differentiation
149
. To induce monolayer neural and neuronal 
differentiation until day 14 in culture, undifferentiated ESCs [approximately 80% 
confluent; Figure 3.3 (B)] were plated on gelatin-coated dishes with N2B27 medium 
for 7 days. On day 7, cells were replated onto coverslips coated with PLL and 
laminin until day 14. Medium was changed every alternate day. To determine an 
appropriate nicotinamide concentration and culture period to potentiate neuronal 
differentiation, nicotinamide was added to the base medium at varying 
concentrations (0.5-20 mM; appendix 2) and cells were treated between days 0 and 7 
or days 7 and 14 (Figure 3.2, Table 3.1). Control groups were not treated with 
nicotinamide.  
Monolayer differentiation studies using the parental 46C-cell line have shown that 
GFP expression driven by Sox1 becomes detectable in cultures at 48 h to 
72 h
149,164,170
. GFP expression appears in approximately 60% of cells after the fourth 
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day of culture
164
; reaching a maximum by the fifth day and remaining at this plateau 
for several days
149
. A slow decline in GFP becomes evident in monolayer cultures at 
day 7 and, by day 8, down-regulation of Sox1 is accompanied by differentiation of 
precursor cells into neurons and glia. Considering this, in further experiments, the 
effect of nicotinamide on the process of neural induction and its influence on NPC 
populations was also investigated. Therefore, two additional culture periods with 
nicotinamide were introduced: day 0 to 2 and day 2 to 7 (Figure 3.2, Table 3.1).   
3.2.2 Immunocytochemistry 
To perform a comprehensive time-course analysis of the effect of nicotinamide on 
the progression through stem cell, neural induction and neuronal differentiation of 
mESCs, immunocytochemistry using fluorescent antibodies, FI measures and 
pluripotent colony area measurements were carried out. Immunocytochemistry was 
performed using primary antibodies against Oct4 (nuclear maker for undifferentiated 
stem cells and determinant of the pluripotent state) and βIII-tubulin (neuron-specific 
cytoskeletal marker); with fluorescence detection of native GFP expression to 
identify the Sox1 expressing cells/progenitor cells (Figure 3.2). Importantly, it should 
be noted that images acquired for FI measurements of GFP
+
 populations were 
captured using equivalent exposure settings across all conditions.  
3.2.3 Image and statistical analysis 
For cell quantification and statistical analysis, cell populations were analysed by 
capturing six to eight random fields per coverslip. Clusters containing mixed 
populations of neural progenitor and neuronal cells were excluded from data 
collection, since these cell networks were not countable. Cell count data were 
averaged across three coverslips per culture and experiments were repeated three to 
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five times (i.e. n = 3–5 independent experiments). All experiments in this chapter 
were statistically interpreted using one-way ANOVA followed by a post-hoc Tukey 
multiple comparison test when required, where more than two independent variables 
were present, and unpaired t test for two conditions. A level of p<0.05 was used as a 
limit for statistical significance. All data are expressed as mean ± SEM. Detailed 
protocols are provided in the Material and Methods chapter.  
 
Figure 3.2 Schematic diagram of time-course analysis of neural and neuronal 
differentiation in the presence of nicotinamide. Exponentially proliferating 
undifferentiated pluripotent stem cells were maintained in FSC/LIF medium from 
passage number 24 to 40 [Figure 3.3 (A)]. For ESC differentiation in adherent 
monoculture, neural commitment and neuronal differentiation is triggered by the 
absence of serum and withdrawal of self-renewal stimulus (i.e. LIF) at day 0. 
Defined culture conditions were established to direct the differentiation of mESCs 
into neuronal cultures. To examine the differentiation potential of the vitamin B3 
metabolite, undifferentiated cells were cultured as monolayers in N2B27 medium in 
the presence of nicotinamide from days 0 to 7 (i.e. early development) or days 7 to 
14 (i.e. late development). The monolayer protocol established by Ying et al 
generates Sox1 expressing cells (neural progenitors) from around day 2 to day 
7
149,164,170
. Therefore, taking advantage of native GFP expression, further studies 
were conducted to investigate whether nicotinamide would influence the conversion 
of Oct4
+ 
undifferentiated stem cells to Sox1GFP neural progenitors and thus drive 
differentiation toward βIII-tubulin+ neurons. The potential of nicotinamide was 
assessed using immunocytochemistry at different monolayer culture periods until 
day 14 (Table 3.1). 
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Experimental Aim Nicotinamide Culture Period Fixation Time 
Effect on Early Neuronal 
Development 
(i.e. Day 0-7) 
Day 0-7 Day 14 
Effect on Late Neuronal 
Development 
(i.e. Day 7-14) 
Day 7-14 Day 14 
Effect on Neural Induction Day 0-2 
Day 2-7 
Day 2 
Day 7 
Table 3.1 In vitro culture periods and fixation time-points. 
 
3.3 Results   
Prior to commencing experimental plating under directed differentiation conditions, 
it was confirmed that ESCs behaved in a normal manner, with respect to their 
proliferation [Figure 3.3 (A)].  
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Figure 3.3 (A) Exponential growth curve of Sox1GFP mESC line. Exponentially 
proliferating 46C ESC cultures, represented by the straight line graph were 
maintained on 0.1% gelatin-coated T25 flasks from passage 25 to passage 42. The 
normal behaviour of cells, as observed in this study, is crucial to obtaining reliable 
and accurate results. (B) Proliferating mouse embryonic stem cells maintained on 
gelatin-coated plastic with LIF (~ 80% confluent). (C) GFP expression observed in a 
neural rosette of 46C derived-progenitor cells in differentiated cultures at day 7, 
plated in N2B27 medium. [(Brightfield (left image), GFP fluorescence (middle 
image) and Sox1GFP 46C cells (right images)]  B-C Scale bars = 100 μm. 
 
3.3.1. Nicotinamide increases the percentage of mESC-derived neurons when 
present at an early developmental stage.  
To determine the differentiation potential of the vitamin B3 metabolite in terms of 
the percentage of neurons generated from mESCs, the effect of nicotinamide was 
investigated on differentiation at an early stage of neuronal development (i.e. day 0-
7) or late developmental stage (i.e. day 7-14).  
Upon exposure of undifferentiated cells to nicotinamide from day 0-7, the percentage 
of βIII-tubulin expressing neurons measured at 14 days of culture was increased in a 
concentration dependent manner, peaking at a dose of 10 mM nicotinamide 
[ANOVA F(4, 268) = 30.1; p<0.001; (Figure 3.4 (A) (B)]. Nicotinamide (10 mM) 
supplementation more than doubled the percentage of βIII-tubulin+ neurons of the 
control value (29.8 ± 1.6% vs. 12.7 ± 0.9% in control cultures). Addition of 5 mM 
nicotinamide also significantly enhanced the proportion of neurons (20.7 ± 2.1%; 
p<0.01), whereas 0.5 and 1 mM were ineffective. Thus, the effect of nicotinamide on 
neuronal differentiation is dose-dependent. With higher levels of nicotinamide (20 
mM), cytotoxicity and widespread cell death were evident at 3-4 days of monolayer 
differentiation, thereby preventing establishment of cell cultures in this condition 
[Figure 3.5 (A)].  
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In contrast, nicotinamide did not induce significant differences in the percentage of 
βIII-tubulin+ neurons between control and 5 or 10 mM nicotinamide conditions, 
when added between days 7 and 14 [ANOVA F4, 268 = 1.9; n.s.; Figure 3.4 (C) (D)], 
indicating that its action is culture stage-dependent. 
Figure 3.4 Effect of nicotinamide addition to culture media on neuronal 
differentiation. (A) Immunocytochemical analysis of immature neuronal marker 
βIII-tubulin (green)-expressing cells and total cells in cultures labelled with DAPI 
(blue). Scale bar = 50 µm. (A) Exposure of undifferentiated cells to 10 mM 
nicotinamide between day 0 and day 7 increases the percentage of βIII-tubulin-
expressing neurons at day 14, compared to untreated cells at 14 days of monolayer 
culture. (B) Bars represent percentage βIII-tubulin-expressing neurons as a 
percentage of total cells. Nicotinamide (5 and 10 mM) generated an increase in the 
percentage of βIII-tubulin-expressing neurons, compared to untreated cells, when 
added to cultures between day 0 and day 7. (D) Bars represent percentage βIII-
tubulin-expressing neurons as a percentage of total cells. Nicotinamide added from 
days 7 to 14 had no significant effect on the percentage of βIII-tubulin-expressing 
neurons.  
***p<0.001, **p<0.01 
 
Nicotinamide-induced cell death (20 mM) was also observed at later stages (i.e. day 
7 to day 14) of neuronal development, indicating that this cytotoxic effect was 
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culture-stage independent, unlike its pro-neuronal differentiation action [Figure 3.5 
(A)]. 
 
Figure 3.5 (A) Cytotoxic effects of high levels of nicotinamide on neuronal 
differentiation. Intact cultures from 24 h to 72 h of monolayer differentiation, 
shown in phase contrast. Higher doses of nicotinamide (20 mM) elicited an obvious 
cytotoxic effect on monolayer cell survival, at 3 days in vitro (DIV). Scale bar = 50 
µm.  
 
In summary, nicotinamide administration to undifferentiated cells at early stages of 
the monolayer protocol exhibited a concentration-dependent enhancement in the 
conversion of mESCs into βIII-tubulin+ neuronal populations, but elicited no effect 
on this parameter at the late stages of ESC differentiation. These data suggest that 
addition of nicotinamide to early differentiation of ESCs may enhance the 
production of homogenous neuronal populations. Importantly, higher levels of 
nicotinamide (20 mM) induced cytoxicity and cell death. 
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3.3.2 The total numbers of cells in nicotinamide-treated cultures were reduced at 
both early and late developmental stages.  
Quantification of DAPI-stained nuclei highlighted a significant reduction in the total 
number of cells treated with nicotinamide [Figure 3.6 (A) (B)]. At day 14, fewer 
cells were counted following nicotinamide administration from day 0-7 [ANOVA F4, 
268 = 19.5; Figure 3.6 (C)] and from day 7-14 [ANOVA F4, 268 = 32.7; Figure 3.6 
(D)]. Specifically, cultures supplemented with 5 mM and 10 mM nicotinamide 
showed a significant decrease in the total numbers of DAPI-labelled cells per mm
2
, 
compared to control conditions at both day 0-7 [2047 ± 69.8 with 5 mM 
nicotinamide, p<0.01; 1754 ± 56.8 with 10 mM nicotinamide, p<0.001 vs. 2430 ± 
71.0 in control cultures] and day 7-14 [1893 ± 101.1 with 5 mM nicotinamide, 
p<0.001; 1290 ±12.8 with 10 mM nicotinamide, p<0.001 vs. 2556 ± 95.1 in control 
conditions].  
 
These data suggest that nicotinamide may be functioning to decrease the pluripotent 
stem cell population (i.e. dividing cells); an important finding which could be 
translated to current ESC differentiation protocols to reduce the potential risk of 
tumourigenesis.  
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Figure 3.6 Nicotinamide treatment reduced the total cell population. (A-B) 
Nicotinamide-treated cultures displayed significantly decreased total cell numbers 
per mm
2
. Total cells in cultures labelled with DAPI (blue). Scale bar = 50 µm. (C-D) 
At day 14, fewer cells counterstained with DAPI were observed following 
nicotinamide treatment from days 0 to 7 and days 7 to 14. 
***p<0.001, **p<0.01  
 
3.3.3 Nicotinamide treatment at early development yielded an enriched population 
of neuronal cells.  
To determine the total number of βIII-tubulin+ neurons per mm2 across all treatment 
groups, values for the percentage of βIII-tubulin+ neurons and the total number of 
DAPI cells per culture were used to calculate the total number of neurons per 
culture. Findings showed that addition of 10 mM nicotinamide to undifferentiated 
cells between days 0 and 7 generated significantly more neurons per unit area at 14 
days, compared to control conditions (ANOVA F4, 274 = 7.6; p<0.01) [466.8 ± 32.9 
vs. 311.7 ± 27.0 with control conditions; Figure 3.7 (A) (B)].  
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Conversely, addition of nicotinamide to cells at day 7-14 significantly decreased 
neuronal numbers per mm
2  
in the 5 and 10 mM conditions (ANOVA F4, 268 = 8.2;  
p<0.01) [200.9 ± 17.9 with 5 mM nicotinamide, 176.5 ± 20.9 with 10 mM 
nicotinamide, p<0.001 vs. 320.4 ± 28.2 in control conditions; Figure 3.7 (A) (C)].  
These crucial findings reveal that addition of nicotinamide at the initial stages of 
ESC differentiation promoted an enrichment in the number of neurons per unit area 
by day 14 of monolayer culture. This occurs partly through directed cell 
differentiation and partly through a reduction in the total number of cells in culture, 
elicited by nicotinamide treatment.  
 
Figure 3.7 Nicotinamide acts at the initial stages of neural differentiation to 
promote neuronal enrichment. (A) Immunocytochemical analysis of immature 
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neuronal marker βIII-tubulin (green)-expressing cells and total cells in cultures 
labelled with DAPI (blue). Representative images demonstrating that nicotinamide 
treatment between days 0-7 causes a reduction in the total number of cells, 
concomitant with an increase in the generation of more neurons per unit area at 14 
days, therefore promoting neuronal enrichment in monolayer cultures. However, 
nicotinamide-treated cultures from days 7 to 14 exhibited significantly reduced total 
cell and neuronal numbers per mm
2
. Scale bar = 50 µm. (B) Addition of 10 mM 
nicotinamide to undifferentiated cells from day 0 to 7 significantly increased the 
number of neurons per unit area compared to control cultures, thereby enriching the 
ratio of neurons to non-neuronal cells at day 14. (C) Nicotinamide (5 and 10 mM) 
caused a significant reduction in neuronal numbers per mm
2
, when added to cultures 
at late differentiation stages.  
***p<0.001, **p<0.01 
 
3.3.4 Nicotinamide promotes the loss of both pluripotent stem cells and neural 
progenitor cells.  
Having shown that nicotinamide reduced the total number of cells (section 3.3.2), its 
effects on the heterogeneous population of undifferentiated mESCs and GFP-
expressing NPCs in culture at day 14 were more thoroughly investigated. In 
particular, the differentiation-inducing abilities of 5 and 10 mM nicotinamide were 
selected to specifically evaluate their effects on stem cell potency and NPCs.  
 
3.3.4.1 The number of colonies expressing Oct4 was dramatically reduced. 
The number of undifferentiated stem cell colonies per field, as determined by 
colonies expressing the stem cell marker Oct4, was reduced by half when 10 mM 
nicotinamide was added to cultures at the early phases (i.e. days 0-7) of neural 
differentiation (ANOVA F2, 108 = 17.0; p<0.001) [number of Oct4 colonies per field: 
3.2 ± 0.5 vs. 6.8 ± 0.5 in controls; Figure 3.8. (A) (B)]. Cells differentiated with 10 
mM nicotinamide from day 7-14 showed a similar effect, where the number of stem 
cell colonies is reduced to approximately one third of the control conditions 
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(ANOVA F2,103 = 38.4; p<0.001) [2.7 ± 0.5 vs. 8.1 ± 0.5 in control groups; Figure 
3.8. (C) (D)].  
Similarly, addition of 5 mM nicotinamide to cultures at early differentiation 
significantly reduced the number of Oct4-expressing colonies (4.4 ± 0.3; p<0.001). 
This effect of the 5 mM concentration was specific to early stages of differentiation 
(i.e. days 0-7) and was not replicated at later differentiation stages. These findings 
implicate a beneficial role for nicotinamide to reduce the numbers of dividing cells 
in adherent monolayer cultures by day 14. 
 
 
Figure 3.8 Treatment of adherent cultures with nicotinamide decreased the 
number of undifferentiated colonies expressing Oct4. (A&C) 
Immunocytochemical analysis of pluripotent stem cell marker Oct4 (red)-expressing 
colonies and total cells in cultures labelled with DAPI (blue) at day 14. Irrespective 
of the nicotinamide treatment period, numbers of undifferentiated colonies were 
lower at day 14, compared to controls. Scale bar = 100 µm. (B) Monolayer cultures 
exposed to both 5 and 10 mM nicotinamide between days 0 and 7 significantly 
decreased the number of pluripotent colonies per field. (D) Nicotinamide-treated 
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cultures (10 mM) exhibited significantly lower numbers of Oct4
+
 colonies at day 14 
(added from day 7-14).  
***p<0.001 
 
 
3.3.4.2 Stem cell pluripotency was down-regulated in nicotinamide conditions. 
This experiment also aimed to investigate if nicotinamide would impact on the self-
renewing capacity of prevailing undifferentiated colonies remaining in culture at day 
14. Round and compact Oct4-expressing colonies are a standard feature of ESC 
culture conditions. Therefore, the loss of the pluripotency regulator Oct4 was 
examined by measuring colony area size (μm2) using Image-J software. Pluripotency 
was assessed within individual DAPI-labelled colonies as the proportion of cells 
expressing the Oct4 protein. Therefore, a ratio of the region of red fluorescence 
(Oct4
+
) compared to blue fluorescence (DAPI
+
) within a fixed area was obtained.  
Interestingly, nicotinamide significantly decreased the size of Oct4-labelled colonies 
in cultures treated between days 0 and 7. The percentage of Oct4-labelled areas 
within DAPI
+
 colonies was significantly smaller in 10 mM nicotinamide cultures 
only [17.5 ± 1.7% vs. 37.7 ± 4.2%  in control conditions; p<0.01; Figure 3.9 (A) 
(B)]. Cells treated between days 7 and 14 did not have any significant differences in 
Oct4 expression [Figure 3.9 (C)].  
The mean area of colonies (μm2)  was plotted against nicotinamide concentrations, 
obtained from cultures treated at the early stages of development only. DAPI-
labelled colonies remained constant in size across all treatment conditions [Figure 
3.9 (D)]. In contrast, 10 mM nicotinamide induced a rapid loss of pluripotency as 
evidenced by a significant reduction in Oct4-positive colony size [2877 ± 625.2 vs. 
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7862 ± 317.1 in controls; p<0.01; Figure 3.9 (E]. This effect was not observed at 
lower concentrations of nicotinamide (i.e. 5 mM).  
In summary, nicotinamide (10 mM) promoted earlier differentiation of mESCs, as 
evidenced by the pattern of Oct4 expression, which showed a rapid reduction 
following early nicotinamide exposure. This important finding forms a mutually 
supportive body of data compatible with the reduction of the total cell population, an 
effect elicited by nicotinamide at the early stages of neural differentiation. This 
suggests that the decrease in the pluripotent cell population underlies the 
significantly lower numbers of total cells in adherent monolayer culture by day 14.  
Figure 3.9 Early nicotinamide treatment accelerates stem cell differentiation (A) 
Semi-quantitative measurements of area size (µm
2
) for the pluripotency marker Oct4 
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(red)-expressing colonies and total cell colonies labelled with DAPI (blue) at day 14. 
Levels of Oct4-expressing cells within DAPI colonies indicated a more striking 
difference in 10 mM nicotinamide conditions, compared to controls (treatment 
period: day 0-7 and differentiated until day 14). Image sets of nicotinamide cultures 
show DAPI-expressing colonies exhibit reduced number of cells expressing high 
levels of Oct4. Regions of low pluripotency are also visible in partially pluripotent 
colonies. Scale bar = 100 µm. (B) Percentage of areas containing cells expressing the 
Oct4 gene within the DAPI-labelled colonies was plotted. Oct4 was observed in less 
areas within DAPI
+
 colonies when treated with nicotinamide. (C) Late treatment of 
nicotinamide at day 7 to 14 had no effect on the size of the proportion of DAPI
+
 
colonies that were Oct4
+
. (D&E) Mean area values for DAPI and Oct4 colony size 
were plotted. DAPI colonies were similar in area (µm
2
) across all treatment 
conditions. Regions of Oct4 expression were markedly reduced in cultures treated 
with 10 mM nicotinamide from days 0 to 7, suggestive of accelerated stem cell 
differentiation. **p<0.01 
 
 
3.3.4.3 Sox1GFP
+
 progenitor populations were decreased in cultures treated with 
nicotinamide. 
Further to examining the undifferentiated Oct4 state, the effect of nicotinamide on 
monolayer-derived Sox1GFP-expressing neural progenitors was also assessed by 
quantifying GFP
+
 cells. Application of 10 mM nicotinamide between days 0 and 7 
significantly reduced the percentage of GFP-expressing NPCs by day 14 of 
differentiation (ANOVA F2, 195 = 16.3; p<0.001) [12.8 ± 1.8% vs. 30.5 ± 2.6% in 
controls; Figure 3.10 (A) (B)]. No significant differences in the percentage of GFP
+
 
cells were found between control and treatment conditions when nicotinamide was 
added at late differentiation stages [Figure 3.10 (C) (D)].   
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Figure 3.10 Nicotinamide treatment decreases the proliferating Sox1GFP
+
 
neural precursor population. Cells were cultured for 14 days in vitro and analysed 
with fluorescence microscopy for GFP expression. (A&C) Images show native GFP 
(green)-expressing cells and total cells in cultures (blue) at day 14. Differences in the 
variability of GFP intensity was noted between cells. Some cells showed intense 
GFP expression (white arrow) and some less strong GFP expression (yellow arrow). 
Scale bars = 100 µm. (A&B) A significant decrease in the Sox1GFP
+
 population was 
observed in 10 mM nicotinamide-treated cultures, in comparison to untreated cells 
(day 0-7 conditions). (C&D) Nicotinamide added between days 7 and 14 did not 
affect the population of Sox1GFP-expressing cells. 
***p<0.001 
 
It should be noted that the well-established neuro-progenitor marker nestin was not 
investigated in this study. A number of reports found that nestin, an intermediate 
filament protein, is not an exclusive neural marker and should be used with caution 
for attributing neural progenitor identity
149,171
. For this purpose, nestin staining was 
tested in the monolayer culture system using an immunofluorescence experiment. It 
was noted that many of the strongly GFP-expressing progenitor cells did not show 
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co-labelling for nestin (Figure 3.11). This observation confirmed that nestin is not a 
reliable neural progenitor marker, so was therefore excluded from this study.  
Figure 3.11 Immunocytochemistry of differentiated mESCs to identify neural 
progenitor cells. Co-localisation of native GFP expression and the neuro-progenitor 
marker Nestin is evident in some cells (yellow arrows). However, many of the GFP-
expressing cells do not co-localise with nestin-positive cells (white arrows). Scale 
bar = 50 µm 
 
 
3.3.4.4 Early nicotinamide administration accelerates the loss of neural progenitor 
populations.  
Within monolayer cultures, variations in the intensity of GFP expression was 
evident, resulting in a spectrum from bright to low intensity GFP
+
 cells [Figure 3.10 
(A)-inset]. It was hypothesised that cells expressing higher levels of GFP represented 
true Sox1
+
 NPCs, and weaker GFP
+
 cells were immature neuronal and glial cells 
containing remnants of GFP protein, despite down-regulation of their GFP gene.  
This is likely due to the longer half-life of the GFP protein (~ 26 h), in contrast to 
endogenous Sox1
172
. 
Therefore, to investigate the effect of nicotinamide on intense and weak Sox1GFP
+
 
neural progenitor populations, GFP
+
 cells were scored for levels of reporter protein 
using FI measures, described previously in chapter 2 (section 2.1.8).  Briefly, GFP-
expressing cells were categorised as ‘weak’ (≤ 0.25 FI units), ‘moderate’ (0.25–0.5 
FI units) and ‘strong’ (≥ 0.5 FI units).  
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Data for mean FI values highlighted a marked reduction in the relative levels of GFP 
expression in cells treated with 10 mM nicotinamide between days 0 and 7, 
compared to all other conditions [ANOVA F5,4410 = 92.5; p<0.0001; Figure 3.12 
(A)]. Further, 10 mM nicotinamide applied for the first 7 days of differentiation 
almost completely eradicated “strong” Sox1GFP-expressing cells (i.e. true Sox1+ 
NPCs) from cultures (0.5 ± 0.5% vs. 10.1 ± 0.9% in control conditions; p<0.001), 
concomitantly decreasing the proportion of “moderate” GFP-expressing cells per 
culture (11.2 ± 5.0% vs. 38.6 ± 0.8% in control conditions; p<0.01). Consequently, 
nicotinamide treatment increased the proportion of weaker expressing GFP
+ 
cells 
which accounted for 88.3 ± 5.51% of the GFP
+
 progenitor population [p<0.001; 
Figure 3.12 (B)], in contrast to control cultures which accounted for 50.8 ± 4.3% of 
the GFP
+
 progenitor population.  
Altogether, these important data indicate that early supplementation of 
differentiating ESC cultures with nicotinamide not only aids the elimination of 
potential tumorigenic cells from cultures, but also promotes an accelerated loss of 
pluripotency, thereby speeding up cell-cycle exit from the ESC state. Further, 
nicotinamide administration at the initial stages of mESC differentiation rapidly 
decreased the Sox1GFP
+
 NPC population.  
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Figure 3.12 Effect of nicotinamide on GFP expression in 46C-derived mESCs 
(A) The scatter graph depicts individual optical densities (arbitrary units) of GFP-
expressing cells at day 14. FI values are plotted on the y-axis against nicotinamide 
concentrations on the x-axis. This scatter plot indicates a significant reduction in 
GFP fluorescence in 10 mM nicotinamide-treated cultures, compared to all other 
conditions. (B) Bar chart showing the proportion of cells with weak (green bars), 
moderate (orange bars) and strong (red bars) levels of GFP expression. The 
proportion of 46C-derived cells displaying “strong” and “moderate” levels of GFP 
expression was significantly decreased in cultures exposed to 10 mM nicotinamide 
between days 0 and 7, concomitant with an increase in “weaker”-expressing GFP+ 
cells, compared with controls and all other conditions.  
***p<0.001, **p<0.01 
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3.3.5 Nicotinamide accelerates ESC-derived neural specification  
Given the direct effect of 10 mM nicotinamide at the early developmental stages of 
ESC differentiation (i.e. day 0-7), this section reports experiments which were 
conducted to further investigate this vitamin concentration on the key developmental 
steps of neural commitment in vitro, in order to gain insight into the mechanism of 
nicotinamide’s action in promoting neuronal differentiation. Adherent monolayer 
cultures supplemented with nicotinamide at day 0 to day 2 and day 2 to day 7 were 
analysed for the expression of markers of undifferentiated ESCs, early neural 
differentiation and early neuronal development in a similar manner to that performed 
previously in this chapter.  
3.3.5.1 Nicotinamide promoted earlier down-regulation of Oct4 in ESCs 
To investigate whether nicotinamide could promote mESC entry to the neural 
lineage in this monolayer culture system, the Oct4 protein was assessed, which is 
known to be down-regulated early during somatic differentiation
149
. Nicotinamide 
added to undifferentiated Sox1GFP knock-in reporter mESCs at the onset of 
differentiation (day 0) caused a dramatic reduction in the number of Oct4-expressing 
colonies per field by day 2 (unpaired t test, t = 6.0; p<0.001) [3.3 ± 0.5 vs. 10.2 ± 0.9 
in controls; Figure 3.13 (A), Figure 3.16 (A)]. A less marked reduction was observed 
in treatment conditions from day 2 to day 7 (unpaired t test, t = 2.5; p<0.05) [3.8 ± 
0.5 vs. 5.3 ± 0.4 in control cultures; Figure 3.13 (B), Figure 3.16 (B)]  
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Figure 3.13 Early nicotinamide treatment reduced the number of colonies 
expressing Oct4. (A&B) The effect of nicotinamide on the undifferentiated mESC 
population was investigated during monolayer differentiation between days 0-2 (A) 
and days 2-7 (B). The number of Oct4-expressing colonies per field was plotted. 
Cells were counterstained with DAPI. 
***p<0.001, *p<0.05  
 
 
3.3.5.2 Nicotinamide accelerated neural induction 
In accordance with other reports, analysis from this study showed a highly 
reproducible up-regulation of native GFP expression in control cultures, driven by 
expression of the Sox1 gene by day 3-4 of monolayer differentiation. Colonies 
containing various intensities of GFP expressing cells initially appeared interspersed 
with GFP
- 
colonies [Figure 3.16 (A)]. Therefore, the effect of nicotinamide on the 
Sox1
+
 progenitor population was assessed at day 4 (treatment: day 0-2) rather than 
day 2, in addition to the day 2-7 culture period. The extent of GFP expression in 
colonies was analysed using FI measurements. An area cover of green fluorescence 
(µm
2
) was expressed as a percentage of the total cell/DAPI
+
 area.  
At day 4, FI values for the nicotinamide-treated group revealed a slight higher trend 
in the extent of green fluorescence in monolayer colonies, albeit these differences 
were not statistically significant [n.s.; Figure 3.14 (A)]. The percentage of native 
GFP-labelled regions within DAPI
+
 colonies was dramatically enhanced in treatment 
cultures by day 4, compared to lower distributions of GFP
+
 expression in controls 
89 
 
(unpaired t test, t = 5.6; p<0.01) [38.1 ± 1.4% vs. 7.6 ± 5.2% in control groups; 
Figure 3.14 (B), Figure 3.16 (A)].  
Monolayer cultures treated with nicotinamide between days 2 and 7 revealed a slight 
downward trend in both GFP
+
 intensity levels and the area coverage of green 
fluorescence co-localised with DAPI
+
 colonies, albeit these differences were not 
statistically significant [n.s.; Figure 3.14 (C) (D), Figure 3.16 (B)]. In summary, 
these data indicate that nicotinamide added from day 0 of the monolayer protocol 
enhanced the processes of neural specification.  
 
 
Figure 3.14 Early nicotinamide treatment accelerated neural induction. (A-
D)The effect of nicotinamide on neural specification was investigated during 
monolayer culture periods: day 0-4 (A&B) and day 2-7 (C&D). FI measurements of 
GFP-expressing colonies were plotted (A&C). Native GFP-labelled areas were 
expressed as a percentage of total cell area (B&D).  
**p<0.01 
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3.3.5.3 Nicotinamide treatment directed earlier expression of young βIII-tubulin+ 
neurons 
Consistent with results highlighting a rapid decline in the ESC state and accelerated 
emergence of GFP
+
 progenitor cells, the expression of βIII-tubulin was also up-
regulated in nicotinamide-treated cultures as early as the neural induction stage in 
this monolayer system. Although βIII-tubulin+ neurons were evident in cultures as 
early as day 2, nicotinamide significantly promoted the generation of immature 
neuronal populations (unpaired t test, t = 2.9; p<0.05) [6.8 ± 1.4% vs. 2.63 ± 0.28% 
in untreated conditions; Figure 3.15 (A), Figure 3.16 (A)]. Surprisingly, a marked 
increase in the percentage of βIII-tubulin+ neurons was also demonstrated in cultures 
treated between days 2 and 7, compared to control conditions (unpaired t test, t = 
3.6;  p<0.001;) [7.3 ± 0.9% vs. 3.3 ± 0.6% in control groups; Figure 3.15 (B), Figure 
3.16 (B)].  
In summary, these data indicate the processes of neural specification and neuronal 
differentiation were accelerated, under the driving force of nicotinamide acting at the 
initial stages of ESC differentiation.  
 
Figure 3.15 Early nicotinamide treatment up-regulated the expression of βIII-
tubulin
+
 neurons. (A&B) The effect of nicotinamide on immature neuronal 
expression was accessed during monolayer culture periods; day 0-2 (A) and day 2-7 
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(B). Percentage of βIII-tubulin+ cells was plotted over total cells, counterstained with 
DAPI.  
***p<0.001, *p<0.05 
 
 
 
 
Figure 3.16 Addition of nicotinamide from day 0 of the monolayer protocol 
accelerated neural induction and neuronal differentiation. Immunofluorescence 
images of pluripotency (Oct4), early neural (native Sox1GFP expression) and 
neuronal (βIII-tubulin) proteins. Monolayer cultures were treated from days 0-2 or 
days 2-7. Nuclei counterstained with DAPI (blue). (A) Nicotinamide acted at the 
initial stages (days 0-2) of monolayer differentiation to markedly down-regulate the 
specific marker for ESCs, Oct4, thereby promoting earlier neuroectodermal cell fate 
commitment, and accelerated the emergence of immature βIII-tubulin+ neurons. (B) 
Nicotinamide added between days 2 and 7 decreased Oct4-expressing colonies and 
slowly down-regulated GFP expression, concomitant with enhanced neuronal 
differentiation.  
Scale bar = 100 µm (Stem Cell and Neural Progenitor State panels). 
Scale bar = 50 µm (Neuron panels). 
 
3.4 Discussion 
 
To my knowledge, this is the first report which investigated whether nicotinamide, 
the metabolic product of vitamin B3, could direct 46C Sox1GFP mESCs toward 
neural and further toward neuronal cells in vitro. This experimental chapter reports a 
protocol that renders nicotinamide sufficient to induce accelerated neural 
specification from mESCs which further progressed to enriched neuronal 
populations with enhanced efficiency, within 14 days of monolayer differentiation. 
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A number of in vitro protocols have been established to trigger the process of neural 
induction to generate regionally specified neuroepthelial progenitors and/or 
terminally differentiated neuronal and glial cells, thereby recapitulating the multistep 
cascade controlling embryonic development in vivo. An initial approach to 
reconstitute neurogenesis in vitro was accomplished through embryoid body (EB) 
formation or by co-culture with stromal cells or conditioned medium. However, it is 
often challenging to manipulate and study differentiation within three-dimensional 
EB aggregates formed in suspension
173
. A more efficient method to achieve neural 
commitment in vitro, avoiding confounding complexities associated with 
multicellular aggregation co-culture systems relies upon an adherent monolayer 
(two-dimensional) culture system using ESCs, established by Ying and co-
workers
164
. This protocol facilitates the rapid generation of neural progenitors 
capable of differentiating into neuronal/glial subtypes, with minimum perturbation of 
the culture or use of uncharacterised media constituents and expensive culture 
reagents
149,164,170,174
. Therefore, this efficient monolayer culture system was ideal for 
this study, to investigate the effects of nicotinamide on directing neuronal 
differentiation in factor-free chemically defined media, without the matrix effects 
associated with EBs.  
The hypothesis under investigation was that nicotinamide could promote enhanced 
differentiation of Sox1GFP reporter mESCs into neuronal populations, to obtain 
higher yields of enriched neuronal cultures toward transplantation therapies for 
neurodegenerative disorders, cell biological investigation, neurological disease 
modelling and pharmaceutical screening. 
 3.4.1 Differentiation to neurons is highly efficient in nicotinamide-treated 
cultures. 
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This study showed that early nicotinamide supplementation to undifferentiated 46C 
cells increased the percentage of neurons in mESC-derived cultures, concomitant 
with a decrease in the total number of cells in culture after 14 days. By adding 
nicotinamide to cells at the onset of differentiation, the efficiency of neuronal 
generation was significantly increased. The timing of nicotinamide supplementation 
to cultures during the early steps of monolayer differentiation is consistent with 
similar protocols reported in the literature, which applied nicotinamide to direct 
differentiation of hESCs into RPE
161,162
, and into human cardiac precursors and 
cardiomyocytes
163
. 
Crucially, accompanying the increase in the proportion of neurons, nicotinamide also 
promoted an enrichment of the neuronal population vs. non-neuronal cells, by 
reducing the total number of cells, as quantified by DAPI staining. Importantly, this 
key finding is in agreement with a previous study which controlled the 
differentiation of human pluripotent stem cells by applying defined factors, including 
nicotinamide at specific time points to generate approximately 80% of cells 
characteristic of RPE phenotype, within 14 days of differentiation
162
.  
Overall, the differentiation-promoting effects of nicotinamide were dose-dependent, 
being significant at 5 mM and 10 mM doses, with 10 mM nicotinamide having the 
most pronounced effects, which was in agreement with previous stem cell 
differentiation studies
159,161,162
. Notably, 10 mM nicotinamide represents a 
considerably higher concentration than the physiological level in vivo. Work carried 
out by Qin et al provided values for nicotinamide concentrations in the brain, which 
ranged from 100 µM to 300 µM
176
. However, it is important to consider that the 
intended application of the findings in this study would be in monolayers in vitro for 
cell transplantation, and vitamin metabolites are classically added to cultures 
94 
 
undergoing differentiation at higher concentrations than the physiological level.
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One reason for this, may be that the functioning of nicotinamide may have 
synergistic effects in vivo and those interacting factors may not be present in vitro. 
Another important point of note is that the level of nicotinamide added to cell 
cultures in vitro may not precisely represent the bioavailable nicotinamide bound to 
serum proteins in vivo. Therefore, the culture concentrations of nicotinamide cannot 
be directly compared to the physiological levels.  
Overall, when added at appropriate concentrations at appropriate developmental 
stages, nicotinamide has an important role to play in directing mESC differentiation 
specifically towards a neuronal lineage, which could prove a useful addition to 
current protocols for directing stem cell differentiation. 
3.4.2 Nicotinamide accelerated the differentiation of both stem and progenitor 
cells towards a neuronal fate. 
Cell-to-cell phenotypic heterogeneity is a common and fundamental characteristic of 
ESCs. However, compounding complexities often arise during in vitro ESC 
differentiation due to this highly heterogeneous nature of in vitro differentiated ESC 
preparations. Asynchronous ESCs often differentiate into lineage-biased subsets
149
 
and contribute to the significant risk of tumourigenesis due to the presence of 
undifferentiated ESCs amongst differentiated progenies in grafted transplants
172
. 
Considering this, it is crucial that tumour-forming cells are eliminated from ESC-
derived preparations.  
By day 14 of monolayer differentiation, nicotinamide treatment (from day 0-7) 
reduced both Oct4
 
and GFP expression of cells in culture, concomitant with the 
elevated expression of neuron-specific βIII-tubulin, indicative of accelerated 
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neuronal differentiation. Two quantitative methods were applied to provide an 
assessment of the effect of nicotinamide on pluripotency: quantification of Oct4 
immunoreactive colonies; and measurement of Oct4-labelled areas within DAPI-
stained colonies. Addition of nicotinamide at both early and late stages of monolayer 
differentiation significantly reduced the Oct4
+
 pluripotent stem cell population from 
cultures at day 14. Indeed, 10 mM nicotinamide promoted earlier differentiation of 
mESCs, as indicated by the pattern of Oct4 expression, which declined more rapidly 
following early nicotinamide exposure.  
In line with these findings, Sox1GFP
+
 NPC numbers were rapidly reduced under the 
driving force of early nicotinamide supplementation, when examined at day 14 of the 
monolayer protocol. It is therefore reasonable to conclude that more NPCs 
differentiated earlier into neurons in the presence of nicotinamide. Specifically, 
semi-quantitative analysis indicated that the proportion of Sox1GFP
+
 cells expressing 
intense GFP was almost eliminated from cultures. Interestingly, the majority of cells 
treated with nicotinamide showed uniformly weaker GFP expression. This detailed 
microscopic analysis of relative GFP intensity levels was used to give a more precise 
measure of the heterogeneity within cell populations, as observed in 46C ESC-
derived cultures, compared with just a cell count of GFP
+
 cells. Furthermore, this 
technique using fluorescent microscopy and Image-J software eliminates 
complexities associated with fluorescent plate readers, which would quantify the 
total GFP fluorescence present in a culture. Additionally, with respect to 
experimental design in this study, an anti-nestin antibody was not selected to 
examine the effects of nicotinamide on the neural progenitor population, since it has 
been reported that nestin is not an exclusive neural marker,
149,177
 which was 
confirmed in this study. Therefore, analysis of GFP alone in the presence and 
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absence of nicotinamide was investigated, where GFP has been reported to faithfully 
mimic endogenous Sox1 expression during early development in the neuroepithelium 
and in NPCs in vitro
149,164,178
.  
Overall, findings in this experimental section support previous evidence where 
nicotinamide was shown to eliminate Oct4
+ 
dividing cells from pluripotent stem cell 
cultures, thereby speeding up differentiation into clinically relevant lineages
161,162,167
.  
3.4.3 Nicotinamide accelerated neural specification of Sox1GFP mESCs. 
Previous studies have linked nicotinamide with a switch in neural progenitors 
towards a neuronal fate in the conversion of human ESCs to other neuronal types
179
. 
Findings from this study determined that nicotinamide is most effective in 
influencing neuronal differentiation at an early developmental time window (day 0-7 
of the 14 day monolayer protocol). A number of neural differentiation studies using 
the mouse knock-in ESC line 46C cultured in monolayers showed that this method 
generates neural progenitors from around day 2-7; therefore the results presented in 
this thesis suggest that nicotinamide may be acting at the initial stages of ESC 
differentiation to influence the transition of mESCs into neuroectoderm or indeed 
driving a switch from neural progenitors to neurons in the differentiating cells. This 
hypothesis is supported by previous data in this experimental chapter showing that 
after the neural progenitor stage [late born Sox1GFP NPCs (day 7)
178
], 
administration of nicotinamide can no longer direct the differentiation of neurons 
(i.e. day 7 to 14).  
Within 2 days of withdrawing LIF and serum from cultures, the number of Oct4-
expressing colonies was dramatically reduced in nicotinamide-treated cultures. 
Interestingly, adherent monolayer cultures exhibited brighter green fluorescence 
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within significantly increased GFP-labelled regions following nicotinamide 
treatment, thereby suggesting that nicotinamide is enhancing neural lineage 
specification, i.e. accelerating the conversion to neuroectoderm cell fate 
commitment. Accompanying the accelerated emergence of progenitor cells, the 
percentage of immature neurons expressing βIII-tubulin was also up-regulated in the 
presence of nicotinamide, i.e. nicotinamide is facilitating rapid neuronal 
differentiation. These data are consistent with similar observations in RA-treated 
Sox1-GFP 46C cultures
174
.  
In this study, it is therefore reasonable to hypothesise that the initial higher frequency 
of Sox1GFP
+
 cells in monolayer cultures may be due to enhanced viability or 
conversion of progenitor cells during the early stages of development. In this regard, 
one study showed that prevention of apoptosis was one of the mechanisms mediating 
the promotion of neural specification by nicotinamide. Nicotinamide was shown to 
reduce cell death of human ESC-derived NPCs upon neural induction, via inhibition 
of PARP, thereby enhancing neutralization
141
. However, it is important to note that 
higher doses of nicotinamide (20 mM) induced cytotoxic effects on cells within 3 
days of application. This is coincident with other differentiation studies which also 
found that high doses of the active metabolites of vitamin A (retinoic acid: 10-6 µM) 
and vitamin C (ascorbic acid: 500-5000 µM) produced obvious noxious effects on 
cell survival
124,174
. In this context, review papers published by Williams et al propose 
a hypothetical link between a hypervitaminosis B3 state and modern disease 
phenomena, resulting from a modern Western diet abundant in meat and vitamin 
supplements
129,180
. Specifically, excess nicotinamide has been linked with 
neurodegeneration, particularly PD
130
, implying that levels of this vitamin require 
tight regulation in order to sustain normal neuronal functioning. Further to this point, 
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this report highlighted the narrow range of concentrations at which nicotinamide is 
active. 
Nicotinamide induced a less marked effect on neural induction between days 2 and 
7, implying that the inductive role of nicotinamide may function during a narrow 
time window prior to or at the stage of Sox1 expression during mESC differentiation. 
A slight decrease in the number of pluripotent colonies per field was observed at the 
end of the culture period. Treatment of monolayer cultures with nicotinamide at the 
initial stages of Sox1GFP expression (day 2) elicited a slight down-regulation of 
GFP expression at day 7. These data show that, in the monolayer culture system, the 
speed at which nicotinamide promoted ESC differentiation into Sox1GFP
+ 
NPCs was 
faster than the rate of loss of Sox1GFP
+
 cells, thereby suggesting an important role 
for nicotinamide from day 0 of monolayer differentiation. Surprisingly, the 
expression levels of βIII-tubulin were dramatically elevated in cultures treated with 
nicotinamide from day 2 to 7. It is therefore clear that nicotinamide can potentiate 
pluripotent stem cell differentiation and promote enhanced derivation of mESC-
derived neurons across a spectrum of developmental stages during ESC 
differentiation. This work is highly relevant to future neural-based protocols as it 
opens up the possibility of applying nicotinamide as a differentiation agent to obtain 
increased yields of neurons. 
3.4.4 Conclusion and Future Studies. 
Results obtained in this study strongly support an important role for nicotinamide at 
the early induction stage during ESC in vitro differentiation, rather than at later 
stages of neuronal differentiation. Importantly, findings outlined in this study are 
exciting, as nicotinamide not only increased and accelerated the differentiation of 
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developing neurons from ESCs, but also generated more enriched neuronal 
populations, and without the support of expensive exogenous factors, therefore 
highlighting potential implications for the cost efficient scale-up of future neural 
cell-based therapies. 
The precise mode of action of nicotinamide in mechanisms underlying the promotion 
of enhanced and accelerated neuronal differentiation remains to be elucidated. A 
number of studies found that some of its effects may be mediated through inhibition 
of PARP or silencing information regulator 2 (SIRT1) (this will be discussed in 
detail in Chapter 5). In future work, it will be of interest to determine if nicotinamide 
mediates neural specification by enhancing cell-cycle exit by reducing the proportion 
of proliferating cells and/or selective apoptosis in non-neural populations. In this 
context, Vaca et al
158
 found that nicotinamide could cause an 80% reduction in ESC 
proliferation, supporting the former mechanism of action, whilst Idelson et al
162
 
found that prevention of apoptosis in neural populations, rather than augmentation of 
their proliferation resulted in enhanced RPE differentiation. Whichever mechanism 
is at work, nicotinamide’s influence in reducing ESC numbers and promoting the 
loss of pluripotency in undifferentiated ESCs, along with reducing the number of 
proliferating progenitor cells could be translated to current ESC differentiation 
protocols, thereby reducing the risk of tumorigenicity in stem cell-derived 
transplants as we advance towards clinical stem cell-based therapies. 
It has been reported that neuronal fate specification and progenitor formation are two 
closely linked processes occurring during ESC differentiation, which may be 
instructed by the same signals
178
. Therefore, findings outlined in this chapter 
strongly suggest that nicotinamide could be applied to current neuronal protocols 
during the early stages of neural differentiation, in combination with factors known 
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to enhance neuronal phenotypes, to promote subtype specification. The next 
experimental chapter builds on these concepts, further investigating whether 
nicotinamide could influence the enrichment and maturity of desired neuronal 
subtypes, pertinent to common neurological disorders, such as PD, HD and 
neuropsychiatric disorders. 
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Chapter 4: Effect of Nicotinamide on Neuronal 
Subtype Differentiation and Maturation from 
Mouse Embryonic Stem Cells In Vitro 
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4.1 Introduction 
Methods for obtaining specific neural subtypes to substitute cells lost to the disease 
process routinely apply intrinsic and extrinsic factors to direct cell fate choice. 
Therefore, identifying factors that regulate specification, differentiation, maturation 
and survival of developing neurons is important. Recently, increased attention has 
also focused on stem cell-derived neuronal subtypes as a valuable platform for 
disease modelling, neurological drug screening and neurotoxicity evaluation, to 
further develop therapeutic strategies to treat a range of neurological illnesses
181
. 
However, like CRT, improved methods are required to convert stem cells to highly 
purified phenotypic neuronal populations in high yields amenable to large screening 
campaigns, and which share similar morphologies to primary neurons in vitro
182,183
. 
Specific neurotransmitters of the BG neurocircuitries have important functions in the 
etiology and treatment of neurological disorders. For example, DAergic and 
serotonergic neurons play important roles in the etiology and treatment of 
neurodegenerative disorders, including PD
78
 and neuropsychiatric diseases
184,185
. The 
neurotransmitters DA and serotonin or 5-hydroxytryptamine (5-HT) are synthesised 
by neurons generated from the boundary between the midbrain and hindbrain, and 
are therefore influenced by similar developmental signals
83
. Midbrain DAergic 
neurons are of clinical importance due to their selective degeneration in PD, leading 
to deficits in the control of movement
186
. Therefore, understanding and identifying 
key signals that increase the development of DAergic neurons may advance the 
promise of CRT for PD. Serotonergic neurons send their projections to cortical brain 
regions, thereby regulating behaviours such as cognitive function and mood. 
Disturbed 5-HT signalling and homeostasis are associated with a myriad of 
neuropsychiatric disorders, including obsessive compulsive disorder, hyperorexia 
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(i.e. a compulsive overeating disorder) and impulsivity
185
. Thus, improved protocols 
to induce in vitro serotonergic differentiation from stem cell sources may prove 
beneficial for developing and testing the safety of therapeutic drug candidates, to 
progress the treatment of psychiatric disorders
185
. Similarly, it is crucial to fully 
control the differentiation of pluripotent stem cells into excitatory glutamatergic 
neurons in a robust and homogenous manner to provide a model system for future 
mechanistic investigation of early disease pathology and neurotoxicity testing, 
pertinent to psychiatric conditions and Alzheimer’s disease (AD)182,183,187. 
Degeneration of inhibitory GABAergic MSNs in the neostriatum underlies the 
neuropathology of Huntington’s disease (HD), a late-onset inherited 
neurodegenerative disorder leading to motor disturbances (i.e. chorea movements), 
together with cognitive and neuropsychiatric impairments
188
. Significant 
advancements have been made in directing pluripotent human stem cells to generate 
both authentic nigral and striatal phenotypes in vitro, required for PD and HD cell-
based therapies respectively
78,79,87,189,190
, however, like PD, further research into the 
signalling pathways governing GABAergic specification and differentiation is 
necessary to convert stem cells to enriched and high yield populations of GABAergic 
MSNs
191
.  
Recently, researchers have reported the significance of nicotinamide to protocols for 
a range of neurological disorders due to its capacity to ameliorate PD
192,193
, 
HD
194,195
, AD
196
 and stroke
131
 in animal models relevant to these diseases. 
Specifically, nicotinamide was shown to improve motor deficits in a Drosophila 
model of PD
193
 and promote neuroprotective effects towards DAergic neurons in 
different PD mouse MPTP models
192
. Nicotinamide has also been reported to 
alleviate motor deficits and upregulate peroxisome proliferator-activated receptor 
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gamma coactivator 1-alpha (PCG-1α; a key regulator of mitochondrial biogenesis 
and respiration) and the neurotrophic factor BDNF in a mouse model of HD
195
;  
decrease neuronal loss and motor impairment in the Drosophila model of HD
194
; 
reduce cognitive deficits in AD transgenic mice
196
, and function as a robust 
neuroprotective agent to enhance neurological outcome and decrease brain infarction 
volume in animal models of stroke
131
. Furthermore, there is growing evidence to 
suggest an important role for nicotinamide during early development, to promote and 
enhance various aspects of cellular morphology and maturation
141,197,198
.  
Building on previous data outlined in Chapter 3, nicotinamide induced neuron-
enriched cultures when added at appropriate concentrations at appropriate 
developmental time-points of monolayer ESC differentiation; however it is not clear 
whether this vitamin B3 metabolite could enhance the generation of neurons enriched 
for particular subtypes implicated in a diverse range of neurological disorders. 
Therefore, based on existing literature linking nicotinamide to neurological protocols 
and methods to enhance cellular development, the hypothesis under investigation in 
this chapter was that nicotinamide could promote the differentiation and/or 
enrichment of specific neurons exhibiting distinct neurotransmitter phenotypes. 46C 
mESC-derived neurons widely express neuronal subtype markers, relevant to a range 
of neurological disorders including PD, HD and neuropsychiatric conditions
170,199
, 
thereby making it an appealing differentiation system to address this hypothesis. 
This experimental chapter aimed to:  
I. Investigate whether nicotinamide promotes the generation of higher yields of 
enriched neuronal subtype populations (i.e. catecholaminergic, serotonergic, 
glutamatergic and GABAergic neurons),  to progress stem cell protocols for 
replacing degenerated neurons for transplantation therapies in BG 
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disorders, biological investigation, neurological disease modelling and 
pharmaceutical screening.  
 
II. To study the effect of nicotinamide on neuronal morphogenesis during early 
development in GABAergic and catecholaminergic populations, since there is 
a major need to generate functional and mature neuronal cell types for HD 
and PD, respectively.  
 
4.2 Experimental Procedure 
This chapter aimed to investigate whether the vitamin B3 metabolite, nicotinamide, 
could promote either the specification and/or maturation of developing neuronal 
subtypes characteristic of the BG neurocircuitries, from the 46C Sox1GFP reporter 
cell line.  
4.2.1 Cell culture and nicotinamide treatment  
To test whether nicotinamide treatment induced neural subtype specification, the 
effects of different nicotinamide concentrations were selected based on their 
previous differentiation-inducing effects, outlined in Chapter 3. Thus, monolayer 
cultures were treated with 5 mM and 10 mM nicotinamide at the initial stages of 
differentiation (i.e. day 0-7), and the cells were further differentiated up to a total of 
14 days (detailed account provided in section 3.2.1).  
4.2.2 Immunocytochemistry 
Immunocytochemistry and fluorescence microscopy were performed to evaluate the 
effect of nicotinamide on different classical neurotransmitters phenotypes of the BG 
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circuitry, which included GABA, glutamate, catecholamine and serotonin. To 
achieve optimum staining results, newly introduced antibodies to the laboratory were 
tested in accordance with the manufacturers’ recommended dilution ranges, to 
establish appropriate working dilutions. Primary neuronal cells known to express a 
particular antigen were selected, to serve as positive controls for the 
immunocytochemistry. Double-label immunofluorescence was used to detect co-
localisation of the neuron specific βIII-tubulin marker with antibodies against the 
inhibitory neurotransmitter GABA, TH (the rate-limiting enzyme in catecholamine 
biosynthesis), vesicular protein VGlut2 (marker for excitatory glutamatergic 
synapses) and 5-HT (immunomarker for serotonin). All cell counts were expressed 
as a percentage of total neurons counterstained with βIII-tubulin, and as a percentage 
of total cells counterstained with DAPI. 
4.2.3 Morphometric analysis 
Morphometric analyses were used to assess the extent of neuronal differentiation in 
the presence of nicotinamide. Fluorescent images were acquired using a high power 
objective lens (i.e. x 40 lens) and importantly, exposure settings were kept constant 
across all conditions. Four morphological parameters were investigated: (1) 
measurement of neurotransmitter content within neuronal cell bodies (soma); (2) 
number of primary neurite branches; (3) length of longest neurite (µm), and (4) total 
neurite extent (µm). Measurements of FI were used to quantify marker expression 
levels of neurotransmitter phenotypes within individual neuronal cell bodies, using 
Image-J software (detailed in section 2.1.8.1), and measures of neurite outgrowth 
were assessed using the ImageJ plug-in NeuronJ (described previously in section 
2.1.8.2).  
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4.2.4 Image and statistical analysis 
Analysis of neuronal morphology and maturation were performed on neurons 
randomly selected from three independent experiments. For all experiments in this 
chapter, statistical analysis was performed by one-way ANOVA followed by a post-
hoc Tukey multiple comparison test when required, using a level of p<0.05 as a limit 
for statistical significance. Data are expressed as mean ± SEM.  
4.3 Results   
4.3.1 Primary antibody optimisation for immunocytochemistry 
Positive staining controls were used to establish optimum working dilutions and 
support the validity of newly introduced antibodies to the laboratory, to ensure an 
accurate interpretation of immunocytochemistry results in this experimental study.  
 
Figure 4.1 Antibody optimisation for immunocytochemistry. Rabbit polyclonal 
GABA antibody was optimised using LGE-derived primary neuronal cultures, 
obtained from E15 rat embryos. Striatal GABAergic neurons are derived from the 
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germinal zones of the LGE located in the subventricular zone of the developing 
telencephalon.
191
 Since the peak period of MSN neurogenesis occurs in the whole 
ganglionic eminence at approximately E14 in the rat,
63
 cultured E15 LGE cells 
should express high levels of relevant antigen expression required for optimising the 
anti-GABA antibody. (A&B) Bright-field images of E15 LGE-derived primary 
neurons at 7 DIV (A) Scale bar = 50 µm; (B) Scale bar = 100 µm. (C&D) LGE 
cultures give rise to the principal source of GABAergic (red)-expressing (projection) 
neurons. The nuclei of all cells in cultures were labelled with DAPI (blue). (C&D) 
Scale bar = 50 µm.  
 
 
Figure 4.2 Antibody optimisation for immunocytochemistry. Rabbit polyclonal 
VGlut2 antibody was optimised using developing cortical-derived primary tissue 
harvested from E15 rat embryos. (A&B) Bright-field images of E15 cortical-derived 
primary neurons (A) Scale bar = 50 µm; (B) Scale bar = 100 µm. (C&D) VGlut2 is a 
glutamate transporter expressed in the membrane of synaptic vesicles. 
Representative images of primary cells dissected from the cerebral cortex showing 
cultures enriched in glutamatergic (red)-expressing neurons. The nuclei of all cells in 
cultures were labelled with DAPI (blue). (C&D) Scale bar = 50 µm. 
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4.3.2 Nicotinamide selectively enhances the production and enrichment of 
neurotransmitter phenotypes from mESCs.  
To determine the potential of the vitamin B3 metabolite, in terms of the percentage of 
specific neurotransmitter subtypes generated from the monolayer-derived Sox1GFP 
knock-in 46C cell line, the effects of nicotinamide on neuronal enrichment and 
differentiation were investigated. In all experiments, undifferentiated cells were 
treated with 5 mM and 10 mM nicotinamide at an early stage of development, i.e. 
between days 0 and 7, and the cells were further differentiated up to a total of 14 
days of the monolayer culture period.  
4.3.2.1 Nicotinamide treatment enhanced the production and enrichment of 
catecholaminergic neurons from mESCs. 
In agreement with previous evidence, factor-free neural differentiation (i.e. N2B27 
differentiation medium without inductive signalling molecules or exogenous growth 
factors) of Sox1GFP mESCs produced low numbers of catecholaminergic-expressing 
neurons per culture, as examined by TH immunocytofluorescence.
164
 However, 10 
mM nicotinamide treatment induced almost a two-fold increase in the percentage of 
cells double-labelled for βIII-tubulin and TH [ANOVA F(2,8) = 132.5;  p<0.001] 
[20.0 ± 0.8% vs. 7.5 ± 0.2% in control conditions; Figure 4.3 (A-C)], thereby 
generating significantly purer TH
+
 neuronal populations. Additionally, in cultures 
exposed to 5 mM nicotinamide, the percentage of catecholaminergic cells per total 
neurons was also significantly higher [13.9 ± 0.3%; p<0.001; Figure 4.3 (C)], albeit 
this effect was not so marked as for 10 mM nicotinamide.  
Consistent with data in Chapter 3, outlining the ability of nicotinamide to promote a 
concentration-dependent increase in the percentage of βIII-tubulin-expressing 
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neurons, nicotinamide treatment also elicited a significant increase in the percentage 
of TH
+
 immunoreactive neurons of the whole cell population, in a concentration 
dependent manner, peaking at a dose of 10 mM [ANOVA F(2,11) = 17.8;  p<0.001]. 
At 10 mM nicotinamide concentration, the percentage of TH
+
 neurons per total cells 
was significantly increased, in comparison to all other treatment groups [4.2 ± 0.5% 
vs. 0.6 ± 0.3% in controls; Figure 4.3 (A-B) (D)].  
These results show that mESCs differentiated in serum-free medium with 
nicotinamide alone, devoid of other exogenous proteins or signalling molecules 
associated with their development in vivo, showed enhanced catecholaminergic 
differentiation and more importantly, enrichment for TH-expressing neurons.  
 
Figure 4.3 Addition of nicotinamide increased and enriched the population of 
catecholaminergic neurons from mESCs. (A&B) Immunocytochemical analysis 
of monolayer cultures supplemented with N2B27 medium without nicotinamide (A) 
and with the addition of 10 mM nicotinamide (B). Representative images show 
immunostaining with antibodies specific to TH (red) and the immature neuronal 
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marker βIII-tubulin (green). Total cells in cultures counterstained with DAPI (blue). 
Scale bar = 50 µm.  
(C) Bars represent percentage TH immunoreactive neurons as a proportion of total 
βIII-tubulin-expressing neurons. Monolayer cultures exposed to both 5 mM and 10 
mM nicotinamide between days 0 and 7 generated significantly enriched yields of 
TH neurons at day 14, in a dose-dependent manner. (D) Bars represent percentage 
TH immunoreactive neurons as a proportion of total cells. Differentiating cultures 
treated with 10 mM nicotinamide show a significant increase in the percentage of 
TH-positive neurons per culture, compared to untreated conditions. 
***p<0.001 
To investigate whether nicotinamide influenced another DAergic marker, co-
expression of TH
+
 neurons with the DAT was investigated. Immunocytofluorescence 
analysis showed that TH
+
 neurons co-labelled with DAT were not detected at day 14, 
in monolayer cultures [Figure 4.4 (A)]. This observation might signify that neurons 
are still at an early stage of terminal differentiation, since DAT is a well-established 
late-stage marker of mature DAergic phenotypes
200
. Equivalently, 
immunofluoresence for the vesicular glutamate transporter protein, VGlut2 
expressed in synaptic vesicles in glutamatergic neurons, was not detected in neurons 
differentiated from mESCs [Figure 4.4 (B)], suggesting that formation of functional 
synapses is still ongoing at this time point of differentiation in adherent cultures.  
 
Figure 4.4 (A) Double-staining techniques 
indicated that DAT (a later marker of 
mature DAergic neurons) was not co-
localised with TH-expressing neurons at 
day 14 of monolayer differentiation. (B) 
Expression of VGlut2 immunoreactivity, a 
glutamate transporter found in the 
membrane of synaptic vesicles was not 
detected in differentiated neuronal cells. 
Scale bars = 50 µm 
 
 
112 
 
4.3.2.2 Nicotinamide treatment enhanced the production and enrichment of         
serotonergic neurons from mESCs. 
Monolayer cultures treated with early administration of nicotinamide also revealed a 
concentration-dependent effect on the differentiation of 5-HT-expressing
 
neurons. 
Cells exposed to 10 mM nicotinamide gave rise to a significantly higher percentage 
of enriched neurons double-labelled for βIII-tubulin and 5-HT [ANOVA F(2,185) = 
11.8;  p<0.001] [36.1 ± 3.6% vs. 9.2 ± 3.1% in control cultures; Figure 4.5 (A-C)]. 
In addition, 5 mM nicotinamide significantly enriched the yield of serotonergic 
neurons expressed as a percentage of all βIII-tubulin+ neurons [28.5 ± 4.3% with 5 
mM nicotinamide; p<0.01; Figure 4.5 (C)]. Consequently, nicotinamide (5 mM and 
10 mM) induced a larger proportion of serotonergic neurons within the total DAPI
+
 
cell population [ANOVA F(2,210) = 14.80] [3.1 ± 0.5% with 5 mM nicotinamide;  
p<0.01; 4.9 ± 0.6% with 10 mM nicotinamide;  p<0.001 vs. 0.8 ± 0.3% in control 
groups; Figure 4.5 (D)]. 
Taken together, these experiments indicate that cultures induced with a period of 
early exposure to nicotinamide enhanced the yield and purity of TH-positive and 5-
HT-positive neurons from mESCs in vitro. Therefore, it is reasonable to speculate 
that nicotinamide treatment in conjunction with appropriate inductive signalling 
factors during neural specification could be important for directing and optimising 
yields of stem cell-derived cells adopting a ventral midbrain/hindbrain fate.  
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Figure 4.5 Addition of nicotinamide increased and enriched the population of 
serotonergic neurons from mESCs. (A&B) Immunocytochemical analysis of 
monolayer cultures supplemented with N2B27 without nicotinamide (A) and with 
the addition of 10 mM nicotinamide (B). Representative images show 
immunostaining with antibodies specific to serotonin (red) and immature neuronal 
marker βIII-tubulin (green). Total cells in cultures counterstained with DAPI (blue). 
Scale bar = 50 µm.  
(C) Bars represent percentage serotonergic immunoreactive neurons as a proportion 
of total βIII-tubulin-expressing neurons. Dose responsive increase in the percentage 
of serotonergic immunoreactive neurons was obtained with nicotinamide, thus 
enriching the yield of serotonin-expressing neurons. (D) Bars represent percentage 
serotonergic immunoreactive neurons as a proportion of total cells. The percentage 
of serotonergic neurons obtained from mESCs increased when nicotinamide was 
added to media up to a concentration of 10 mM.  
***p<0.001, **p<0.01.  
 
4.3.2.3 Nicotinamide treatment enhanced the production of GABAergic neurons 
from mESCs. 
Double immunofluorescence with anti-GABA and neuron-specific βIII-tubulin 
demonstrated that the majority of Sox1GFP-derived neurons were immunopositive 
for GABA, in line with other studies using the Sox1GFP knock-in 46C cell line
164,172
. 
114 
 
Interestingly, in undifferentiated cultures exposed to 5 mM and 10 mM nicotinamide 
concentrations, the percentage of GABA-expressing neurons co-labelled with βIII-
tubulin was not significantly different from levels obtained under control conditions 
[Figure 4.6 (A-C)]. Therefore, nicotinamide did not enrich the proportion of neurons 
expressing the inhibitory neurotransmitter, GABA.  
However, consistent with the higher proportion of βIII-tubulin neurons observed in 
nicotinamide groups, 10 mM nicotinamide-stimulated conditions doubled the 
percentage of GABAergic neurons of the total cell population labelled with DAPI, 
compared to untreated cells [ANOVA F(2,153) = 35.4;  p<0.001] [22.8 ± 1.2% vs. 
10.7 ± 0.8%; Figure 4.6 (A-B) (D)]. No significant differences in the percentage of 
GABA-expressing neurons were observed between control and 5 mM nicotinamide 
treatment conditions.  
 
Figure 4.6 Addition of nicotinamide increased the population of GABAergic 
neurons from mESCs. (A&B) Immunocytochemical analysis of monolayer cultures 
supplemented with N2B27 without nicotinamide (A) and with the addition of 10 mM 
nicotinamide (B). Representative images show immunostaining with antibodies 
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specific to the inhibitory neurotransmitter GABA (red) and immature neuronal 
marker βIII-tubulin (green). Total cells in cultures counterstained with DAPI (blue). 
Inhibitory GABAergic neurons represented the most prevalent neuronal subtype in 
Sox1GFP mESC-derived monolayer cultures. Scale bar = 50 µm.  
(C) Bars represent percentage GABAergic immunoreactive neurons as a proportion 
of total βIII-tubulin-expressing neurons. Nicotinamide had no effect on this 
parameter. (D) Bars represent percentage GABAergic immunoreactive neurons as a 
proportion of total cells. Nicotinamide (10 mM) added to media generated a 
significant increase in the percentage of the total GABAergic cell population, 
compared against control groups.  
***p<0.001 
 
To assess whether nicotinamide influenced the population of mature striatal 
GABAergic MSNs, cultures were processed immunocytochemically with antibodies 
against GABA and the striatal specific marker, Dopamine and cAMP-regulated 
Phosphoprotein (DARPP-32). Immunocytofluorescence analysis showed that mature 
DARPP-32 expressing GABAergic neurons were undetectable under the 
differentiation conditions used in this monolayer culture system (Figure 4.7), and 
which may also further support the hypothesis that 46C-derived neurons are at an 
early stage of maturation at day 14 of monolayer differentiation. 
 
Figure 4.7 Double-staining techniques indicated that DARPP-32 (a marker of 
striatal projection neurons) was not co-localised with GABA-expressing neurons at 
day 14 of monolayer differentiation. Scale bar = 50 µm 
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In summary, these data demonstrate that Sox1GFP derived-mESCs differentiated 
with an early exposure to nicotinamide exhibit higher yields of catecholaminergic, 
serotonergic and GABAergic neurons per culture. Importantly, differentiated cell 
populations induced with nicotinamide were selectively enriched for 
catecholaminergic and serotonergic neurons, but not for GABAergic cells. These 
important findings suggest that nicotinamide added at appropriate concentrations at 
the onset of the ESC differentiation process, may function as an important signalling 
factor to determine neural commitment/subtype specification to certain 
neurotransmitter phenotypes in vitro. 
 
4.3.3 Nicotinamide differentiation accelerates the early stages of neuronal 
development in catecholaminergic and GABAergic populations.  
The effect of the vitamin B3 metabolite on neurodevelopment and maturation was 
next investigated in Sox1GFP mESC-derived catecholaminergic and GABAergic 
neuronal populations. Early neuronal development commences with elongation of 
neurite processes followed by axon differentiation, dendritic branching and synaptic 
formation
201
. Therefore, the effect of nicotinamide on a series of distinct maturation 
stages during differentiation was studied to assess primary neurite outgrowth (i.e. 
length of the longest neurite), total neurite outgrowth and the number of primary 
neurite branches per neuron.  
In addition, similar to GFP immunoreactivity (outlined in Chapter 3, section 
3.3.4.4.), catecholaminergic and GABAergic neurons exhibit variations in the 
intensity of TH and GABA expression respectively, resulting in a spectrum from 
weak to strong fluorescence. It was hypothesised that cells expressing higher levels 
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of immunostaining represented more mature neuronal subtypes, since strong staining 
reflects more neurotransmitter content. Therefore, to investigate the effect of 
nicotinamide on weak and intense-expressing neuronal subtypes, individual cell 
bodies were scored for levels of protein using FI measures, described previously in 
Chapter 2 (section 2.1.8.1).  Briefly, GABA and TH-expressing cells were 
categorised as ‘weak’ (FI ≤ 0.1 units) and ‘strong’ (FI ≥ 0.2 units).  
4.3.31 Nicotinamide promotes various aspects of TH
+
 neuronal morphology 
Image analysis indicated that for TH
+
 cells, the average primary neurite length was 
significantly higher in 10 mM nicotinamide conditions than those of control and 5 
mM nicotinamide conditions [123.6µm  ± 6.5 for 10 mM groups; p<0.001; 97.9µm 
± 7.0 for 5 mM groups; n.s., vs. 74.5µm  ± 6.1 in controls; Figure 4.8 (A-B) (D)].  
Further, binning the data into the proportion of TH
+
 neurons with short (≤ 60µm), 
medium (60-120µm) and long (≥ 120µm) primary neurite processes, confirmed that 
10 mM nicotinamide treatment increased neurite extensions in cells derived from 
Sox1GFP mESCs. Specifically, the proportion of 46C-derived TH
+
 cells displaying 
“long” primary neurite outgrowths was significantly increased in cultures exposed to 
10 mM nicotinamide only [0.4 ± 0.1 vs. 0.1 ± 0.1 in control conditions; p<0.05; 
Figure 4.8 (E)], concomitant with a significant decrease in the proportion of 
“shorter” TH+ primary neurites [0.1 ± 0.0 vs. 0.4 ± 0.0 in control groups; p<0.05; 
Figure 4.8 (E)].  
Monolayer cultures treated with 10 mM nicotinamide also resulted in TH
+
 neurons 
with significantly increased total neurite extent [197.9µm ± 11.5 vs. 118.8µm ± 7.0 
in controls groups; p<0.05; Figure 4.8 (F)]. Although the numbers of neurites per 
neuron were not changed [Figure 4.8 (G)], nicotinamide promotes neurite elongation 
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in TH
+
 cells, thus suggesting an important role at the early maturation stages of 
neuronal development.  
In agreement with the rapid maturation effect elicited by 10 mM nicotinamide, a 
substantial increase in the proportion of catecholaminergic cells displaying more 
neurotransmitter content was observed. Cultures treated with 10 mM nicotinamide 
revealed an upward trend in the percentage of neurons per culture displaying 
“strong” TH immunofluorescence [0.9 ± 0.0 vs. 0.4 ± 0.2 in untreated conditions; 
Figure 4.9 (C) (H)], concomitant with a marked downward trend in the percentage of 
“weak” TH-expressing cells in differentiated cultures (0.1 ± 0.0 vs. 0.6 ± 0.2 in 
controls). Therefore, following brief exposure to nicotinamide between day 0 and 7, 
mESC-derived TH
+
 neurons appeared to more mature since they possessed extended 
primary neurite outgrowths and increased total neurites, correlating with a 
pronounced upward trend in the percentage of TH
+ 
neurons expressing intense 
immunoreactivity.  
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Figure 4.8 Nicotinamide enhanced neuronal maturation in DAergic 
populations. (A-B) Representative images of TH
+ 
neurons in (A) monolayer control 
conditions and (B) cultures with 10 mM nicotinamide. Morphometric analyses were 
performed on fluorescent images inverted to black and white for clarity. (C) The 
levels of protein expression in TH-expressing neuronal cell bodies were assessed to 
establish the degree of maturation of neurons with and without nicotinamide 
treatment. Some cells showed intense TH immunoreactivity (yellow arrows) and 
some less strong TH expression (white arrow). Scale bars = 50 µm. (D) The scatter 
graph depicts individual readings for primary neurite length in TH-expressing cells 
at day 14. Average neurite length was significantly increased in 10 mM 
nicotinamide-treated cultures, compared to all other conditions. (E) Bar chart 
showing the proportion of cells with short (green bars), medium (orange bars) and 
long (red bars) values of primary neurite outgrowth (µm). The proportion of 46C-
derived cells displaying “short” primary processes was significantly decreased in 
cultures exposed to 10 mM nicotinamide between days 0 and 7, concomitant with an 
increase in “longer” primary neurites, compared with controls. (F) In addition to 
increased primary neurite extension in TH-expressing cells, increases in total neuritic 
extent (µm) were highly significant in 10 mM nicotinamide cultures versus controls. 
(G) The number of primary neurites per neurons was not significantly different 
across all conditions. (H) Bar chart showing the proportion of cells with weak 
(brown bars) and strong (red bars) levels of TH expression (arbitrary units), 
indicative of neurotransmitter content within cell soma. A marked upward trend 
showing the proportion of 46C-derived cells displaying “strong” levels of TH 
expression was demonstrated in cultures exposed to 10 mM nicotinamide, 
concomitant with a downward trend in “weaker”-expressing TH+ cells, compared 
with controls and 5 mM nicotinamide conditions.  
*p<0.05 
 
4.3.3.2 Nicotinamide promotes various aspects of GABAergic neuronal 
morphology. 
Similar to morphometric analysis performed in TH-expressing neuronal populations, 
several types of GABAergic neuronal morphologies were also observed in 
monolayer cultures at day 14 of differentiation, i.e. GABAergic neurons with short, 
medium and long neurite processes, and these neurons exhibited differences in 
fluorescence intensities.  
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Data for mean primary neurite outgrowth values highlighted a significant increase 
for neurite length in postmitotic GABA neurons treated with 10 mM nicotinamide 
[116.2µm ± 6.2 vs. 80.9µm ± 4.4 in controls; p<0.001; Figure 4.9 (A-B) (D)]. 
Similarly, 5 mM nicotinamide treatment promoted a significant increase in neurite 
length [102.1µm ± 5.1; p<0.05; Figure 4.9 (D)].  
Specifically, in 10 mM nicotinamide conditions, an upward trend in the proportion 
of cells exhibiting “medium” (51.5 ± 1.3 vs. 47.8 ± 4.6 in controls; n.s.) and “long” 
(34.5 ± 2.9 vs. 15.2 ± 1.2 in controls; n.s.) neurite outgrowths were shown, 
subsequently resulting in a significant reduction of the proportion of GABAergic 
neurons displaying “short” primary neurite branches [14.0 ± 2.4 vs. 36.9 ± 4.2 in 
control conditions; p<0.001; Figure 4.9 (E)]. Similarly, cells exposed to 5 mM 
nicotinamide revealed a comparable trend, resulting in a significant reduction in the 
proportion of neurons displaying “shorter” neurite lengths compared to untreated 
cultures [19.9 ± 0.4 vs. 36.9 ± 4.2 in control conditions; p<0.05.; Figure 4.9 (E)]. 
Further, total neurite extent was significantly increased in 10 mM nicotinamide 
cultures, compared to controls [146.9µm ± 6.7 vs. 104.3µm ± 5.1 in control groups; 
p<0.001; Figure 4.9 (F)]. Nicotinamide treatment induced no significant changes in 
the number of primary neurites per neuron, compared to untreated conditions [Figure 
4.9 (G)].  
In cultures treated with 10 mM nicotinamide, enhanced maturation of GABAergic 
neurons at the early stages of neurodevelopment was further evidenced by elevated 
levels of neurotransmitter content within neuronal cell bodies. Binning analysis 
showing the percentage of 46C-derived neurons exhibiting “weak” and “strong” 
levels of GABA immunoreactivity indicated an upward trend in the percentage of 
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neurons expressing intense GABAergic staining, observed in cultures differentiated 
with 10 mM nicotinamide [0.6 ± 0.0 vs. 0.5 ± 0.1 in untreated conditions; Figure 4.9 
(C) (H)]. Correspondingly, the percentage of weak-expressing GABAergic neurons 
was reduced in 10 mM nicotinamide-treated cultures [0.4 ± 0.0 vs. 0.5 ± 0.1 in 
control conditions; Figure 4.9 (C) (H)].  
 
 
Figure 4.9  Nicotinamide enhanced neuronal maturation in GABAergic 
populations. (A-B) Representative images of GABAergic neurons in (A) monolayer 
control conditions and (B) cultures with 10 mM nicotinamide. (C) Some cells 
showed intense GABA immunoreactivity (yellow arrows) and some less strong 
GABA expression (white arrows). Scale bars = 50 µm. (D) The scatter graph depicts 
individual readings of primary neurite length (µm) in GABA-expressing cells at day 
14. Average primary neurite length was significantly increased in 5 mM and 10 mM 
nicotinamide-treated cultures, compared to control conditions. (E) Bar chart showing 
the proportion of cells with short (green bars), medium (orange bars) and long (red 
bars) values of primary neurite outgrowth (µm). The proportion of 46C-derived cells 
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displaying “short” primary processes was significantly decreased in cultures exposed 
to 5 mM and 10 mM nicotinamide between days 0 and 7, concomitant with an 
obvious increased trend in “longer” neuritic processes, compared with controls. (F) 
Greater neurite extents were shown in 10 mM nicotinamide cultures versus controls. 
(G) There was no difference in the number of primary neurites per neurons between 
controls and nicotinamide-stimulated conditions. (H) Bar chart showing the 
percentage of cells with weak (brown bars) and strong (red bars) levels of GABA 
immunoreactivity(arbitrary units), correlating to the levels of neurotransmitter 
content within cell soma. An upward trend showing the proportion of 46C-derived 
cells displaying “strong” levels of GABA expression was demonstrated in cultures 
exposed to 10 mM nicotinamide, which correlated with a downward trend in 
“weaker”-expressing GABAergic cells, compared with controls and 5 mM 
nicotinamide conditions.  
***p<0.001, **p<0.01, *p<0.05 
 
In summary, differentiation with nicotinamide (10 mM) rapidly enhanced early 
morphological features in TH
+
 and GABAergic
+
 cells. These data suggest that 
nicotinamide may exert a neurite promoting action on young neuronal subtypes. 
Moreover, upregulated levels of the expression of selected neuronal subtype proteins 
further confirmed the accelerative effect of nicotinamide on neuron maturation. 
These findings strongly support previous data outlined in Chapter 3, highlighting the 
importance of nicotinamide-promoted differentiation to rapidly induce the loss of 
stem cell identity, accelerate neural fate and in turn accelerate neuronal maturation 
during early development.  
4.4 Discussion 
Findings demonstrated in this experimental chapter show that the biologically active 
vitamin B3 metabolite, nicotinamide, not only functions as a neuroprotective agent in 
several neurodegenerative diseases, as reported in the literature but also has an 
important role to play during cell differentiation. The ESC monolayer model system 
was chosen for this study since DAergic, serotonergic and GABAergic neurons can 
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be efficiently obtained from Sox1GFP
+
 populations
172,202
, thus making it an ideal 
system to fully evaluate the effects of nicotinamide on neuronal subtype lineage 
analysis and neurodifferentiation. In order to address the question whether 
nicotinamide stimulates DAergic, serotonergic and GABAergic differentiation, 
mESCs carrying a neuroepithelial specific vital reporter (Sox1GFP knock-in 46C cell 
line) were exploited in combination with N2B27 neural differentiation medium, 
independent of exogenous and inductive signalling molecules and without the 
requirement of feeder cells. 
In this study, a novel function for nicotinamide during neural subtype differentiation 
was shown: namely altering the proportion of neurons expressing specific 
phenotypic properties in a concentration-dependent manner, thus generating 
selectively enhanced and/or purer neuronal subtype yields pertinent to a range of 
BG-associated disorders. In addition, its function was also associated with enhanced 
neurite elongation and increased levels of neurotransmitter content within the cell 
bodies of distinct neuronal subpopulations, therefore indicative of an accelerative 
effect on the maturation of Sox1GFP-derived neurons. These important findings 
provide crucial evidence that under serum-free and factor-free differentiation 
conditions, enhanced neural subtype commitment and neuronal morphogenesis were 
predominantly due to the independent effect of nicotinamide, applied during distinct 
stages of SC neural fate (i.e. day 0-7).  
4.4.1 Nicotinamide promotes neural phenotype differentiation in the absence of 
exogenous inductive molecules from ESCs.  
With relevance for future treatment of PD, ongoing research into stem cell sources 
such as ESCs, adult stem cells and iPSCs are being considered for DA neuronal 
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replacement therapies
74
. However since the most advanced work to date is being 
undertaken with ESCs
78,79,155
, this chapter investigated whether nicotinamide may be 
a useful signalling molecule to generate DAergic neurons from mESCs in vitro. To 
my knowledge, this current experimental study presents the first report investigating 
the effect of nicotinamide on the production of catecholaminergic cells in a 
monolayer differentiation paradigm, and showed that administration of this 
compound at the initial stages of ESC differentiation enhances the yield of TH-
expressing neurons. 
In control cultures, no appreciable numbers of TH
+
 cells were observed, which is 
also in line with other studies where few DAergic cells are generated in the absence 
of the ventralising signals; Shh and FGF8
199
. However, 10 mM nicotinamide 
treatment directly increased the percentage of TH
+
 neurons of the total cell 
population. In addition, nicotinamide increased the percentage of TH
+
 neurons per 
total neurons, producing purer DAergic neuronal yields and highlighting the 
relevance of nicotinamide for catecholaminergic differentiation. A study conducted 
under similar monolayer differentiation conditions (a total of 14 days of 
differentiation) reported that the number of TH
+
 neurons (expressed as a percentage 
of the total βIII-tubulin+ population) derived from Sox1GFP+ populations increased 
when Shh and FGF8 were applied at peak neurogenesis (i.e. Sox1
+
 NPC production), 
corresponding to ~28% of the percentage of TH-expressing neurons versus ~9% in 
control cultures (comparable to 7.5 ± 0.2% in control conditions reported in this 
experiment)
178
. These important observations suggest that nicotinamide 
supplementation alone during ESC differentiation displayed almost a similar potency 
to these well-established inductive signalling factors, thus suggesting a strong 
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applicative potential for nicotinamide in current restorative cell-based protocols for 
PD. 
The effect of nicotinamide was also focused on 5-HT differentiation from mESCs in 
vitro. The 5-HT-synthesising neurons represent another ventral cell fate generated in 
vivo, originating from the anterior and posterior of the isthmic organiser, which 
provides a source of signalling factors regulating midbrain and hindbrain 
patterning
83
. Therefore, methods developed for generating DAergic neurons from 
stem cell sources share similar differentiation pathways with serotonergic neurons in 
vivo
203
. Interestingly, in addition to enhanced and enriched DAergic differentiation 
with nicotinamide, comparable effects were also observed with respect to 
serotonergic differentiation from the 46C Sox1GFP cell line, suggesting that 
nicotinamide is also important for directing serotonergic neuronal fates. Specifically, 
treatment of monolayer cultures with 10 mM nicotinamide in particular had a distinct 
activity in promoting differentiation of ESCs into significantly higher and purer 
serotonergic neuronal yields. In light of these findings, future work should 
investigate the effect of nicotinamide with Shh, FGF8 and noggin (a known agonist 
of BMP), shown to also be important during hindbrain serotonergic neuronal 
differentiation
185,203
, which may further increase and enrich yields of serotonergic 
neurons in ESC culture systems, to open new therapeutic perspectives for the 
treatment of neuropsychiatric disorders. With relevance to serotonin and PD, 
postmortem studies show that the pathology in PD extends past the striatal region
204
 
and the DAergic system
205
. Specifically, PD animal model studies highlighted a link 
between dysfunction of the norepinephrine and serotonergic neuronal systems with 
the occurrence of non-motor symptoms
206,207
, which was further confirmed by 
several positron emission tomography reports in PD patients
208,209
. In this context, 
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Politis et al recently reported a major loss of 5-HT expressing neurons in PD 
patients, particularly in raphe nuclei and regions receiving serotonergic projections 
involved in the regulation of functions such as sleep, mood and emotion.
205
 
Interestingly, this phenomenon was observed in patients who had previously been 
treated with DAergic fVM tissue grafts 13-16 years earlier. Politis and colleagues 
therefore propose that additional grafts of 5-HT expressing neurons may be required 
in future PD cell-based therapies to ameliorate non-motor symptoms by restoring 
serotonergic neurotransmission in affected cerebral targets
205
. In this context, 
nicotinamide may prove beneficial in future protocols for producing high and 
enriched yields of 5-HT neurons from stem cells in vitro.  
MSN GABAergic neuronal differentiation derived from pluripotent sources such as 
hESCs or hiPSCs has been explored, however the differentiation efficiency was low 
for striatal GABAergic neurons
210,211
.  In this study, under control conditions, the 
vast majority of neuronal cells produced by monolayer culture were GABA
+
, 
reflecting similar findings in other studies using Sox1-GFP-derived cultures
164,172,212
. 
Research conducted by Chung et al showed that FACS-purified GFP
+
-derived 
GABAergic neurons represented 51.1 ± 4.9% of the total neuronal population at day 
10 of differentiation; Shin and colleagues showed that the percentage of GABAergic 
neurons obtained under physiological oxygen levels at day 17 of monolayer 
differentiation corresponded to 70-75 % of the βIII-tubulin population213, in line with 
the cell-counting analysis performed in this experiment after 14 days of monolayer 
culture. Results reveal that nicotinamide (10 mM) treatment of mESCs could 
stimulate a significant increase in the production of GABAergic neurons of the total 
cell population; however this compound did not selectively enrich the proportion of 
GABA-expressing neurons generated from Sox1GFP
+
 cells. Nevertheless, this does 
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not negate the potential of nicotinamide as a useful candidate in future protocols for 
accelerating maturation in GABAergic populations.  
GABA
+
 neurons were checked for striatal lineage by immunostaining with DARPP-
32, which is expressed in all MSN neurons in the striatum
214
. Expression of DARPP-
32 was not detected in terminally differentiated cultures at day 14, however, most 
studies report that stem cell-derived cultures generate 10-20 % DARPP-32
+
 
MSNs
215
. Thus, to fully determine the effects of nicotinamide on MSN-
differentiation, future work should focus on the effects of nicotinamide in 
conjunction with ventralising factors using Shh or an agonist, purmorphamine, 
which are necessary to promote the emergence of a forebrain phenotype from 
ESCs
215
, or indeed with RA which has been shown to function a key GABAergic 
differentiation signal in the BG circuitry
191
.  
Finally, the effect of nicotinamide was also investigated on glutamatergic 
differentiation. Challenges arise in glutamate immunocytochemistry due to the 
difficulty involved in accurately distinguishing immunocytochemical staining, 
resulting from metabolic glutamate, from labelling caused by transmitter 
glutamate
216
. Therefore, with respect to experimental design in this study, an anti-
glutamate antibody was not selected, which was previously employed in the report 
conducted by Chung and colleagues
172
. Instead, βIII-tubulin+ neurons were analysed 
by immunocytochemistry for co-expression with the glutamate transporter marker, 
VGlut2. Glutamatergic neurons were not detected in this experimental system at day 
14 leading to the hypothesis that monolayer-derived cells are still at the early phases 
of termination undergoing the formation of functional synapses, since VGlut2 is 
expressed in the membrane of synaptic vesicles. Collectively, the absence of VGlut2 
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and DAT under the differentiation conditions established in this study are consistent 
with similar observations in Sox1-GFP 46C cultures
170
.   
4.4.2 Nicotinamide accelerates the formation of neuronal processes.  
Several reports support a role for nicotinamide in cellular maturation and 
differentiation processes
141,198,217
. Therefore, the effects of nicotinamide on cell 
morphology in TH-expressing and GABAergic-expressing populations were next 
addressed. During neurogenesis, following cell-cycle exit, immature neurons initiate 
the formation and elongation of neurites, which ultimately develop into axons and 
dendrites. In this context, this study reports a positive role for nicotinamide at the 
initial phases of neuronal maturation in young subpopulations. Specifically, 
increased primary neurite outgrowth and total neurite output were observed in 
GABAergic and DAergic neuronal populations. Thus, Sox1GFP-derived neurons 
differentiated with nicotinamide between days 0 and 7 undergo neuronal 
morphogenesis earlier than cells induced with N2B27 medium alone. These findings 
are consistent with the faster differentiation of ESCs, earlier emergence of Sox1GFP
+
 
NPCs and, as a consequence, βIII-tubulin+ neuronal cells in nicotinamide-treated 
monolayer cultures; findings outlined in Chapter 3. This rapid maturing effect 
elicited by the vitamin B3 metabolite was further confirmed by stronger GABA and 
TH immunofluorescence, indicative of increased levels of neurotransmitter content 
within cell bodies. These data obtained from both transmitter phenotypic populations 
signify an important role for nicotinamide at the initial stages of neuronal 
maturation. 
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4.4.3 Conclusion and Further Studies 
Nicotinamide selectively enhanced and enriched the production of catecholaminergic 
and serotonergic neurons and, moreover, enhanced various aspects of neuronal 
morphology in catecholaminergic and GABAergic populations. In accordance with 
findings in Chapter 3, these data suggest that nicotinamide may function as a critical 
instructive molecule at the initial stages of embryonic stem cell differentiation, to 
rapidly and efficiently direct lineage specific differentiation /neural commitment to 
highly enriched neuronal lineages by eliminating non-neural cells. 
With respect to PD, it is important to point out that the majority of TH
+
-expressing 
DA neurons generated under these monolayer differentiation conditions in the 
absence of patterning factors are heterogeneous with regard to regional identities and 
may not represent midbrain specific DAergic phenotypes
178
, since their 
differentiation is dependent on Shh signalling
218
. Considering this, in future work, it 
will be of interest to investigate the combined effect of nicotinamide with the 
sequential treatment of factors functioning during normal development to promote 
midbrain specific DAergic neurons. In addition, to investigate the effects of 
nicotinamide on glutamatergic differentiation, it will be necessary to differentiate 
neurons for a longer culture period and then investigate whether nicotinamide 
influences glutamatergic differentiation at a later time point of the monolayer 
protocol. To determine an appropriate later time point, the extent of differentiation 
could be checked for the presence of the synaptic proteins Syn1 and PSD 95, which 
are pre- and post-synaptic markers respectively. Their expression is localised in a 
“punctate pattern” along neurites, similar to the pattern of expression for VGlut2170.  
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Future work will also be required to elucidate the mechanisms underlying the 
promotion of accelerated neuronal maturation, which would lead to a greater 
understanding of neuronal differentiation. A possible explanation for this additional 
effect of nicotinamide on enhanced neuronal development may be that this signalling 
molecule directly induces genes linked to neuronal maturation or with the mature 
state. 
The next chapter will focus on elucidating the mechanism(s) mediating neural 
specification by nicotinamide - that is, induction of cell-cycle exit and/or selective 
apoptosis in non-neural populations, and will also address the possible role of 
sirtuins (silent information regulator 2 (Sir2) family of proteins) during mESC 
differentiation in the Sox1GFP model system.  
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Chapter 5: Investigation of the Mechanism(s) 
Underlying the Enrichment and Enhancement 
of Neuronal Differentiation by Nicotinamide. 
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5.1 Introduction  
A major challenge for advancement of clinical neuronal replacement therapies is the 
production of high yields of purified neuronal populations of appropriate phenotype 
with control over proliferation to prevent tumourigenesis. Previous findings 
demonstrated that treatment of mESC (46C Sox1GFP reporter cell line) monolayer 
cultures with the vitamin B3 metabolite, nicotinamide, at the early onset of 
development decreased the total number of cells in cultures, resulting in a greater 
ratio of neurons to non-neuronal cells. Specifically, by day 14, nicotinamide 
treatment (from day 0-7) reduced the populations of undifferentiated cells and 
Sox1GFP
+
 progenitors, in addition to reducing Oct4
 
and GFP expression in the 
cultures concomitant with enhanced expression of βIII-tubulin, indicative of 
accelerated neuronal differentiation. Thus, this marked reduction in distinct cell 
populations forms a mutually supportive body of data compatible with the previous 
data showing reduction of the total cell population at this time point. The cellular 
mechanisms of nicotinamide in this regard are currently unknown. Therefore, the 
hypotheses under investigation in this study were to determine whether nicotinamide 
promoted inhibition of proliferation, and/or whether nicotinamide induced cell death 
in specific cell populations.  
Further, nicotinamide has been extensively characterised as a potent inhibitor of 
sirtuins, which were identified as NAD+-dependent Class III histone deacetylases. 
Sirtuin proteins are known to play important roles in cellular processes including 
aging, inflammation, and stress resistance
219
. Specifically, the cellular 
[NAD
+
]/[NADH] ratio controls the deacetylase activity of sirtuins, where NAD
+
 
functions as an activator and nicotinamide and NADH work as inhibitors
220
.  
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There are seven known sirtuins (SIRT1-7) in mammals which are linked with varied 
subcellular localisation and enzymatic activity. The most extensively studied sirtuin, 
SIRT1, deacetylates a wide range of histones and non-histone proteins
221
, and  is 
ubiquitously expressed throughout the brain
222
. Initially SIRT1 was described as a 
nuclear protein shown to shuttle to the cytoplasm during neuronal differentiation and 
neurite outgrowth
219,223
. SIRT2 and SIRT3 exhibit NAD-dependent deacetylase 
activity
219
. SIRT2 represents a cytoplasmic protein known to deacetylate tubulin, and 
has also been described in the nucleus during cell-cycle progression
219
. SIRT3, 
SIRT4 and SIRT5 represent mitochondrial sirtuin proteins; however they are each 
implicated in different enzymatic activities. SIRT4 functions as an ADP-
ribosyltransferase, whereas SIRT5 is involved in distinct activities such as NAD-
dependent demalonylase, desuccincylase, and deacetylase activities
219
. SIRT6 
displays deacetylase and ADP-ribosyltransferase activities and is associated with 
chromatin in the nucleus
219
. SIRT7 is a NAD-dependent deacetylase which functions 
as a nucleolar protein
219
.  
Interestingly, SIRT1 plays an important role in mESC differentiation
224
, particularly 
during differentiation into neural progenitors
223,225
. In this regard, there is strong 
evidence linking SIRT1 with a cell-fate decision switch in progenitor cells towards 
neurons or astrocytes [Figure 5.1 (A-C)]. Inhibition of SIRT1 has been shown to 
determine neural cell fate by manipulating the differentiation of neural precursor 
cells towards a neuronal lineage, at the expense of a glial fate
225
. Since the 46C 
Sox1GFP cell line has also been reported to generate glial cell types
169,170
, this study 
sought to determine whether this mechanism is operative, i.e. does the SIRT1 
inhibitor, nicotinamide, reduce glial commitment at the expense of neurons in the 
monolayer protocol? 
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SIRT1 has also been shown to be important for DA neuronal differentiation, and its 
spatial regulation may prove crucial in TH gene regulation
226
. In this context, during 
neurogenesis, SIRT1 undergoes a transient nuclear translocation to promote neuronal 
differentiation [Figure 5.1(A)]
223
. Given that nicotinamide promoted the 
differentiation of TH
+
 neurons in Chapter 4 (section 4.3.2.1), immunocytochemistry 
was used to assess the localisation of SIRT1 within distinct neural populations across 
a spectrum of developmental stages. Furthermore, a reduction in SIRT1 expression is 
conducive to neural fate determination and induction of neuronal differentiation
227
. 
Therefore, to investigate whether SIRT1 is down-regulated during differentiation, 
the expression of SIRT1 at the protein level was assessed at different stages of the 
monolayer protocol.  
To thoroughly investigate these hypotheses, experiments were designed to assess the 
influence of nicotinamide on cell viability, apoptosis, proliferation and SIRT1 
expression during monolayer differentiation. This experimental chapter aimed to:  
I. Measure the effect of nicotinamide on cell viability in differentiating 
monolayer cultures. 
  
II. Investigate the causes of the cell number reduction in nicotinamide-treated 
cultures – e.g., induction of cell-cycle exit and/or induction of cell death in 
specific cell populations.  
 
III. Perform a preliminary study to evaluate SIRT1 expression during mESC 
differentiation in the Sox1GFP model system. 
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IV. Verify whether nicotinamide affects glial commitment at the expense of 
neurons in Sox1GFP-derived mESCs.  
 
 
Figure 5.1 The role of SIRT1 during neurogenesis. (A) It has been reported that 
SIRT1 is predominantly localised in the cytoplasm in NPCs. Under differentiation 
conditions, SIRT1 translocates to the nucleus to interact with the nuclear receptor co-
repressor (N-CoR). This complex (i.e. N-CoR/SIRT1 complex) binds to the Hes1 
gene (downstream target of Notch, which promotes neural lineage entry
149
), thereby 
directing a switch in NPCs towards neuronal differentiation. Representative image 
shows immunostaining with antibodies specific to SIRT1 (red) and the neuronal 
marker βIII-tubulin (green). SIRT1 staining is shown to be primarily nuclear within 
the soma, under differentiation conditions (DIV 7). (B) Inhibition of SIRT1 
promotes neural progenitors toward neuron differentiation. Under reducing 
conditions, the transcription factor Hes1 recruits the CREB binding protein (CBP), 
which activates Mash1 transcription (implicated during neuronal differentiation) and 
directs NPCs to assume a neuronal fate. Representative image show immunostaining 
with antibodies specific to SIRT1 (red) and the neuronal marker βIII-tubulin (green). 
(C) In an oxidising environment, SIRT1 binds with Hes1 on the Mash1 promoter, 
resulting in histone deacetylation. The transcription of Mash1 is repressed, thereby 
directing NPC differentiation in favour of astrogenesis. Representative image shows 
immunolabeling with anti-glial fibrillary acidic protein (GFAP; a principal 
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intermediate filament protein of astrocytes). Diagram adapted from Rodriguez et 
al
228
. (A-C) Scale bars = 50 µm. 
 
5.2 Experimental Procedure 
Cells were treated for 7 days with 10 mM nicotinamide, and then assays performed 
at 7 and 14 days, which consisted of: viability, apoptosis, proliferation and SIRT1 
expression.   
5.2.1 Cell culture and nicotinamide treatment 
Sox1GFP reporter mESCs were cultured in serum-free medium supplemented with 
N2 and B27, as previously described.  
5.2.2 Immunocytochemistry 
Cell immunofluorescence was carried out in accordance with the protocol outlined in 
section 2.1.5.1. In this experimental chapter, the antibodies used for 
immunocytochemistry were against Oct4, βIII-tubulin, GFAP, NG2 [Neuron-glial 
antigen 2; chondroitin sulphate proteoglycan 4; a chondroitin sulfate proteoglycan 
surface marker of oligodendroglial progenitor cells (OPCs)] and SIRT1. In addition, 
fluorescence detection of native GFP expression was used to identify the Sox1 
expressing cells/progenitor cells in adherent monolayer cultures.  
5.2.3 Cell viability assay 
The viability of 46C-derived cells was measured using the Countess
TM
 Automated 
Cell Counter, which was based on the trypan blue exclusion method to distinguish 
viable from nonviable cells. Viable and non-viable cell counts were counted using 
the automated cell counting system, following manufacturer guidelines. Three counts 
per sample were averaged to obtain one value per replicate (i.e. n = 3). Cell viability 
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was calculated as follows: number of viable cells/total number of cells (viable + non-
viable). Detailed protocols are provided in the Material and Methods chapter.  
5.2.4 Apoptotic assay 
The effect of nicotinamide on apoptosis was investigated at day 7 and day 14 in 
adherent Sox1GFP-derived cultures. Apoptosis was determined using an in situ 
TUNEL assay, to preferentially label DNA strand breaks generated during apoptosis. 
This method was combined with examination of cell nuclei integrity, and 
microscopy assessments of cellular morphology were performed using fluorescence 
and phase contrast microscopy. Thus, cells undergoing apoptosis were quantified 
only when they stained positively in the TUNEL assay and exhibited a pyknotic 
nucleus (caused by chromatin condensation). Healthy and apoptotic cells were 
plotted as a percentage of the total numbers of DAPI-stained nuclei per microscopic 
field. A detailed protocol for this experiment is provided in section 2.1.7.  
5.2.5 Cell proliferation assays 
The goal of this study was to assess the influence of nicotinamide on cell 
proliferation, by utilising an EdU cell proliferation assay approach in situ in 
Sox1GFP-dervied cultures. To investigate whether nicotinamide elicited an effect on 
the proliferation of undifferentiated mESCs, progenitor cells and neurons, the 
number of cells that incorporated EdU following exposure to nicotinamide (from day 
0-7) within these distinct cell populations was calculated at days 7 and 14. This was 
achieved using double-staining techniques to identify EdU/Oct4 and EdU/βIII-
tubulin double-labelling in control and treated cultures. Co-labelling of EdU with 
native Sox1GFP-expression was used to identify progenitor cells which had 
undergone mitosis. To test for differences in proliferation between the two 
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conditions, the percentage of proliferating cells was determined by calculating the 
number of proliferating cells/total cells and the number of proliferating cells/specific 
cell types. A detailed protocol for this EdU incorporation study is provided in section 
2.1.6.   
5.2.6 Image Analysis 
All cell counts were produced from a minimum of six random fields per coverslip. 
Cell clusters containing mixed populations of neural progenitor, neuronal and glial 
cells were excluded from data analyses, since individual cells within these dense 
networks could not be reliably identified.  
5.2.7 Statistical Analysis 
In each experiment, data from three coverslips per culture were averaged, with all 
experiments bring repeated 3-5 times (i.e. n = 3–5 independent experiments). Data 
replicates were analysed using an unpaired Student t test. Results were considered 
statistically significant for p values less than 0.05. Data are expressed as mean ± 
SEM. 
 
5.3 Results  
5.3.1 Early nicotinamide treatment reduced total live cell numbers, but did not 
affect cell viability in monolayer cultures. 
In section 3.3.2, manual quantification of DAPI-stained nuclei at day 14 showed that 
10 mM nicotinamide during the first 7 days of differentiation reduced cell number. 
In the present study, a Countess™ automated cell counter was used to validate this 
analysis by measuring the number of viable cells in control and nicotinamide-treated 
cultures at 7 and 14 days respectively. Further, to rule out the possibility that 
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widespread cell death underlies the reduction in cell number; the influence of 
nicotinamide (10 mM) on cell viability in differentiating monolayer cultures was 
assessed at different developmental stages. In the present study, viability was 
assessed in terms of both total and percentage viable cells in 0.5 ml N2B27 media.  
Administration of 10 mM nicotinamide from day 0 to 7 of monolayer differentiation 
generated a significant reduction in the total number of live cells by day 7, in 
contrast to control conditions (unpaired t test, t = 3.6) [433,333 ± 350,000 vs. 
2800000 ±  476,638 in control conditions; p<0.05; Figure 5.2 (A-B)]. However, 
nicotinamide did not affect culture viability at this time-point (unpaired t test, t = 1.3; 
n.s.) [81.5 ± 0.5% vs. 87.0 ± 3.2% in control conditions; Figure 5.2 (C)].  
These parameters were also addressed in cultures treated with nicotinamide from day 
0-7 and further differentiated up to a total of 14 days. This also revealed a decrease 
in absolute live cell numbers in nicotinamide-treated cultures (unpaired t test, t = 1.6; 
n.s.) [94,444 ± 27,981 vs. 219,722 ± 75,195 in control conditions; Figure 5.2 (D)], in 
agreement with the data collected previously by manual counting. As at day 7, early 
nicotinamide administration did not alter the viability of cultures at day 14 (unpaired 
t test, t = 0.4; n.s.) [76.3 ± 3.8% vs. 72.0 ± 9.8% in control conditions; Figure 5.2 
(E)].  
To conclude, data generated from live cultures using the automated cell counting 
system strongly suggests that the reduction in cell number in nicotinamide conditions 
does not result from an induction of cell death, since the cell viability did not 
significantly differ from control culture.  
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Figure 5.2 Nicotinamide reduced the number of live cells in cultures derived 
from Sox1GFP mESCs, without altering cell viability. Monolayer cultures were 
exposed to nicotinamide between days 0 and 7, and viability assessed in terms of 
both total and percentage viable cells at days 7 and 14 of differentiation. (A) Phase 
contrast images of mESC monolayer cultures after 7 days in differentiation medium, 
without and with nicotinamide treatment. A marked reduction in cell density in 
nicotinamide-treated cultures was evident at day 7 in vitro, compared to untreated 
cultures. Scale bar = 100 µm. (B) Administration of 10 mM nicotinamide between 
days 0-7 significantly reduced the number of viable cells at 7 DIV. (C) Nicotinamide 
did not elicit any significant differences in the percentage of viable cells remaining 
in the cultures. (D&E) Nicotinamide administered during the first 7 days of 
differentiation induced a reduction in live cell numbers at 14 DIV, without evidence 
of toxicity. *p<0.05 
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5.3.2 Addition of nicotinamide at the initial stages of embryonic stem cell 
differentiation did not induce apoptosis in Sox1GFP-derived cultures.  
To verify the previous results in section 5.3.1, showing that nicotinamide (10 mM) 
treatment did not alter cell viability in mESC-derived cultures; the effect of this 
small molecule on apoptosis was further investigated by means of the TUNEL 
technique, in combination with morphological analysis of cell nuclei (Figure 5.4). 
This effect was evaluated using fluorescence and phase contrast microscopy to 
quantify the pyknotic (condensed or fragmenting morphologies; Figure 5.3) and total 
(healthy plus pyknotic) nuclei per microscopic field at 7 and 14 days, respectively.  
 
Figure 5.3 During the early process of apoptosis, cell shrinkage and pyknosis are 
visible in cell nuclei counterstained with DAPI, using fluorescent microscopy. (A) 
Representative image shows monolayer cells stained with DAPI at 4 DIV, exhibiting 
condensed nuclei (indicated by the yellow arrow), or pyknotic or fragmented nuclei 
(indicated by the white arrows), which are characteristic of apoptotic cells. Nuclear 
integrity was also studied via phase contrast microscopy (inset). White arrows 
indicate pyknotic nuclei. Scale bar = 50 µm.  
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Nicotinamide addition during the early stages of differentiation did not significantly 
alter the percentage of apoptotic cells at day 7, relative to untreated groups (unpaired 
t test, t = 0.5, n.s.) [15.8 ± 2.1% in nicotinamide treated vs. 14.4 ± 1.4% in control 
conditions; Figure 5.4 (B)]. Similarly, by day 14, the percentage of nuclei exhibiting 
pyknosis and TUNEL staining did not significantly differ from control cultures 
(unpaired t test, t = 0.1, n.s.) [11.3 ± 1.4% in nicotinamide treated vs. 11.5 ± 0.4% in 
control conditions; Figure 5.4 (C)].  
Together, these findings strongly suggest that the reduced total cell population in 
nicotinamide-treated cultures was not due to induction of apoptosis. Instead, these 
data suggest a reduction in the proportion of proliferating cells - that is, nicotinamide 
enhances cell-cycle exit to promote neuronal differentiation.  
 
Figure 5.4 Addition of nicotinamide during the early stages of neural 
differentiation does not induce apoptosis in adherent monolayer cultures. (A) 
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Apoptosis was determined by evaluation of nuclear integrity and by TUNEL assay at 
days 7 and 14. Representative images show immunocytochemical labelling of 
TUNEL-positive cells (red) and total cells in culture counterstained with DAPI 
(blue). Apoptotic cells were quantified when they stained positively in the TUNEL 
assay and exhibited a pyknotic nucleus (Merge). Scale bars = 50 µm. (B&C) The 
percentages of apoptotic cell populations were not significantly altered by early 
nicotinamide treatment in adherent monolayer cultures at days 7 (B) and 14 (C), 
respectively.  
 
5.3.3. Nicotinamide treatment reduced the proportion of proliferating cells in 
monolayer cultures by promoting the exit of neural progenitors from the cell cycle.  
With respect to the decline in the total cell number at day 7 and day 14, the next 
hypothesis under investigation was to determine whether nicotinamide was acting to 
direct cells to exit the cell cycle and become postmitotic, in line with the accelerative 
effect on neuronal differentiation and maturation reported in the previous chapters 3 
and 4.  
5.3.3.1 BrdU incorporation assay was not a reliable technique to measure 
proliferation activity in monolayer cultures. 
5-bromo-2'-deoxyuridine (BrdU) is incorporated into de novo synthesised DNA as a 
substitute for thymidine. This incorporation assay permanently labels cells 
undergoing proliferation, including daughter cells until it is diluted out through 
multiple rounds of cell division
229
.  
Initially, mESC-derived control and treatment cultures were incubated with BrdU 
(10 µM) for the first 7 days of differentiation to label all dividing cells. The rationale 
behind this experimental design was to reveal the proportion of cells that were 
proliferating during a defined time period (i.e. in the presence of nicotinamide during 
days 0-7), rather than performing a pulse-labelling experiment prior to cell fixation 
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which would only reveal the cells that were proliferating at the time of sample 
collection. However, BrdU treatment for 7 days demonstrated cytotoxic effects, 
evidenced by widespread monolayer cell death during this process (data not shown).   
Therefore, the experimental design in this study was altered in accordance with other 
cell proliferation methods published in the literature.
230
 Monolayer cells were pulsed 
for 1 h with BrdU (10 µM) at day 7, prior to fixation, to label proliferative cells. 
Detection of BrdU is determined by immunostaining with specific anti-BrdU 
antibodies (appendix 3)
229
. In this context, a major disadvantage of this proliferation 
assay is that the complementary base pairing in double-stranded DNA hinders access 
of the antibody (i.e. anti-BrdU) to BrdU subunits
231
. Therefore, harsh denaturing 
conditions involving HCl are required to facilitate antibody access to BrdU inserted 
into genomic DNA, often resulting in tissue damage including degradation of the 
specimen structure
229
. Furthermore, it has been reported that BrdU labelling is rarely 
compatible with other staining assays
229
.  
The present study showed that BrdU-labelling generated an ambiguous staining 
pattern, where BrdU immunostaining was undetectable within DAPI-stained cell 
nuclei. Instead, immunofluorescent labelling was shown to be localised within 
apparent artefacts/dead cell fragments (Figure 5.5). Thus, given these drawbacks, an 
alternative method to measure cell proliferation during monolayer differentiation 
was required.  
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Figure 5.5 BrdU assay proved an unreliable technique to measure cellular 
proliferation in the monolayer protocol. (A) Immunocytochemical labelling of 
BrdU (green) and total cells in culture (blue). Representative images show punctate 
green staining, which was not specific to cell nuclei, and was characteristic of non-
specific immunostaining picked up by dead cell fragments. Thus, evidence of cells 
undergoing proliferation could not be observed using the BrdU incorporation assay 
in monolayer cultures at day 7. Scale bar = 50 µm  
 
5.3.3.2 Detection of the EdU cell proliferation assay was accomplished in the 
monolayer protocol.  
An alternative assay was established to investigate the effect of nicotinamide on cell 
proliferation during monolayer differentiation. This approach was based on the 
incorporation of another thymidine analog, EdU into de novo DNA during 
monolayer differentiation. EdU-labelling is detected by click chemistry (i.e. covalent 
cross-linking of its ethynyl group with a fluorescent azide). Due to the small size and 
chemical nature of the fluorescent azide, effective diffusion is facilitated through 
fixed samples to readily access incorporated EdU nucleosides in genomic DNA
229
. 
Therefore, unlike the BrdU incorporation assay, no harsh treatments with HCl are 
necessary, and the physical integrity of specimens is preserved. Further, it has been 
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demonstrated that the EdU proliferation assay can be reliably performed with other 
immunostaining techniques. In this study, EdU was shown to provide an easy and 
sensitive alternative to the BrdU assay, evidenced by its incorporation into the DNA 
of DAPI-stained cell nuclei at day 7 of differentiation [Figure 5.6 (A)].  
The first goal of this experiment was to measure the percentage of proliferating cells 
in cultures treated with N2B27 alone or with addition of nicotinamide from day 0-
day 7. Monolayer cultures received EdU for 1 h prior to cell fixation at the end of the 
7 day culture period. This pulse-labelling experiment revealed that 61% of cells in 
cultures that had been differentiated without nicotinamide showed positive EdU 
signal, whereas only 29% of cells in the cultures containing nicotinamide were 
labelled with EdU (unpaired t test, t = 10.6, p<0.001) [28.7 ± 2.9% vs. 60.7 ± 0.9% 
in control conditions; Figure 5.6 (A-B)]. Collectively, these data suggest that N2B27 
medium alone supports a higher level of continued proliferation in monolayer 
cultures at day 7 of differentiation, whereas exposure to 10 mM nicotinamide during 
days 0-7 promotes the exit of dividing cells from the cell cycle. 
Nicotinamide was previously found to induce accelerated neural fate commitment 
and in turn neuronal maturation during early development. Therefore, the second aim 
of this study was to determine whether this vitamin B3 derivative was directing cells 
to exit the cell cycle at an earlier time point than cell-cycle exit in untreated cultures. 
To achieve this, EdU-labelled cells were classified as having either strong or weak 
incorporation of EdU in their cell nuclei [Figure 5.6 (A-inset)]. Using the NIS-image 
software, strongly labelled cells were characterised as exhibiting expression levels 
usually within the intensity range of 240-260, and were interpreted as those that had 
exited the cell cycle immediately after incorporating EdU in S-phase (i.e. the 
synthesis phase that represents the stage of the cell cycle in which DNA replication 
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occurs; between G1 phase and G2 phase). Weak EdU expression was more 
commonly observed at levels of 140-160, and was interpreted as resulting from 
either late S-phase incorporation prior to cell fixation resulting in limited uptake of 
EdU, or from EdU dilution following one or more cycles of cell division. Thus, since 
weakly-expressing EdU labelled cells are open to several interpretations, the effect 
of nicotinamide on cells displaying “strong” EdU labelling was quantified.  
The percentage of EdU-labelled cells in nicotinamide-treated cultures exhibiting 
“strong” expression levels were slightly reduced, however did not significantly differ 
from control cultures (unpaired t test, t = 1.4, n.s.) [11.3 ± 3.6% in nicotinamide 
treated cultures vs. 17.4 ± 2.2% in control conditions; Figure 5.6 (C)].  
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Figure 5.6 Inhibition of Sox1GFP-derived cell proliferation by nicotinamide. 
(A) Assessment of EdU immunoreactivity was made using standard fluorescence 
microscopy. Fluorescent images show EdU
+
 cells (green), co-labelled with DAPI 
nuclear staining (blue). Scale bar = 50 µm. Arrows indicate cells expressing strong 
EdU labelling (yellow) and weaker EdU immunostaining (white). Some EdU-
labelled cells demonstrated the formation of doublets following mitosis (indicated by 
white and yellow arrows). A reduction in cell proliferation was observed in 10 mM 
nicotinamide-treated cultures, in contrast to control groups. Scale bar = 50 µm (B) 
The data provided by EdU incorporation indicated that mESC-derived cells 
differentiated with 10 mM nicotinamide resulted in a reduction in cell proliferation, 
compared to control conditions. (C) The percentage of strongly labelled EdU-
positive cells indicated a downward trend in cultures treated with nicotinamide from 
day 0-7, compared to untreated groups. 
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***p<0.001 
 
5.3.3.3 Early nicotinamide administration reduced proliferation of the Sox1GFP
+ 
cell population.  
To gain further insight into the effects of nicotinamide on the cell cycle, the uptake 
of EdU was measured within specific cell populations in control and treatment 
cultures. In this study, the percentage of Oct4, Sox1GFP
+
 and βIII-tubulin-expressing 
cells double-positive for EdU were analysed. Here, it should be noted that images 
were acquired using a high power objective lens (i.e. x40 magnification), to 
accurately identify individual cells co-labelled with EdU.  
At day 7, the percentage of undifferentiated stem cells per field was determined by 
quantifying individual cells expressing the stem cell marker, Oct4. Findings showed 
that addition of 10 mM nicotinamide between days 0 and 7 caused a slight decrease 
in the proportion of Oct4
+
 cells, expressed as a percentage of total cells (unpaired t 
test, t = 1.0, n.s.) [16.9 ± 5.9% in nicotinamide treated cultures vs. 23.6 ± 3.3% in 
control conditions; Figure 5.7 (A-B)]. However, the percent of EdU labelled cells 
within the Oct4
+
 population was comparable to controls (unpaired t test, t = 0.5, n.s.) 
[9.2 ± 4.0% in nicotinamide treated cultures vs. 11.5 ± 1.8% in control conditions; 
Figure 5.7 (A-B)]. 
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Figure 5.7 Colocalisation of EdU and the undifferentiated cell marker, Oct4. 
(A) Immunofluorescent images of EdU-labelled (green) and double-labelled 
undifferentiated cells (Oct4, red) in monolayer cultures at day 7.  The nuclei of all 
cells in cultures were labelled with DAPI (blue). Scale bar = 50 µm. (B) 
Nicotinamide treatment generated a slight reduction in the percent of Oct4-
expressing cells by day 7, but did not alter the percent of EdU-labelled cells within 
this population. 
 
In contrast, proliferation was significantly reduced in progenitor cells co-localising 
Sox1GFP
+ 
expression and EdU-labelling (unpaired t test, t = 4.8, p<0.01) [3.0 ± 
2.0% in nicotinamide treated cultures vs. 13.2 ± 0.6% in control conditions; Figure 
5.8 (A-B)], and the percentage of GFP
+
 cells was also significantly decreased by day 
7 (unpaired t test, t = 3.8; p<0.05) [9.7 ± 6.4% in nicotinamide treated cultures vs. 
33.6 ± 0.3% in control conditions; Figure 5.8 (A-B)].  
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This important finding shows that 10 mM nicotinamide is functioning during early 
development to restrict Sox1
+
 precursor proliferation.
 
 
Figure 5.8 Colocalisation of EdU and native GFP-expressing progenitor cells. 
(A) Immunofluorescent images of EdU-labelled (red) and double-labelled native 
GFP (green)-expressing cells in monolayer cultures at day 7.  The nuclei of all cells 
in cultures were labelled with DAPI (blue). Scale bar = 50 µm. (B) Nicotinamide 
treatment significantly reduced the percentage of GFP-expressing cells, concomitant 
with a decrease in the percent of EdU-labelled cells in the Sox1GFP-postitive 
population. 
 **p<0.01; *p<0.05 
 
Subsequently, 10 mM nicotinamide had a significant effect on neuronal 
differentiation, concomitantly increasing the βIII-tubulin-positive neuronal 
population (unpaired t test, t = 10.8 p<0.001) [15.2 ± 0.9% in nicotinamide treated 
cultures vs. 3.6 ± 0.4% in control conditions; Figure 5.9 (A-B)]. Colocalisation of 
EdU and βIII-tubulin demonstrated no detectable difference in the levels of 
152 
 
incorporation between treated and untreated cultures (unpaired t test, t = 0.2, n.s.) 
[0.8 ± 0.1% in nicotinamide treated cultures vs. 0.9 ± 0.1% in control conditions; 
Figure 5.9 (A-B)]. Since the vast majority of βIII-tubulin-expressing neurons were 
rarely double-labelled for EdU, it is reasonable to conclude that many of the 
differentiated neurons were postmitotic at the stage of differentiation when EdU was 
applied to the cultures.   
 
 
Figure 5.9 Colocalisation of EdU and the immature neuronal marker βIII-
tubulin.  
(A) Immunofluorescent images of EdU-labelled (red) and double-labelled βIII-
tubulin (green)-expressing cells in monolayer cultures at day 7.  The nuclei of all 
cells in cultures were labelled with DAPI (blue). Scale bar = 50 µm. (B) 
Nicotinamide treatment significantly enhanced expression of neuron-specific βIII-
tubulin, without altering the percentage of EdU-labelled cells within the neuronal 
population. 
 ***p<0.001 
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Collectively, important and novel data generated in this study indicate that 
nicotinamide is involved in the switch between proliferation and differentiation 
during early development. Specifically, addition of this small molecule during the 
initial stages of embryonic stem cell differentiation enhanced cell cycle exit to halt 
proliferation of neural progenitors, thereby driving a switch from neuroectodermal 
precursors to neurons within differentiating cultures. This result is in line with the 
effect of nicotinamide (between days 0-7) on accelerated neuronal differentiation and 
maturation by day 14. Furthermore, this section provides further evidence that 
nicotinamide is most effective in influencing neuronal differentiation at an early 
developmental time window.  
5.3.3.4 EdU incorporation was not detected at day 14 of monolayer differentiation.   
To test for differences in proliferation in undifferentiated ESCs, Sox1GFP
+
 
progenitor cells, and βIII-tubulin+ cells at day 14, cultures were maintained as 
feeder-free adherent monolayers from day 0-7, using serum-free N2B27 medium  in 
the presence/absence  of nicotinamide treatment. At day 7, cultures were incubated 
with 10 µM EdU for 1 h to label all diving cells, and cells were then replated onto 
coverslips coated with PLL and laminin until day 14. At this point, cell samples were 
processed for immunocytochemistry.  
It was observed that EdU incorporation was not detectable in monolayer cultures. 
This finding suggests that EdU may have been incorporated into de novo synthesized 
DNA at day 7, but diluted out through multiple rounds of cell division by day 14 of 
differentiation or cell death (Figure 5.10).  
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Figure 5.10 Immunocytochemical labelling of EdU (red) and total cells in 
culture (blue). EdU-labelling was undetectable at day 14 of the monolayer protocol 
following an EdU pulse-labelling experiment at day 7. This observation suggests a 
dilution of EdU label caused by cell division. Representative images show punctate 
red staining, which was not specific to cell nuclei, possibly characteristic of non-
specific immunostaining picked up by dead cell fragments. Scale bar = 50 µm.  
 
5.3.4 Under monolayer differentiation conditions, nuclear SIRT1 staining in 
neural progenitor and neuronal cell populations is down-regulated during 
monolayer differentiation.  
It has been reported that SIRT1, an NAD
+
-dependent histone deacetylase is highly 
expressed in mESCs, in contrast to differentiated tissues
224
. Therefore, Sox1GFP-
derived undifferentiated pluripotent mESCs, maintained in FSC/LIF medium (i.e. 
culture media for mESC proliferation; appendix 2) were selected to serve as a 
positive control to establish optimum working dilutions of anti-SIRT1 antibody 
(Figure 5.11; appendix 3).  
Figure 5.11. Anti-SIRT1 optimisation for immunocytochemistry. Rabbit 
polyclonal SIRT1 antibody was optimised using undifferentiated mESC cultures as a 
positive control. (A) Immunostaining of mESC cultures with anti-SIRT1 (red) and 
DAPI staining (blue), which was used to visualise cell nuclei. 46C-derived mESC 
cultures strongly expressed SIRT1 in their cytoplasm (yellow arrow) and cell nuclei 
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(white arrow); visualised by fluorescent and phase contrast microscopy. Scale bar = 
50 µm.  
 
5.3.4.1 SIRT1 is predominantly localised in the nucleus during monolayer 
differentiation.  
It has previously been reported that SIRT1 plays a modulatory role during neuronal 
differentiation
232
. A study carried out by Hisahara et al, found SIRT1 to be localised 
within the cytoplasm of embryonic and adult NPCs, but was transiently localised to 
cell nuclei in response to differentiation stimulus (Figure 5.1)
223
. Therefore, in this 
study, defined culture conditions were established to direct the differentiation of 
46C-derived mESCs into neuronal cultures. Immuno-stained differentiated cells 
were visualised using a 40x lens to accurately visualise subcellular structures. 
Immunocytochemisty showed that SIRT1 is predominalty localised within the 
nucleus of monolayer-derived cells at 14 DIV (Figure 5.12).  
Figure 5.12. SIRT1 localisation under adherent monolayer differentiation 
conditions. Immunofluorescence detection of Sox1GFP-derived cultures labelled 
with anti-SIRT1 (red). DAPI staining (blue) was used to stain the total cell 
population and to visualise cell nuclei. Merge image shows that SIRT1 is highly 
expressed in differentiated cells at day 14 of the monolayer protocol, and revealed 
that SIRT1 staining is primarily nuclear. Scale bar = 50 µm 
 
 
156 
 
5.3.4.2 A progressive and substantial decrease in SIRT1 expression was observed 
during Sox1GFP-derived monolayer differentiation. 
SIRT1 expression has been reported to be down-regulated during differentiation of 
hESCs and mNSCs
233,234
. Therefore, in this study, expression levels of SIRT1 were 
monitored in neural and neuronal cell populations, as they matured from day 7 to day 
14 of adherent monolayer differentiation.  
During the first 7 days of differentiation, SIRT1 was shown to be strongly expressed 
in monolayer cultures, in contrast to day 14 [Figure 5.13 (A-B)]. Notably, higher 
levels of SIRT1 staining were shown within GFP
- 
populations at day 7; these could 
potentially be undifferentiated cell colonies [i.e. Oct4
+
 colonies; Figure 5.13 (A)]. 
Immunofluorescence staining of SIRT1 at day 7 revlealed that SIRT1 expression 
was predomiantly nuclear in βIII-tubulin-expressing cells.  
Interestingly, by day 14, decreases in the overall expression levels of SIRT1 were 
observed in cultures. Specifically, SIRT1 nuclear staining was shown to be reduced 
in distinct neural populations, i.e. GFP
+
 and βIII-tubulin+ cells at this time point 
[Figure 5.13 (B)]. 
These preliminary observations demonstrate that SIRT1 expression progressively 
decreases in ESC-derived cultures as time in vitro increases, in line with previous 
findings reported in the literature
234,235
. Based on this evidence, a decrease in SIRT1 
expression may play a role in supporting neuronal differentiation
235
. Furthermore, it 
has been reported that the spatial regulation of SIRT1 is critical for inducing the 
neuron-specific transcription programme (Figure 5.1)
228
. In this context, 
immunostaining results suggest that differential SIRT1 localisation exists between 
undifferentiated mESCs (detected in the nucleus and cytoplasm), in contrast to 
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differentiated neural and neuronal cell populations which showed SIRT1 staining to 
be primarily nuclear.  
Figure 5.13 Expression of SIRT1 in Sox1GFP-derived monolayer cultures. 
Immunocytochemical analysis of cells expressing the immature neuronal marker 
βIII-tubulin (green) or native GFP (green), co-labelled with anti-SIRT1 (red). Scale 
bar = 50 µm. (A) Levels of SIRT1 were initially high in cultures assessed at day 7 of 
the monolayer protocol. In particular, SIRT1 was strongly expressed within GFP-
negative populations, possibly indicative of pluripotent stem cell colonies. Double-
staining analysis revealed that SIRT1 expression was mostly located within the cell 
nucleus of βIII-tubulin+ cells at seven days of differentiation. (B) As time in culture 
increases, SIRT1 expression was shown to decrease. Colocalisation of nuclear 
SIRT1 expression was observed in GFP
+ 
progenitor cells and βIII-tubulin-expressing 
cells at day 14, albeit in decreased levels compared to day 7.  
 
5.3.4.3 Addition of nicotinamide to monolayer cultures elicited no effect on glial 
differentiation. 
SIRT1 inhibition has been linked to alterations in NPC cell-fate decisions in vitro, 
causing increased differentiation of NPCs into neurons, at the expense of astrocytes 
(Figure 5.1)
236
. Further, previous results in this experimental chapter showed that 
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nicotinamide, a SIRT1 inhibitor, functioned during early development to direct a 
switch from neural progenitors to neurons, by inhibiting proliferation. For this 
purpose, this study aimed to test whether nicotinamide could also direct glial 
differentiation from Sox1GFP mESC-derived monolayer cultures. 
Immunocytofluorescence analysis was performed to investigate the expression of the 
astrocyte marker, GFAP and the early OPC marker, NG2, in differentiated cultures 
at day 14. Total numbers of cells expressing GFAP and NG2 were presented as a 
percentage of the total DAPI cell count.  
GFAP-expressing cells exhibiting long cellular projections
169,237
, similar to those of 
radial glial cells, were detected at day 14, albeit in small numbers [Figure 5.14 (A)], 
in striking contrast with the number of βIII-tubulin –expressing neurons generated at 
this time point (section 3.3.1). There was no significant effect on the percentage of 
GFAP
+ 
cells at day 14 in cultures of cells incubated with nicotinamide between days 
0 and 7 compared to control cultures, (unpaired t test, t = 1.0, n.s.) [0.3 ± 0.1% in 
nicotinamide treated cultures vs. 0.5 ± 0.2% in control conditions; Figure 5.14 (A-
C)]. Similarly, there was no difference in NG2 expression when comparing 
differentiated cells treated with or without nicotinamide (unpaired t test, t = 1.2, n.s.) 
[3.2 ± 0.5% in nicotinamide treated cultures vs. 2.3 ± 0.6% in control conditions; 
Figure 5.14 (B-C)]. 
Taken together, these data reveal that the GFAP protein and the early OPC marker, 
NG2 were expressed in very few cells of the Sox1GFP-derived cultures at day 14; 
constituting less than 5% of the total cell population. In addition, mature GFAP
+
 
cells displaying characteristic large flattened cell bodies [Figure 5.1 (C)] were absent 
from monolayer cultures at this time-point. Thus, it is reasonable to conclude that 
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day 14 of monolayer differentiation might be too early to assess for the effect of 
nicotinamide on glial fate, in line with previous reports in the literature
169,170,238
. 
 
 
 
Figure 5.14 Treatment of adherent cultures with nicotinamide elicited no effect 
on glial differentiation. Immunofluorescence images of glial populations generated 
from mESC-derived monolayer cultures, showing immunostaining with antibodies 
specific to the astrocyte marker, GFAP (A) and the OPC marker,  NG2 (B). (A) 
GFAP-expressing cells with leading processes and elongated cell bodies (inset) were 
observed at day 14 of monolayer differentiation. (B) Higher magnification image of 
monolayer cells immunostained for NG2 (inset), displaying a prominent cell with 
multiple processes, representative of their morphology in vivo. Cell nuclei 
counterstained with DAPI (blue). Scale bar = 50 µm. (C) GFAP
+
 and NG2
+
 cells 
were detected in cultures at a very low percentage. No significant effects on glial 
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expression (i.e. GFAP or NG2 production) were demonstrated following induction 
with 10 mM nicotinamide treatment between days 0-7.  
 
5.4 Discussion 
5.4.1 Nicotinamide did not induce apoptosis or alter cell viability in monolayer 
cultures.  
For nicotinamide-induced neuronal differentiation to be of benefit to future neural-
cell based therapies, it is crucial that this compound does not decrease the total cell 
population by inducing cell death or reducing overall cell viability in differentiating 
cultures. In this context, since higher concentrations of nicotinamide (i.e. 20 mM) 
elicited cytotoxic effects on monolayer cell survival (section 3.3.1), one of the 
hypotheses under investigation in this study was to determine whether 10 mM 
nicotinamide caused a reduction in cell number (section 3.3.2) by inducing cell 
death.  
By adding nicotinamide to cells at an early stage of the differentiation, a decrease in 
total live cell numbers was observed at 7 and 14 days; verified using an automated 
cell counting system, based on trypan blue viability analyses. Crucially, 
undifferentiated ESCs cultured in the presence of 10 mM nicotinamide (from day 0-
7) showed no differences in cell viability of the remaining cells at days 7 or 14, when 
compared with control cultures. These results were further confirmed by analysis of 
pyknosis and TUNEL staining of apoptotic cells, demonstrating that nicotinamide 
did not increase apoptosis levels in monolayer cultures at these time points. 
Collectively, this evidence strongly suggests that of the addition of nicotinamide to 
future neural cell-based therapies offers a safe method to direct differentiation. As 
importantly, these findings strongly indicate that nicotinamide may be functioning 
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instead to cause a reduction in the proportion of proliferating cells, to cause a 
decrease in total cell numbers.  
5.4.2 Nicotinamide regulates the cell cycle to halt proliferation of Sox1GFP-
derived neural progenitor cells.  
Neural differentiation requires cells to exit the cell cycle and become postmitotic, 
during in vitro and in vivo development
239
. Thus, regulating the transition between 
proliferation and differentiation is fundamental to neurogenesis. In this respect, 
control of cell cycle is crucial in the differentiation of ESCs, as we advance towards 
clinical stem cell-based therapies.  
Vitamins have been reported to influence cell cycle progression in cancer cell 
lines
240–242
. Further, a reduction in proliferation has previously been reported upon 
exposure of ESC-derived cultures to 10 mM nicotinamide
158
. The ability of 
nicotinamide to regulate the number of neurons produced and function as an inducer 
of neural maturation during monolayer differentiation, reported previously in 
chapters 3 and 4, served as early evidence that nicotinamide may be driving this 
neural proliferation-to-differentiation switch during development.  
Based on this evidence, the present study therefore sought to investigate the 
influence of nicotinamide on DNA synthesis in proliferating monolayer-derived 
cells. This hypothesis  was addressed using an EdU incorporation assay, which was 
demonstrated to be a much more sensitive method than BrdU detection, in agreement 
with findings in the literature
231
. Initial findings generated in this study reported that 
control cultures induced with N2B27 differentiation medium alone contained more 
proliferating cells, in contrast to cultures exposed to nicotinamide, where the 
population of proliferating cells was reduced by half at day 7 of the monolayer 
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protocol. This early and robust effect suggests that nicotinamide may be acting at the 
initial stages of ESC differentiation to influence the transition of mESCs into 
neuroectoderm or indeed driving a switch from neural progenitors to neurons in the 
differentiating cells. Similarly, the vitamin A derivative, RA has been shown to 
regulate the proliferation-to-differentiation switch
242
. Specifically, RA has been 
reported to promote differentiation and inhibit cell proliferation by directing cell 
cycle arrest in ESCs
239,243
. With particular relevance to the findings discussed in this 
thesis, early administration of RA to differentiating adherent mono-cultures was 
found to restrict the proliferation of Sox1
+
 neuroectodermal precursors, resulting in 
enhanced neurite outgrowth and βIII-tubulin expression243. In the present study, 
nicotinamide significantly reduced the percentage of GFP
+
 cells, concomitant with a 
decrease in the number of actively proliferating Sox1GFP
+
 NPC cells. As far as I am 
aware, this is the first report to demonstrate that the vitamin B3 metabolite is 
influencing a similar switch to RA - that is a neural proliferation-to-differentiation 
switch from neural progenitors to neurons.  
5.4.3. Analysis of SIRT1 expression during ESC differentiation 
The present study showed that, in mESCs, SIRT1 expression levels were initially 
high but were down-regulated during neuronal differentiation, in agreement with 
similar expression patterns reported in the literature
228,234,235
. In this context, 
inhibition of SIRT1 by nicotinamide has been shown to direct NPCs toward motor 
neuron differentiation
160
, suggesting a further role for SIRT1 down-regulation during 
neural differentiation. In addition, a reduction in SIRT1 expression may be a 
prerequisite for successful differentiation
234
, since it has been reported that over-
expression of SIRT1 inhibits neural differentiation
235
. In this study, SIRT1 staining 
was shown to be expressed in βIII-tubulin+ cell nuclei as early as day 7 of 
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differentiation, implying that SIRT1 is required at the early stages of the 
differentiation process. 
5.4.4 The role of SIRT1 during neuronal development.   
SIRT1 also plays an important role during neural development
221
, regulating brain 
structure and neuronal morphology through axon elongation
244
, neurite outgrowth 
and branching
201,227,245,246
. With particular relevance to the findings outlined in the 
previous experimental chapter 4, SIRT1 knockdown with small hairpin RNA has 
been reported to promote neurite extension
227
, and increase neurite number and total 
neurite output
246
. Nicotinamide also inhibits another member of the sirtuin family, 
SIRT2, which deacetylates βIII-tubulin, and also plays a relevant role in regulating 
the extension of cell processes
198
. Similarly, SIRT2 knockdown was also shown to 
increase hippocampal neurite outgrowth
247
 and the arborisation complexity observed 
in primary oligodendrocyte precursors
248
. These findings indicate that the specific 
effect of nicotinamide on the appearance of postmitotic neurons, observed in sections 
4.3.3.1 and 4.3.3.2 may be mediated by SIRT1/SIRT2 inhibition. Therefore, in future 
work, to test whether nicotinamide primarily enhances neuronal maturation in 
Sox1GFP-derived neural subtypes by mechanisms that involve SIRT1/2 
downregulation, treatment of mESC cultures with small molecule compounds such 
as the SIRT1/2 inhibitor cambinol or a SIRT1 pharmacologic activator, resveratrol 
between days 0-7 of monolayer differentiation should address this hypothesis.  
It should be noted that other publications report that SIRT1 overexpression, an effect 
mimicked by resveratrol and NAD, regulates dendritic development in hippocampal 
neurons, while interfering with the catalytic deacetylase activity of SIRT1 by 
nicotinamide treatment decreased the number of primary and secondary dendrites
201
. 
These findings are consistent with similar observations in neurons differentiated in 
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the presence of SIRT inhibitors, which exhibited fewer and shorter neurites than 
control conditions
223
. In this regard, SIRT1 is likely to have a complex and perhaps 
context-specific effect in neuron biology. It can be hypothesised that nicotinamide 
may function as an activator or inhibitor of SIRT1, based on cellular requirements. 
Further, it cannot be excluded that differences associated with specific properties of 
distinct cellular models may explain the inconsistent nature of SIRT1 findings in the 
literature. 
5.4.5 Conclusion and Further Studies 
In conclusion, data generated in this study strongly supports a role for nicotinamide 
in neural commitment of Sox1GFP-derived ESCs and in down-regulating neural 
progenitor proliferation. In addition, the influence of nicotinamide on SIRT1 may be 
necessary for the correct establishment of specific differentiation programmes during 
ESC development.  
Future studies into how nicotinamide regulates cell-cycle exit would lead to a greater 
understanding of its role during neuronal differentiation. In this regard, cell 
proliferation and differentiation are tightly coordinated by cell cycle controls, 
implicating the formation of complexes between cyclins and cyclin-dependent 
kinases (CDKs), a process inhibited by cyclin-dependent kinase inhibitors (CKIs)
239
. 
Kim et al hypothesised that RA functions to supress cyclin genes leading to an 
induction of CKI genes, thereby accelerating cell-cycle exit and promoting ESC 
neural differentiation
239
. Therefore, it will be of interest to determine whether 
nicotinamide acts in a similar manner to regulate cell cycle genes during ESC 
differentiation.  
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Since targets of SIRT1 include master transcription factors and cell cycle 
regulators
249
, it will also be important to thoroughly explore the functioning of 
SIRT1 during ESC differentiation. Based on preliminary observations investigating 
SIRT1 protein expression at different stages of adherent monolayer differentiation, it 
will be necessary to ascertain whether SIRT1 activity is down-regulated following 
nicotinamide treatment in neural and neuronal populations. This could be assessed 
using a SIRT1 activity assay, employed by Zhang and colleagues
160
. In this study, 
the SIRT1 inhibitor, nicotinamide, did not influence glial commitment, in 
accordance with a number of reports
179,234,236
. However, in future work, it will be 
necessary to differentiate Sox1GFP-derived cells for a longer culture period and then 
investigate whether nicotinamide influences glial differentiation at a later time point 
of the monolayer protocol, since a neurogenic switch to gliogenic NPCs has been 
reported in later monolayer cultures, at approximately day 16
169
. 
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Chapter 6: Effect of Nicotinamide on Midbrain 
Dopaminergic Neuron Production from Mouse 
Pluripotent Stem Cells  
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6.1 Introduction  
Efficient induction of ventral mDA neurons from pluripotent stem cell sources is 
critical for advancing their potential in neuronal replacement therapies relevant to 
PD
166
. In this regard, the therapeutic use of pluripotent stem cells will require robust 
and safe methods for generating mDAergic neurons in vitro. Thus, understanding the 
molecular signalling cascades governing cell fate choice during DA neuron 
development is fundamental. To date, a successful method for promoting the correct 
specification and development of mDA neurons in vitro relies upon the addition of 
key developmental morphogens to the differentiation media, to induce a cascade of 
gene transcription resembling normal development in vivo, and therefore steer 
midbrain-specific DA cell fate from pluripotent stem cells
50
. Regulatory factors 
implicated in mDA neuron development are discussed in detail in the introductory 
Chapter 1. 
Findings reported in Chapter 4 (section 4.3.2.1) highlighted an essential role for 
nicotinamide during catecholaminergic development. Specifically, a monolayer 
differentiation procedure completely devoid of exogenous proteins and signalling 
molecules associated with DA neuron development in vivo was devised, to fully 
elucidate if nicotinamide functions as an instructive small molecule for 
catecholaminergic differentiation in vitro. This study presented evidence for the first 
time that administration of this vitamin metabolite during an early developmental 
time-window of ESC monolayer differentiation significantly enhanced and enriched 
the generation of Sox1GFP mESC-derived TH
+
 neurons by day 14. However, there 
are a number of limitations associated with this ESC differentiation model. It is clear 
that neural progenitors and neurons in general could be derived from mESCs with 
higher frequency (detailed in section 3.3.1 and 3.3.4.3) than the production of TH
+ 
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neurons (section 4.3.2.1), under the experimental conditions applied. In Chapter 3, 
the heterogeneous nature of ESC in vitro differentiation was demonstrated using the 
Sox1GFP model system; highlighting the presence of undifferentiated mESCs and 
GFP-expressing NPCs within differentiated progenies in monolayer cultures at day 
14 (section 3.3.4.1 and 3.3.4.3). Heterogeneity is a common feature across ESC 
differentiation paradigms, resulting in the presence of intermediate progenitor cells 
of distinct stages of development and/or regional identity in differentiating cultures, 
thereby generating heterogeneous responses to specific inductive signalling 
molecules
87
. Further, it has been reported that the acquisition of a midbrain specific 
DAergic cell fate is not supported under Sox1GFP mESC monolayer differentiation 
conditions, evidenced by the absence of key midbrain markers such as Foxa2, 
Lmx1a and Pitx3 in the study carried out by Parmer and Li (2007)
250
.  
To address some of these issues, the current study aimed to translate earlier work 
with nicotinamide to a recent novel method of mDA neuron differentiation
87
, to 
potentiate the robust production of authentic midbrain-specific DAergic neurons and 
therefore explore the full potential of this vitamin B3 metabolite in its ability to drive 
pluripotent stem cells towards a DA neuron cell fate. This protocol is based on 
modifications to the original adherent monolayer differentiation protocol established 
by Ying et al (2003)
199
 and offers an ideal and small-molecule-based paradigm
87
. 
Moreover, this novel differentiation method offers several advantages over current 
protocols of producing midbrain-specific DA neurons, due to its ability to direct the 
highly efficient generation of functional, “authentic” mDAergic neurons via 
generation of intermediate epiblast cells. Populations of this intermediate epiblast 
cell, derived from post-implantation blastocysts (E5.75–E6.5) are more homogenous 
than the original stem cell populations (i.e. ESCs; derived from the ICM of an 
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embryo at the earlier blastocyst stage; Figure 6.1)
251
, and share defining features 
associated with human ESCs
252
 used in current protocols for PD
78,79,155
. Furthermore, 
pluripotent epiblast cells are more synchronised
87
 and should therefore respond much 
more consistently to external signals for neural induction in vitro.  
Based on these findings, one of the primary aims of this study was to determine 
whether nicotinamide could direct a more developmentally primed stem cell 
population to midbrain specific DAergic neurons, based on monolayer differentiation 
system developed by Jaeger and colleagues
87
. Briefly, Jaeger et al (2011) explored 
the temporal actions of FGF signalling in mDA neuron fate specification of mouse 
pluripotent stem cells and reported that a brief inactivation of FGF/extracellular-
signal-regulated kinase (ERK) signalling upon neural induction induced mDA neural 
progenitor characteristics. Successive activation of FGF signalling resulted in the 
maintenance of DAergic competence in differentiating monolayer cultures. 
Furthermore, FGF inhibition directed a midbrain specific fate in the derived DA 
neurons at the expense of other regional identities such as forebrain and caudal 
neural fates. Subsequent combinatorial stimulation with Shh, FGF8 and an array of 
survival-promoting factors applied in a stepwise manner directed the robust 
differentiation of “authentic” mDA neuronal yields from both human and mouse 
pluripotent stem cells.  The authors demonstrated that it was possible to obtain TH 
expression in over 52% of the neurons, which efficiently co-expressed midbrain 
specific markers including Foxa2, Lmx1a and Pitx3. 
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Figure 6.1 Schematic diagram representing the conversion of mESCs to novel 
epiblast cells during embryonic development in vivo and in vitro. Pluripotent 
mESCs are derived from the ICM at the early blastocyst stage
253
, and are dependent 
on LIF and BMP signalling to maintain their pluripotency. Following implantation, 
occurring at approximately E4.5 in mouse embryos, pluripotent ICM cells constitute 
an epithelial layer, known as the epiblast, which differentiates during gastrulation to 
generate the three primary germ layers (i.e. endoderm, mesoderm and ectoderm), 
giving rise to all adult tissues. For almost 25 years, mESCs represented the only 
pluripotent cell type derived from mouse embryos, prior to implantation in the 
uterus
251
. However, the discovery that novel epiblast cells could be isolated from the 
late epiblast layer of rodent post-implantation embryos (E5.75-6.5) indicated that 
additional stages of pluripotency could be stabilised in vitro
252,254
. Thus, conversion 
of “naïve” mESCs (pre-implantation embryos) into somatic cell lineages occurs via 
the primitive ectoderm/epiblast stage (post-implantation embryos), when pluripotent 
EpiSC lines dependent on activin/nodal and FGF signalling to sustain their 
pluripotent state are derived
252,254
. Therefore, generation of EpiSCs from mESCs in 
vitro can be achieved using chemically defined activin and basic fibroblast growth 
factor (bFGF)-containing medium. “Developmentally primed” EpiSCs robustly 
differentiate into the major somatic cell lineages, including DAergic neurons.  
 
To my knowledge, the combinatorial/synergistic effects of nicotinamide with 
signalling factors implicated in the induction and maintenance of mDAergic 
neurogenesis has not been reported before. Therefore, the hypothesis under 
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investigation in this experimental chapter was that nicotinamide combined with 
appropriate protein growth factors and small molecules, applied at appropriate 
concentrations and time points previously determined to direct DAergic 
specification
87
 could further augment mouse pluripotent stem cell differentiation into 
enriched midbrain specific DAergic neuronal populations. To thoroughly explore the 
full potential of nicotinamide, Sox1GFP mESCs were induced to convert into 
specialist mEpiSCs of the late epiblast, and the effects of this vitamin metabolite on 
DAergic differentiation were then examined in both mouse pluripotent stem cell 
populations representative of different developmental states. This experimental 
chapter aimed to:  
I. Investigate whether nicotinamide combined with mDAergic related signalling 
molecules promotes the generation of higher yields of enriched mDA 
containing neurons from mESCs.  
 
II. Generate EpiSCs from the Sox1GFP mESC knock-in ESC line. 
 
III. Investigate if early nicotinamide treatment of these epiblast cells potentiates 
the generation of mDAergic neurons.  
 
6.2 Experimental Procedure 
Given the direct stimulatory effect of early nicotinamide (10 mM) supplementation 
on catecholaminergic differentiation (section 4.3.2.1), this experimental chapter 
sought to further evaluate the potential of this vitamin concentration in directing 
mDA fate from mouse pluripotent stem cell sources: i.e. Sox1GFP reporter mESCs 
and mEpiSCs. Therefore, nicotinamide treatment was introduced to an adherent, 
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small-molecule-based neural differentiation paradigm, developed by Jaeger et al, 
which employed the temporally controlled exposure of mouse pluripotent stem cells 
to an FGF/ERK-deficient environment, together with inductive signalling molecules 
pertinent to  mDA neuron development
87
.  
6.2.1 mESC differentiation with midbrain DAergic neural-inducing factors and 
nicotinamide treatment. 
Sox1GFP reporter mESCs were maintained feeder-free, as previously outlined 
(Chapter 2, section 2.1.3.1)
87,199,250
. Briefly, 46C-derived monolayer cultures were 
treated with 10 mM nicotinamide at the early stages of neural differentiation (i.e. day 
0-7), and the cells were further differentiated up to a total of 14 days. Where 
indicated (Figure 6.2), N2B27 medium was supplemented with PD0325901 (1 µM; 
to temporally block FGF/ERK activity; Axonmedchem, Groningen, The 
Netherlands), ventralising signals Shh (200 ng/ml; R&D systems, Abingdon, UK) 
and FGF8b (100 ng/ml; PeproTech, London, UK), and pro-survival factors GDNF 
(10 ng/ml; PeproTech), BDNF (10 ng/ml; PeproTech) and AA (0.2 mM; Sigma, 
Aldrich, UK).  
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Figure 6.2 Schematic procedure to investigate the influence of nicotinamide on 
the induction of midbrain specific DA neuron differentiation from Sox1GFP 
mESCs. Exponentially proliferating undifferentiated pluripotent mESCs were 
maintained in FCS/LIF medium. Withdrawal of self-renewal stimulus (i.e. LIF), 
where the cells are switched to N2B27 is designated as day 0 of monolayer 
differentiation. Defined culture conditions
87
 were established to direct the 
differentiation of 46C mESCs into mDAergic neuronal cultures. To examine the 
differentiation potential of the vitamin B3 metabolite on mDA neuron production, 
undifferentiated cells were cultured as monolayers in N2B27 medium in the presence 
of nicotinamide during the early stages of ESC differentiation, combined with the 
stepwise addition of key inductive and maturation signalling factors at distinct time 
points of mDA neuron differentiation, until day 14.  
Brief pharmacological inhibition of FGF/ERK signalling upon neural induction, 
reported to induce midbrain-specific traits in differentiating cultures
87
, was achieved 
using a PD compound (potent MEK blocker: PD0325901) between days 3 and 5. 
Shh and FGF8b were added between days 5-9, which spans the peak of neurogenesis 
(i.e. Sox1
+
 NPC production is at its peak). A panel of survival-promoting factors; i.e. 
GDNF, BDNF and AA were added to cultures between days 9-14, to promote the 
survival and maturation of 46C mESC-derived TH-expressing neurons. The potential 
of nicotinamide in this experimental paradigm was assessed for 
immunocytochemistry at day 14 of monolayer differentiation, with antibodies 
specific to the dopaminergic neuron marker, TH (red) and the immature neuronal 
marker, βIII-tubulin (green).  
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6.2.2 Conversion of naïve mESCs to the primed mEpiSC pluripotent state, via 
activin and bFGF treatment. 
mEpiSCs were generated from the 46C Sox1GFP reporter cell line and maintained in 
a pluripotent and self-renewing state by bFGF and Activin/Nodal signalling 
(appendix 2)
252
. This protocol is detailed in the Material and Methods’ chapter 
(section 2.1.4.1).  
6.2.3 EpiSC differentiation with mDAergic neural-inducing factors and 
nicotinamide treatment. 
Monolayer neural differentiation of mEpiSCs was established based on the protocol 
developed by Jaeger et al (2011)
87
.  One modification to this differentiation 
procedure was devised in the present study; i.e. presence/absence of 10 mM 
nicotinamide between days 0 and 7. Briefly, mEpiSCs were plated on fibronectin-
coated plastics and cultured in EpiSC media, until approximately 50-60% 
confluency. Cultures were rinsed twice with PBS and switched to retinol-free (RF) 
N2B27 differentiation medium (appendix 2); designated as day 0 of monolayer 
differentiation. Similar to 46C mESC differentiation, medium with factors was 
replenished every alternate day. Where indicated (Figure 6.3), the concentration of 
added small molecule factors was: presence/absence of nicotinamide (10 mM), 
PD0325901 (1 µM), Shh (200 ng/ml), FGF8b (100 ng/ml), GDNF (10 ng/ml), 
BDNF (10 ng/ml) and AA (0.2 mM), which were added to differentiating monolayer 
cultures every alternate date until day 14, after which the cells were processed for 
immunocytochemistry. A detailed protocol of EpiSC differentiation is provided in 
the Material and Methods’ chapter (section 2.1.4.2).  
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Figure 6.3 Schematic procedure for inducing DA neuron differentiation from 
mEpiSCs, using a small-molecule-based strategy with nicotinamide treatment. 
Proliferating undifferentiated pluripotent EpiSCs were maintained in EpiSC medium, 
supplemented with activin and bFGF, until approximately 50-60% confluency. To 
induce monolayer neural differentiation of EpiSCs, self-renewal stimuli (i.e. 
activin/bFGF) were removed and the cells were switched to RF-N2B27 (i.e. day 0 of 
monolayer differentiation). To examine the differentiation potential of the vitamin B3 
metabolite on mDAergic neuronal production from mEpiSCs, undifferentiated cells 
were cultured as monolayers in RF-N2B27 medium in the presence of nicotinamide 
from days 0 to 7, and combined with the stepwise addition of inductive and 
maturation signalling factors at distinct stages of mDA neuron differentiation, until 
day 14. A brief inhibition of FGF/ERK signalling on exit of the lineage-primed 
epiblast pluripotent state was achieved using a PD compound (potent MEK blocker: 
PD0325901) between days 0 and 2. PD0325901 was administered at an earlier time 
point since neural induction was accelerated in the EpiSC differentiation system 
(occurs during the first 2-3 days of EpiSC differentiation). Shh and FGF8b were 
applied between days 5-9 and an array of survival-promoting factors were added to 
cultures during neuronal differentiation between days 9-14. The potential of 
nicotinamide in this experimental paradigm was assessed by immunocytochemistry 
at day 14 of monolayer differentiation.  
 
6.2.4 Immunocytochemistry 
To study the effect of nicotinamide on mDAergic generation from pluripotent mouse 
stem cell sources, immunocytochemical staining was performed as previously 
described (Material and Methods’ chapter, section 2.1.5.1), using primary antibodies 
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against the neuron-specific postmitotic βIII-tubulin marker and TH, the early marker 
of DA neurons. Cell nuclei were counterstained with DAPI.  
6.2.5 Image and statistical analysis 
For preliminary assessment of the effects of nicotinamide treatment on mDA 
neuronal generation from 46C-derived mESCs, cell quantification of TH
+
 neurons 
(expressed as a percentage of the total cell population) was performed manually on 
6-8 random fields of view. Cell count data were averaged across three coverslips per 
culture and experiments were repeated three to five times (i.e. n = 3–5 independent 
experiments). To determine the preliminary effects of nicotinamide on mDA neuron 
differentiation of mEpiSCs, the average number of TH-expressing neurons per field 
was quantified manually from 6-8 random fields of view, in each well of a 12-well 
tissue culture plate (i.e. n = 1).  
In this experimental chapter, where multiple data replicates were collected, treatment 
groups were compared using an unpaired t test. Results were considered statistically 
significant for p values less than 0.05. Where specified, data plotted on graphs are 
expressed as mean ± SEM.  
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6.3 Results 
 
6.3.1 Enhanced generation of TH-expressing cells from mESCs via adherent 
monolayer differentiation. 
Following a total of 14 days of differentiation, using inductive signalling molecules 
but without nicotinamide, a substantial number of βIII-tubulin+ neurons, 
corresponding to enhanced yields of TH
+
 cells was evident under defined culture 
conditions, following the stepwise treatment of 46C-derived ESC cultures with small 
molecule signalling factors implicated during normal DAergic development in vivo. 
High-density βIII-tubulin+ and TH+ neuronal cell clusters were frequently observed 
under this culture paradigm (Figure 6.4 and 6.5).  
 
Figure 6.4 Enhanced generation of TH-expressing neurons, derived from 46C 
mESCs via monolayer differentiation. (A) Immunofluorescence images of TH
+
 
neuronal populations generated from mESC-derived monolayer cultures, showing 
immunostaining with antibodies specific to the DA neuronal marker, TH (red) and 
the  immature neuronal marker,  βIII-tubulin (green). Double-staining techniques 
indicated co-localisation of TH-expressing neurons with βIII-tubulin+ neurons, at day 
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14 of monolayer differentiation. The nuclei of all cells in cultures were labelled with 
DAPI (blue). Under defined differentiation conditions,
87
 higher frequencies of TH 
immunoreactive cells were robustly produced, compared to monolayer cultures 
without exogenous inductive and pro-survival signalling factors, in which no 
appreciable numbers of TH
+
 cells were detected (detailed in section 4.3.2.1). Scale 
bar = 100 µm. 
 
Figure 6.5 (A) TH-expressing cells were frequently observed in cell clusters, 
counterstained with DAPI, which displayed obvious neuronal morphologies. Scale 
bar = 100 µm. 
 
6.3.2 Stepwise directed differentiation of 46C-derived mESCs to mature neuronal 
cultures.  
Treatment of mESCs during the course of their differentiation with well-established 
inductive molecules, which have been successfully applied in a number of in vitro 
differentiation protocols, particularly to direct mDA neuron differentiation (Figure 
6.2)
78,87
 results in the development of neuronal morphologies and formation of TH
+
 
cell networks, observed in a more mature neuronal culture system (Figure 6.6).  
 
179 
 
 
Figure 6.6 Enhanced neuronal maturation in mESC-derived cultures. (A) 
Extensive axonal branching and elaborate neuronal networks (inset) in βIII-tubulin+  
neuronal
 
populations (green) were observed; a possible contribution of the combined 
effects of GDNF, BDNF and the vitamin C metabolite, AA, during the late stages of 
neuronal development. The nuclei of all cells in cultures were counterstained with 
DAPI (blue). (B-D) TH immunoreactive cells displayed enhanced neuronal 
morphologies, increased neurite outgrowth, and formed TH
+
 neuronal networks, 
following 14 days of differentiation. (A-D) Scale Bars = 100 µm.  
 
6.3.3 Nicotinamide treatment enhances the production of TH-expressing cells 
from mESCs.  
To determine the potential of the vitamin B3 metabolite, in terms of the percentage of 
TH
+
 cells generated from the monolayer-derived Sox1GFP knock-in 46C cell line, 
nicotinamide treatment was included in the Jaeger protocol, outlined in section 6.2.1. 
Sox1GFP mESCs were differentiated up to a total of 14 days of the monolayer 
culture period (Figure 6.2).  
Under this differentiation method, early supplementation of 10 mM nicotinamide 
(i.e. day 0-7) elicited a significant increase in the percentage of TH
+
 immunoreactive 
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neurons of the whole cell population (unpaired t test, t = 11; p<0.001) [12.7 ± 0.4% 
vs. 6.2 ± 0.4% in control conditions; Figure 6.7 (A-C)].  
With respect to cell quantification in this experiment, individual βIII-tubulin-
expressing neurons were not quantified manually for data analyses due to the high 
density of βIII-tubulin+ neuronal networks. Therefore, it was not possible to express 
the number of TH
+
 cells as a proportion of total neurons, to determine if this effect is 
associated with an enrichment of TH
+
 versus total neurons.   
The current study further confirms an important role for nicotinamide during the 
early stages of ESC differentiation, possibly at the level of NPC formation, to direct 
the production of ESC-derived TH
+
 neurons during monolayer differentiation. It is 
reasonable to conclude that nicotinamide may function synergistically with protein 
signalling molecules such as Shh and FGF8 during neural specification to direct 
differentiating neural progenitors adopting a DAergic cell fate. 
 
Figure 6.7 Enhanced production of TH
+
 neurons, derived from 46C mESCs via 
monolayer differentiation with nicotinamide treatment. Immunocytochemical 
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analysis of monolayer cultures supplemented with N2B27 medium without 
nicotinamide (A) and with the addition of 10 mM nicotinamide (B). Representative 
images show immunostaining with the antibody specific to TH (red). Total cells in 
cultures counterstained with DAPI (blue). Scale bar = 50 µm. The percentage of TH
+
 
neurons obtained from mESCs increased when 10 mM nicotinamide was added to 
media. (C) Bars represent percentage TH immunoreactive neurons as a proportion of 
total cells. Differentiating cultures treated with 10 mM nicotinamide show a 
significant increase in the percentage of TH-positive neurons per culture, compared 
to control conditions. 
***p<0.001 
 
6.3.4 Small molecule induced induction of mESCs into a primed epiblast state. 
In the next part of the study, pluripotent mEpiSCs were successfully established 
from Sox1GFP mESCs under directed EpiSC culture conditions without LIF but 
including activin and bFGF induction, to sustain the self-renewal capacity and 
pluripotency in EpiSC cultures (Figure 6.8).   
Cells were routinely passaged every other day, and 10-15 passages were required to 
purify epiblast cultures from mESCs. Unlike mESC maintenance, EpiSCs are not 
trypsinised to a single cell suspension. Thus, cell cultures are not counted for 
passaging, therefore passaging densities must be determined empirically. The plating 
density of EpiSCs is important to maintain their undifferentiated state, and also to 
ensure that cells are not plated sparsely/at low densities, as this would result in extra 
population doublings to reach confluency. 
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Figure 6.8 Derivation of EpiSCs from Sox1GFP knock-in cell line. 
Representative brightfield cell images of EpiSC cultures. (A&B) EpiSCs should 
form flat, compact and rounded colonies with an epithelial morphology. Prominent 
nucleoli and a high nuclear/cytoplasmic ratio are both characteristic of EpiSC 
cultures. (B) It is important that colonies show sharp, defined borders, with no 
evidence of differentiation. (C&D) When converting mESCs to EpiSC cultures, it is 
important to observe the morphology of the cells and ensure that they form tightly 
packed colonies without forming 3D structures (indicative of differentiation) (C) or 
dissociating into single cells (D). Scale bar = 100 µm.  
 
6.3.5 Differentiation of mEpiSCs with nicotinamide supplementation into DAergic 
neuronal populations.  
 
Nicotinamide treatment was introduced to a novel method of mDA neuron 
differentiation, to investigate its effect on the differentiation of pluripotent epiblast 
cells, derived from the Sox1GFP mESC line. EpiSCs were subjected to a monolayer 
differentiation protocol (Figure 6.3), previously established in ESCs
87
. In this study, 
further efforts were made to enhance the population of TH-expressing neurons by 
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addition of nicotinamide to the early stages of EpiSC differentiation, combined with 
the sequential application of inductive signalling molecules to potentiate DAergic 
differentiation from EpiSCs.  
TH
+
 neuronal cells located in dense DAPI
+
 and βIII-tubulin+ cell clusters were not 
included in data collection, since these neural networks were unquantifiable and 
therefore not expressed as a percentage of total neurons or as a percentage of total 
cells counterstained with DAPI (Figure 6.9). Further, due to the high density of cells 
in clusters, it was not possible to provide a quantitative assessment in terms of the 
number of TH neurons independent of treatment. Thus, preliminary findings in this 
EpiSC differentiation study are presented as the mean TH
+
 neuronal cell count per 
field, observed in low density areas. 
Preliminary data suggest that nicotinamide did not induce significant differences in 
the mean number of TH
+ 
neurons per field of view, when added between days 0 and 
7 of EpiSC neural differentiation. However, it is important to point out that the 
results of this study are preliminary and were obtained from one experiment (i.e. n = 
1); therefore further work to optimise the EpiSC model system is necessary. 
Although further optimisation is required using both the mESC and mEpiSC 
differentiation models to establish appropriate plating densities, important 
preliminary findings generated under the mESC experimental paradigm strongly 
suggest that nicotinamide may function as a key factor to stimulate a higher extent of 
differentiation toward a DAergic cell fate in ESCs.  
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Figure 6.9 Effect of nicotinamide on the generation of TH-expressing neurons, 
from mEpiSCs via monolayer differentiation. (A) Representative images of neural 
differentiation of mEpiSCs by inactivating the FGF signalling pathway. 
Immunocytofluorescence images show total cells in cultures labelled with DAPI 
(blue), and immunostaining with antibodies specific to immature neuronal marker 
βIII-tubulin (green-expressing cells) and TH (red). Scale bar = 100 µm. (B) 
Immunocytochemical analysis of monolayer EpiSC-derived cultures supplemented 
with RF-N2B27 medium without nicotinamide and with the addition of 10 mM 
nicotinamide. Representative images show immunostaining with the antibody 
specific to TH (red). Nicotinamide added during the early stages of EpiSC 
differentiation elicited no effect on the average number of TH-expressing neurons 
per field. Scale bar = 100 µm. (C) Bars represent the mean TH
+
 neuronal cell count 
per field. Preliminary results show that nicotinamide, when added between days 0 
and 7, did not induce differences in the number of TH
+
 neurons per field between 
control and 10 mM nicotinamide conditions.  
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6.4 Discussion 
Identification of differentiation conditions to direct efficient commitment to a 
DAergic cell fate is crucial to maximise the potential of pluripotent stem cells 
towards a CRT for PD. The current study utilised pluripotent mESCs and mEpiSCs 
to identify the effects of nicotinamide on DAergic neural differentiation. This 
experimental chapter provides further crucial evidence that the biologically active 
vitamin B3 metabolite, nicotinamide, functions as a key factor to direct the 
development of TH
+
 neurons from mESCs. Thus, this important preliminary finding 
strongly suggests that our understanding of the genetic cues governing the induction 
of mDA NPCs and the specification of the mDA neuronal cell fate is far from 
complete, despite rapid progress over the past few years.  
6.4.1 Nicotinamide significantly enhances TH
+
 neuronal differentiation from 
Sox1GFP mESCs.   
To my knowledge, the current study presents the first report demonstrating 
significantly enhanced neural conversion of mESCs to TH
+ 
neurons, using 
nicotinamide supplementation during the early stages of ESC in vitro development. 
Specifically, nicotinamide added to monolayer cultures, at an effective concentration 
(i.e. 10 mM) previously determined to efficiently promote catecholaminergic 
differentiation, stimulated a significant increase in the production of TH-expressing 
neurons of the total cell population. This finding highlights the reproducible nature 
of the effect of nicotinamide on catecholaminergic differentiation, using two distinct 
experimental paradigms
87,201
. It should also be noted that attempts to increase the 
number of DAergic neurons by nicotinamide induction should focus on the early 
developmental time window of ESC development (i.e. day 0-7). In this regard, 
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nicotinamide does not have a further instructive role during neuronal differentiation 
of NPCs (i.e. day 7-14; section 3.3.1). 
Another important point of note from this study established that 10 mM 
nicotinamide supplementation alone during mESC-derived TH
+
 neuronal 
differentiation (generated 4.2% of TH
+
 cells per culture; section 4.3.2.1;), displayed 
almost a similar potency to the yield of TH-expressing cells per culture produced in 
control conditions (6.2%), under the experimental paradigm devised by Jaeger et al 
Thus, this vitamin B3 metabolite functioned as an important signalling molecule to 
direct the production of new TH-expressing cells from ESCs, sharing a similar 
potency to well-established extracellular factors known to induce mDA specification. 
In other studies, the vitamin A metabolite, RA has been reported to function 
synergistically with Shh, FGF and BMP to direct the patterning of differentiating 
progenitor cells, by directing differentiating rostral-like cells to develop caudal 
characteristics
257
. 
Due to the highly-dense βIII-tubulin+ neuronal networks observed under this mESC 
differentiation paradigm, it was not possible to quantify individual βIII-tubulin-
expressing neurons localised within elaborate networks of axonal processes; a 
possible attribution of the neuroprotective factors administered between days 9 and 
14 of differentiation. Therefore, it was not feasible to determine whether TH
+
 
neuronal enrichment was further enhanced by nicotinamide in the current monolayer 
differentiation system. Nevertheless, preliminary data do not negate the potential of 
nicotinamide as a useful candidate in future protocols for increasing TH
+
 cell 
differentiation. In future work, neuronal cultures plated at various cell densities 
should be investigated, to optimise mESC seeding densities in order to reduce the 
number of high-density neuronal networks by day 14 of monolayer differentiation. 
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Alternatively, confocal microscopy may prove advantageous to quantify TH
+
/βIII-
tubulin
+–cells to confirm colabeling for both markers, and therefore determine 
whether nicotinamide further enhances cultures enriched for DAergic neurons, 
toward generating homogenous populations of DAergic neurons suitable for a 
transplantation therapy for PD. 
DAergic neurons are localised throughout the vertebrate CNS, with the largest 
assembly in the midbrain. However, approximately 25 % of DA containing neurons 
are present in other brain regions
178
 Many in vitro differentiation studies determine 
mDA neuronal phenotype by assessing for TH expression in differentiated 
cultures.
203
 However, TH expression is observed in all catecholaminergic neuronal 
subtypes, such as adrenergic and noradrenergic neurons
258
. In this regard, the Parmer 
and Li study reported that TH immunoreactive neurons co-expressed Nurr1, a gene 
characteristic of DAergic markers but excluded from other catecholaminergic 
neurons, therefore indicating that Sox1GFP-derived TH
+
 neurons are likely 
DAergic
178
. Since the protocol established in this study included appropriate 
instructive patterning molecules necessary for directing DA cell fate, it is reasonable 
to speculate that the majority of TH-containing neurons reflect DAergic populations. 
However, it was also reported that under the Sox1GFP model system,  monolayer-
derived TH expressing neurons do not express additional mesencephalic phenotypic 
markers
178
. Thus, the extent to which 46C mESCs generated DA neurons co-
expressing midbrain markers in the presence of nicotinamide remains to be 
elucidated in an alternative pluripotent stem cell model.  
6.4.2 Neural differentiation of epiblast-derived stem cells.  
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Studies performed in mice models highlighted two distinct pluripotent states in vivo, 
which can be mimicked in vitro
252,254
. Specifically, classic mESC cultures are 
obtained from preimplantation embryos, whilst epiblast cells are derived from 
postimplantation embryos. However, significant differences exist between mESCs 
and mEpiSCs. mEpiSCs share many defining features with both pluripotent hiPSC 
and hESC sources, such as signalling pathways to maintain their pluripotent state; 
stability of their epigenetic status; cellular morphologies, and their ability to 
differentiate similarly under defined culture conditions
251
. During early 
embryogenesis, the epiblast contains more progressed pluripotent cells derived from 
the ICM, thereby generating the most immediate precursors of the early somatic 
lineages
259
. Thus, the EpiSC differentiation system serves as an advantageous model 
to investigate germ-layer specification, since these developmentally primed cells 
epitomise the last pluripotent state prior to gastrulation. Furthermore, the broad 
similarities that exist between epiblast cells and hESCs derived from the late epiblast 
indicate that cells of human origin more closely reflect characteristics of mEpiSCs 
than mESCs
252
. Thus, the potential of nicotinamide was examined in a more efficient 
protocol using intermediate epiblast cells
87
.  
Neural differentiation using mEpiSCs was based on a strategy which offered several 
advantages over current strategies for directing DAergic differentiation
87
. Firstly, 
this protocol has demonstrated a propensity to direct midbrain regional identity in 
the generated DA neurons more readily from pluripotent cell sources including 
mEpiSCs, miPSCs and two hESC lines. Furthermore, previous protocols using ESCs 
to generate TH
+
 neuronal populations have often proved unreliable and highly 
variable between experiments, which may be due to the temporal and spatial 
heterogeneity observed in ESC-derived NPCs
87
. However, Jaeger and colleagues 
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reported a simple strategy to enhance the generation of TH
+
 neurons co-expressing 
Foxa2, Lmx1a and Pitx3, likely due to the more synchronous conversion of EpiSCs 
to the neuroepithelial fate, thereby facilitating efficient capture of mDA-competent 
progenitors. Further, previous findings outlined in Chapter 4 demonstrated a bias 
toward the generation of high yields of GABAergic neurons from mESCs (61%), 
with a maximum of 7.5% TH
+
 neurons reported in control conditions, without any 
exogenous stimuli. Interestingly, the Jaeger study found that neural progenitors 
exposed to sequential treatment with the small inhibitory PD molecule and 
ventralising signals (i.e. Shh and FGF8) displayed reduced expression of non-DA 
immunomarkers, therefore indicating the necessity of appropriate signals required to 
direct efficient mDA fate specification and differentiation
87
.  
However, it is clear from this study that extensive optimisation of the EpiSC model 
is required to improve culture conditions and plating densities for differentiation of 
EpiSCs, to fully evaluate the effects of nicotinamide on mDA specification and 
differentiation. It is important to note that the midbrain DA neuron protocol 
established by Jaeger and colleagues is suboptimal for inducing TH
 
immunoreactive 
cells, co-expressing FOXA2, Pitx3 and Lmx1a expression
87
. Therefore, in future 
work is will be of interest to determine whether nicotinamide further augments mDA 
neuron differentiation.  
6.4.3 Conclusion and Further Studies 
This study provides an important foundation for the role of nicotinamide in 
differentiation of mESCs, however further studies are essential. Although a number 
of optimisation issues including plating densities need to be overcome with respect 
to the mESC and mEpiSC differentiation protocol, it is encouraging to note that 
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combinatorial use of nicotinamide with appropriate inductive and pro-survival 
signalling molecules generates significantly increased TH
+
 neuronal populations 
from Sox1GFP mESCs. However, complications can arise when a protocol 
established in a mouse model system is adapted for use with human cells. Therefore, 
translation of the potential of the small molecule nicotinamide to a more efficient 
protocol using the EpiSC model, comparable to the human differentiation system is 
crucial. Further optimisation of this novel method will provide new information on 
the importance of vitamin B3 in the production of new mDA nerve cells. Moreover, 
access to a large and enriched population of midbrain dopaminergic cell types, using 
the EpiSC differentiation protocol, should yield a scalable source of neurons for 
evaluation in preclinical models to test the potential of nicotinamide, and its ability 
to promote neural differentiation, towards development of future neural cell-based 
therapies for patients. In these contexts, other areas worth investigating in future 
studies include the influence of nicotinamide on SIRT1 during DA 
neurogenesis
226,232,260
. 
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Chapter 7: Summary and General Discussion 
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7.1 Summary of thesis findings 
Knowledge of the effects and timing of inductive molecules is fundamental for 
advancing prospective therapies to generate neuronal populations from ESCs. In this 
regard, a monolayer system, comprising a cell line engineered to express a reporter 
of neural specification, Sox1GFP, was employed here, to facilitate direct 
visualisation of the neural progenitor state in living cells with fluorescence 
microscopy. This advantageous feature of the 46C line allowed, for the first time, a 
detailed investigation of the effects of the vitamin B3 metabolite, nicotinamide, on 
ESC-derived cell populations at any point during monolayer differentiation. It was 
demonstrated in this thesis, for the first time, that nicotinamide plays an important 
role in directing mESC differentiation specifically towards a neuronal lineage.  
 
The findings presented in this thesis can be summarised as follows: 
 
 By adding nicotinamide to cells at an early stage of the monolayer protocol, 
differentiation of Sox1GFP mESCs was directed rapidly into the neural 
lineage. Nicotinamide added at later stages of differentiation  had no effect 
on neuronal induction.  
 In nicotinamide-treated cultures, the marker for pluripotent ESCs, Oct4, was 
down-regulated rapidly, concomitantly  increasing GFP
+
 neural precursor 
cells and immature neurons at day 4. By day 14, nicotinamide treatment 
(from day 0-7) reduced both Oct4
+
 and GFP expression concomitant with 
enhanced expression of neuron-specific βIII-tubulin, indicative of accelerated 
neuronal differentiation.  
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 Treatment with nicotinamide at the initial stages of ESC differentiation not 
only promoted neuronal differentiation, but also reduced the total number of 
cells in adherent monolayer cultures by day 14 of differentiation. This 
important finding showed that this vitamin derivative fucntions to promote 
the enrichment of neurons versus non-neuronal cells.  
 Nicotinamide selectively enhanced the production of specific neuronal 
phenotypes, i.e. catecholaminergic and serotonergic neuronal populations.  
 The differentiation-promoting effects of nicotinamide were dose dependent, 
being significant for 5 mM and especially 10 mM doses. High doses of 
nicotinamide (20 mM) showed an obvious noxious effect on cell suvival. 
Crucially, cultures treated with 10 mM nicotinamide doses demonstrated  no 
adverse effects on cell viability or cell death.  
 The mechanims by which nicotinamide reduced total cell numbers in cultures 
and by which cells alter their fate were addressed by investigating cell cycle 
exit and apoptotic mechanisms in specific cell populations. For the first time, 
nicotinamide was demonstrated to act at the initial stages of ESC 
differentiation to suppress Sox1 precursor proliferation, thereby promoting 
the transition from neural progenitors to neurons. This important finding is in 
agreement with the ability of nicotinamide to efficiently commit cells to a 
neuronal fate, and accelerate maturation and neurite formation in 
catecholaminergic and GABAergic populations.  
 In a preliminary study to address the mechanism of action of nicotinamide on 
neuronal differentiation, the expression of a potential target for its action, 
SIRT1, was shown to progressively decrease in monolayer cultures with time 
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in vitro, in agreement with reports showing that down-regulated SIRT1 
expression is fundamental to support neuronal differentiation.  
 Immunocytochemical analyses further indicated that the sub-cellular 
localisation of SIRT1 is predominantly nuclear in neural progenitor and 
neuronal cell populations. Given that SIRT1 has been reported to modulate 
chromatin structure by deacetylating specific lysine residues in histones
261
, 
these observations support function of the target protein within the neuron.  
 The potential of nicotinamide was combined with external signalling factors 
known to enhance a DAergic phenotype. Specifically, nicotinamide 
functioned synergistically with signalling molecules implicated in the 
induction and maintenance of mDAergic neurogenesis to enhance TH-
expressing neuronal populations from Sox1GFP mESCs.  
 Pluripotent mEpiSCs were successfully established from Sox1GFP mESCs 
under directed EpiSC culture conditions. In future work, optimisation of this 
differentiation model should enable access to a large and enriched population 
of mDAergic cell types to test the potential of nicotinamide on their survival 
and maturation.  
 
The immediate implications of these findings towards the potential of nicotinamide, 
a derivative of vitamin B3, in future neuronal replacement therapies have been 
discussed in detail within each experimental chapter. ESCs are considered to be an 
invaluable in vitro biological tool not only for examining the mechanisms of 
pluripotency, but also to study effects of different factors for directing cell fate 
decisions throughout early development. Further to this, ESCs facilitate disease 
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modelling, pharmacological screening and most importantly, serve as an unlimited 
source of pluripotent cells toward regenerative therapies.  
Currently, the challenge in ESC biology to advance the potential of pluripotential 
stem cell sources is to establish criteria for determining effective differentiation
61–63
. 
In this regard, significant issues need to be resolved before cells are translated to the 
clinic, including the production of high yields of purified neuronal populations of 
appropriate phenotype with control over proliferation to prevent tumorigenesis
63
. 
Novel findings presented in this thesis suggest that nicotinamide may be a key 
external signalling factor in helping to achieve this goal, to translate effective 
laboratory cell-based protocols to patients in clinical trials. The discussion here will 
consider future development of this PhD project.  
7.2 General discussion 
Results presented in this thesis establish that nicotinamide functions as a regulator of 
neuronal differentiation and neurite outgrowth and maturation, thus supporting 
previous evidence of the fundamental role of vitamins and their metabolites during 
early development
104,115,126,128,161–163,191,239,242,243,262
.  
The importance of vitamin signalling in the development of mDA neurons was 
recently reported in a proteomics study
263
, which identified key signalling molecules 
linked to vitamin B3 and vitamin D3 specifically. Protein expression in the rat 
embryo during mDA neuronal development was studied using an iTRAQ proteomics 
approach, and successfully identified signalling proteins including: nicotinamide 
nucleotide dehydrogenase, vitamin D receptor and vitamin D binding prepeptide
263
. 
Therefore, expression of key signalling proteins for these vitamins is present at the 
correct time and place to direct mDA neurogenesis. Further, the final experimental 
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chapter presented in this thesis (Chapter 6), reported that the combinatorial use of 
nicotinamide with appropriate inductive and pro-survival signalling molecules 
generated significantly increased TH
+
 neuronal populations from Sox1GFP mESCs. 
This critical finding, shows for the first time, that the vitamin B3 metabolite 
functions as a key factor in directing ESCs adopting a DAergic fate.  
 
7.2.1. Future directions to identify distinct mechanisms underlying nicotinamide-
induced DAergic neural lineage-specification of Sox1GFP mESCs.  
Detailed knowledge of the exact timing of action of small molecules during neuronal 
differentiation is not only critical for establishing effective differentiation protocols 
to direct clinically relevant lineages for regenerative therapies, but also to uncover 
mechanisms underlying small molecule induced lineage-specification of pluripotent 
stem cells. Therefore, with respect to future mechanistic investigations related to this 
project, it will be necessary to establish the exact time-window of ESC 
differentiation where nicotinamide predominantly acts on cells to increase TH
+
 
neuronal production (i.e. between days 0-7).  
Findings presented in this thesis provide critical insight into the effects of 
nicotinamide during the initial phases of ESC development. It is interesting to note 
that addition of nicotinamide from day 0 of monolayer differentiation elicited a more 
potent effect on neuronal differentiation by day 7, which promoted significantly 
enhanced yields of βIII-tubulin+ neurons [15.2% vs. 3.4% in control groups; section 
5.3.3.3, Chapter 5], in contrast to nicotinamide treatment between days 2-7 [7.3% vs. 
3.3% in control groups; section 3.3.5.3, Chapter 4], which showed less effect.  
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Sox1 expression is detectable in all NPCs during early time points of embryonic 
development, but is not detectable in the VM at the stage when DAergic neurons are 
produced during embryonic development in vivo
178
. Since, the time-window for 
DAergic specification is quite narrow (i.e. pre-Sox1 expression stage, tightly linked 
with the acquisition of a pan-neuroectodermal fate), it will be of interest to determine 
whether nicotinamide exclusively promotes DAergic differentiation in progenitor 
cells prior to Sox1 expression (i.e. day 0-2), or during the stage of Sox1GFP
+
 NPC 
formation (early born progenitor cells observed between days 3-4, and late born 
progenitors detected at day 7).  Further to this point, in experimental chapter 4, a 
plausible explanation for the early differentiation-inducing effects of nicotinamide 
on catecholaminergic and serotonergic populations may be that this early time 
window (i.e. day 0-2) precedes the generation of TH and 5-HT NPCs, thereby 
suggesting that nicotinamide may drive the ontogenetically early processes for 
DAergic and serotonergic specification, analogous to those which occur at the 
midbrain-hindbrain organiser and the primitive streak during normal development in 
vivo.  
Thus in future work to uncover the key developmental stage where nicotinamide acts 
during neuronal development, further experiments will be required, to determine the 
effects of nicotinamide on the process of neural induction (days 0-2), or between 
days 2-7 to investigate its influence NPC populations (day 2-7). Of particular interest 
to this study, it will be necessary to further differentiate the cells for a total of 14 
days rather than examining differentiated cultures for TH expression at days 2 and 7 
respectively, since Parmer and Li reported the presence of very few TH-expressing 
neurons at day 10 of differentiation, using the Sox1GFP model system
178
. 
Alternatively, the use of other reporter cell lines, such as the Pitx3GFP knock-in cell 
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line to track midbrain-specific DA differentiation from stem cells in vitro, would 
provide further insight into the effects of nicotinamide on DAergic fate specification.  
Currently, the precise mechanism by which nicotinamide exerts its actions on 
developing neurons remains to be elucidated. One interesting hypothesis for the 
precise mode of action of nicotinamide in mechanisms underlying the promotion of 
enhanced TH
+
 neuronal differentiation, is a potential for SIRT1, a critical factor 
reported for stem cell function, that acts by controlling cell fate decision
232,233
. 
Specifically, it was previously reported that nicotinamide directed cardiac lineage 
specification from the pluripotent state of hESCs
163
. A follow-up study reported that 
nicotinamide promoted nuclear translocation of NAD dependent histone deacetylase 
SIRT1 and global chromatin silencing, thereby suggesting that a predominant 
epigenetic mechanism via SIRT1 underlies the nicotinamide-induced hESC cardiac 
fate determination
259
. Similarly, with respect to DAergic differentiation, SIRT1 has 
been reported to play a role in Nurr1 control of TH expression in human NSCs, 
during DA neurogenesis
226
. 
For future development of this project, to investigate the specific elements of the 
SIRT1 signalling mechanism during neuronal development, it will be necessary to 
block this pathway to assess how it affects neuronal differentiation. This hypothesis 
could be addressed using a blocking experiment with a small molecule inhibitor of 
downstream targets of their known signalling pathway, or by introducing short 
interfering RNA to inhibit expression of downstream targets. 
7.2.2 Future directions to address whether there is a synergistic effect of the active 
forms of vitamin B3 and vitamin D3 on the development of DA neurons? 
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A number of reports show that neuronal development in the CNS is dependent on a 
complex array of multiple signalling factors
44,263
. Currently, it is not known whether 
vitamin metabolites act independently or in concert with each other, through 
converging pathways to influence neuronal development during ESC differentiation. 
In this context, nicotinamide has been reported to cooperate with RA or vitamin D3 
to regulate cell differentiation and cell cycle arrest
264
. The effects of calcitriol (active 
metabolite of vitamin D3) are mediated through the binding of this ligand to its 
nuclear receptor and heterodimer formation with RXR and RAR
104
. In turn, these 
retinoid receptors interact with other coactivator and corepressor nuclear receptors, 
thereby initiating the expression of more than 500 genes
265
. Endogenous RXR 
ligands found in the CNS are capable of activating heterodimers formed between 
RXR and the orphan nuclear receptor
266
, Nurr1 in vivo; an essential transcription 
factor required for the development and maintenance of mDA neurons
267
. Thus, it is 
likely that vitamin metabolites function in defined locations, at appropriate 
developmental stages, and that different combinations function synergistically to 
direct neuronal development.  
In future studies, it will be of interest to investigate vitamin metabolites, such as 
nicotinamide and calcitriol in combination, at the stage of differentiation where they 
were reported to predominantly function. Orme et al (2013) reported that calcitriol 
acts at a late stage of differentiation to promote neuroprotection in vitro to midbrain 
DA neurons by up-regulating GDNF expression
104
. Therefore, to investigate this 
hypothesis, nicotinamide applied at the initial stages of ESC differentiation could be 
critical for rapidly and efficiently promoting neural commitment to highly enriched 
neuronal lineages, before specifically defining a DAergic phenotype with calcitriol 
and other molecules, detailed in section 6.2.1. It is important to consider that 
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application of nicotinamide throughout the 14 days of monolayer differentiation (i.e. 
day 0 to day 14) may prove advantageous to keep pluripotent cells to a minimum, as 
discussed in Chapter 3.  
 
7.2.3 Future directions to translate the potential of nicotinamide to a functional 
protocol of mDA differentiation.  
To develop cells for PD therapy, cells must possess the capacity to generate mDA 
neurons, ideally those of SNpc character. In this regard, mESCs demonstrate a lack 
of ability to produce TH
+
 neurons possessing mesencephalic markers when 
differentiated under monolayer conditions
178
. Efficient monolayer neural 
differentiation requires low cell density, suggesting that close cell-cell interaction is 
essential for induction of an mDA neuronal phenotype
50
. Thus, in this thesis, it was 
not possible to evaluate the effects of nicotinamide on midbrain specific DA 
differentiation using the Sox1GFP mESC model system. Further optimisation of 
mEpiSC neural differentiation model would overcome this obstacle, which is known 
to potentiate the generation of midbrain specific DAergic neurons
87
. 
Another important concern for directed differentiation protocols is the functional 
evaluation of neuronal populations generated, to determine whether cells display 
appropriate physiological behaviours to those of the same phenotype in vivo
268
. 
Based on the previous effects of nicotinamide on enhanced neuronal maturation of 
derived catecholaminergic cells from mESCs (section 4.3.3), it will be interest to 
examine whether this vitamin B3 metabolite also functions as an inducer of neural 
maturation in midbrain specific DAergic populations, derived from developmentally 
primed epiblast cells.  
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Further to this point, clinical motor features appear in PD patients, when over 60% of 
DAergic neurons have been lost, causing an 80% depletion of striatal DA levels. It 
has been hypothesised that the lag between the appearance of motor symptoms and 
DAergic neuronal loss may be due to a compensatory mechanism, where remaining 
DAergic neurons sprout to maintain striatal innervation
269
. Thus, small molecule 
factors with the ability to promote DAergic neurite outgrowth hold much promise to 
significantly prolong the pre-symptomatic stage of PD. 
 
Thus, this thesis describes the pivotal functioning of nicotinamide as a regulator of 
neuronal differentiation and maturation, thus supporting previous evidence of the 
fundamental role of vitamins and their metabolites during early development. The 
implications for this project are wide. In particular, novel findings generated from 
this project are very exciting, as nicotinamide uniquely appears to drive dopamine 
neuron differentiation as effectively as known cocktails of signalling factors 
routinely applied in current published methods. Thus, nicotinamide may become a 
valuable component of cell culture solutions to aid the conversion of stem cells to 
dopamine neurons, helping to increase the efficiency of this process, the safety of the 
cells produced, and reduce costs, as we progress towards a patient-specific therapy 
for PD. 
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Appendix 1: Medium and solution components 
 
FCS/LIF medium, 10% for 550 ml: 
 
Media and solution components Quantity Supplier 
Glasgow Modified Eagles 
Medium 
500 ml Invitrogen, Paisley, UK 
Foetal bovine serum 51 ml Biosera, East Sussex, UK 
Non-essential amino acids  5.5 ml (10 mM) Invitrogen, Paisley, UK 
L-glutamine  5.5 ml (1 mM) Sigma, Aldrich, UK 
Sodium pyruvate  5.5 ml (100 mM) Invitrogen, Paisley, UK 
β-mercaptoethanol  550 µl (0.1 M) Sigma, Aldrich, UK 
Leukaemia inhibitory factor 100 U/ml Made in house 
 
N2B27 medium, for 50 ml: 
N2B27 medium (for 50ml): 2B27 medium (for 50ml) 
Media and solution components  Quantity Supplier 
DMEM/F12 24.5 ml Invitrogen, Paisley, UK 
Neurobasal medium 24.75 ml Invitrogen, Paisley, UK 
N2 250 µl Fisher Stem cellientific, 
Loughborough, UK 
B27 500 µl Fisher Stem cellientific, 
Loughborough, UK 
L-glutamine  500 µl (1 mM) Sigma, Aldrich, UK 
β-mercaptoethanol  50 µl (0.1 M) Sigma, Aldrich, UK 
 
 
EpiSC Retinol-free N2B27 medium, for 50 ml: 
 
Media and solution components Quantity Supplier 
DMEM/F12 24.5 ml Invitrogen, Paisley, UK 
Neurobasal medium 24.75 ml Invitrogen, Paisley, UK 
N2 250 µl Fisher Stem cellientific, 
Loughborough, UK 
B27 (without vitamin A) 500 µl Fisher Stem cellientific, 
Loughborough, UK 
L-glutamine 500 µl (1 mM) Sigma, Aldrich, UK 
β-mercaptoethanol  50 µl (0.1 M) Sigma, Aldrich, UK 
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EpiSC proliferation medium (Added to retinol-free N2B27 medium), for 50 ml: 
 
Media and solution components Quantity Supplier 
Human FGF-2 (bFGF) 60 μl PeproTech, London, UK 
Activin 40 μl R&D Systems, Abingdon, 
UK 
 
Nicotinamide (Dose-response assay), for 15 ml N2B27 medium: 
1 mM stock solution; base medium = Neurobasal medium 
 
Nicotinamide Molarity Stock Solution  
0.5 mM 7.5 µl 
1 mM 15 µl 
5 mM 75 µl 
10 mM 150 µl 
20 mM 300 µl 
 
EdU Click-iT® reaction cocktail 
 
EdU Click-iT® reaction cocktail Quantity: for 1 coverslip 
1X Click-iT® EdU reaction buffer 430 µl 
CuSO4 20 µl 
Alexa Fluor® azide 1.2 µl 
1X Click-iT® EdU buffer additive 50 µl 
Total Volume 500 µl 
 
 
TdT reaction cocktail 
 
TdT reaction cocktail Quantity: for 1 coverslip 
TdT reaction buffer 94 µl 
EdUTP 2 µl 
TdT 4 µl 
Total Volume 100 µl 
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TUNEL Click-iT® reaction cocktail 
 
TUNEL Click-iT® reaction cocktail Quantity: for 1 coverslip 
Click-iT® reaction buffer 97.5 µl 
Click-iT® reaction buffer additive 2.5 µl 
Total Volume 100 µl 
 
 
112 solution: 10 ml penicillin-streptomycin-amphotericin B (5000 U/ml), 12 g 
glucose dissolved in 28 ml sterile water, and 10 ml 200 mM L-glutamine  
 
Gelatin solution (0.1%): 1% gelatin solution was made up in distilled H20 (dH20), 
autoclaved to sterilise and stored at 4ºC. Stock solution was further diluted in 
sterilised water for a working solution. 
 
PFA, 4%: 18 g Disodium hydrogen phosphate (Na2HPO4), 9 g Sodium Chloride 
(NaCl), and 40 g PFA were added to 700 ml dH20 overnight. The pH was adjusted to 
7.3 with orthophosphoric acid or sodium hydroxide (NaOH), and dH20 was added to 
make the volume up to 1 L.  
 
Primary culture medium, for 50 ml: 42.75 ml Neurobasal medium, 5 ml foetal 
bovine serum, 1.25 ml 112 solution (see appendix), 500 µl B27 and  500 µl 
penicillin-streptomycin-amphotericin B (5000 U/ml).  
 
TBS: 12 g trizma base and 9 g NaCl were made up in 1 L dH20. The pH was 
adjusted to 7.4 using 32% HCl. 
 
Trypsin solution for ESTEM CELL (0.025%): 490 ml PBS, 5 ml chick serum, 
0.186 g EDTA and 5 ml 2.5% trypsin were mixed together. The solution was filter-
sterilised (0.2 µm) and aliquoted. Aliquots were stored at -20°C. 
 
TXTBS: 250 ml TBS and 500 µl triton X-100 were mixed together. The pH was 
adjusted to 7.4 using 32% HCl. 
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Appendix 2: Antibody Lists 
 
 
Primary Antibody Dilution Supplier 
Cell 
Mouse anti-Oct4 1:100 Santa Cruz 
Mouse anti-Nestin 1:200 BD Sciences 
Mouse anti-βIII-tubulin 1:500 Covance 
Rabbit anti-βIII-tubulin 1:500 Covance 
Rabbit anti-GABA 1:750 Sigma 
Rabbit anti-VGlut2 1:150 Synaptic Systems 
Rabbit anti-Tyrosine hydroxylase 1:1000 Chemicon 
Mouse anti-Serotonin 1:500 Abcam 
Rabbit anti-DARPP-32 1:1000 Chemicon 
Rat anti-BrdU 1:1000 Oxford Biotechnology 
Rabbit anti-SIRT1 1:250 Millipore 
Rabbit anti-GFAP 1:500 DakoCytomation 
Mouse anti-NG2 1:150 Millipore 
 
 
Secondary Antibody Dilution Supplier 
Goat anti-mouse Alexa Fluor 547 1:300 Cheshire Sciences 
Goat anti-mouse Alexa Fluor 490 1:300 Cheshire Sciences 
Goat anti-rabbit Alexa Fluor 488 1:300 Cheshire Sciences 
Goat anti-rabbit Alexa Fluor 547 1:300 Cheshire Sciences 
   Goat anti-rat Alexa Fluor 488 1:300 Cheshire Sciences 
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Appendix 3: Manuscript Articles 
 
Published article: 
1. Griffin, S. M., Pickard, M. R., Orme, R. P., Hawkins, C. P. & Fricker, R. A. 
Nicotinamide promotes neuronal differentiation of mouse embryonic stem 
cells in vitro. Neuroreport, 24, 1041–6 (2013). 
 
*Some of the data included in Chapter 3 was accepted for publication by 
Neuroreport on 25 September 2013. 
 
Conference article publications (Special edition journal issues): 
Conference: 3-6/9/2013, International Symposia on Neural Transplantation 
(INTR12), Cardiff, UK.  
1. Griffin, S. M., Pickard, M. R., Orme, R. P., Hawkins, C. P. & Fricker, R. A. 
Nicotinamide promotes neuronal differentiation of mouse embryonic stem 
cells in vitro. Neuroreport  25, 139–163 (2014).  
 
Conference: 7/5/2014, Association of British Neurologists Meeting (ABN), Cardiff, 
UK.  
2. Griffin S. et al The influence of nicotinamide on the development of 
neurons. J Neurol Neurosurg Psychiatry (2014); 85:e4 doi:10.1136/jnnp-
2014-309236.199 
 
Manuscripts in preparation: 
1. Griffin SM, Pickard MR, Orme RP, Hawkins CP, Williams AC, Fricker RA. 
Accelerated and efficient neuronal differentiation of Sox1GFP mouse 
embryonic stem cell in vitro. (2016) 
 
2. Griffin SM, Pickard MR, Orme RP, Hawkins CP, Williams AC, Fricker RA. 
Nicotinamide enhances the development of dopamine and serotonin neurons 
from mouse embryonic stem cells – a key player in the etiology of 
Parkinson’s disease?  (2016) 
 
3. Griffin SM, Williams AC, Fricker RA. Vitamins and the brain: A review of 
nicotinamide’s key functions in early embryonic development. (2016) 
 
4. Griffin SM, Williams AC, Fricker RA. Nicotinamide: therapeutic potential 
in Parkinson’s disease. (2016)  
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Appendix 4: Lists of talks in conferences 
 
1. 26/11/2014: Careers in Neuroscience Symposium, Galway, Ireland 
 
2. 27-28/11/2014: Network for European CNS Transplantation & Restoration 
(NECTAR) Data Blitz Presentation, Galway, Ireland. 
 
3. 9-11/12/2015: Network for European CNS Transplantation & Restoration 
(NECTAR) Data Blitz Presentation, Lund, Sweden. 
 
 
Appendix 5: Awards 
 
1. Poster presentation: 26/4/2012, Keele Postgraduate Symposium 2012, Keele, 
UK - won the first prize. 
 
2. Poster presentation: 12/7/2012, Vitae Midlands Hub Research Exhibition, 
2012, Coventry, UK - won the second prize. 
 
3. Travel award to attend International Symposia on Neural Transplantation 
(INTR12), Cardiff, UK, 2013. 
 
4. Travel award to attend Network for European CNS Transplantation & 
Restoration (NECTAR) Meeting, Galway, Ireland, 2014. 
 
5. Travel award to attend Network for European CNS Transplantation & 
Restoration (NECTAR) Meeting, Lund, Sweden, 2015. 
 
 
